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Summary 
Prostate cancer (PC) is the most common cancer found in men in the Western world.  
Predominantly, the pathogenesis of PC is driven by aberrant androgen receptor (AR) 
signalling, resulting in heightened cell proliferation and cell survival.  Current treatment 
options target the AR signalling cascade by androgen ablation therapy, whereby anti-
androgens antagonistically bind to the AR. This prevents AR activity, thus inhibiting 
transcription of genes involved in cell proliferation, survival and metastasis.   However, 
eventually androgen ablation therapy leads to relapse, as the cancer succumbs to a low 
androgen environment, leading to a poorer prognosis with limited treatment options, 
otherwise known as ‘castration resistant PC’ (CRPC). This is where new clinical 
interventions are urgently required. One mechanism that could allude to androgen 
independent PC, is the down-regulation of AR co-repressors.  One such co-repressor is 
known as Prohibitin (PHB). PHB is ubiquitously expressed in mammalian cells and 
displays anti-proliferative functions.  Prior to this project, it was identified that AR 
signalling leads to the down-regulation of PHB at both a transcript and protein level 
and causes PHB to dissociate from the chromatin. However, over-expression of PHB 
leads to the down-regulation of androgen responsive genes, and its increased association 
with the chromatin.  Thus within PC, both the AR and PHB are in a dynamic 
opposition.  This project identified that PHB has a repressive role on the cell cycle by 
holding the cell population within the G1 phase.  RNA-sequencing and Q-PCR data 
identified that PHB had a significant repressive role on gene families involved in DNA 
replication and cell cycle regulation and progression. Such gene families include cyclins, 
E2Fs and MCMs. MCMs are gene targets of E2Fs, and therefore it was assessed if PHB 
had an effect on the promoter activity of two MCM genes; MCM5&6. Interestingly, 
with PHB over-expression, repression of both MCM5&6 promoter activity was seen. It 
was then identified that PHB physically interacts with E2F1 in androgen responsive PC 
cells.  However this interaction was reduced upon androgen stimulation of the AR.  
This led to the preliminary mechanism that PHB can bind to E2F1, potentially 
preventing E2F from binding to MCM promoter regions, leading to an inhibition of the 
cell cycle in PC cells.  Moreover, it was identified that androgen stimulation led to a 
likely dephosphorylation event happening to the PHB protein that could explain how 
PHB dissociates from the chromatin and E2F1.  Signalling pathways that could lead to 
the non-genomic activation of the AR was narrowed down to the Src-pathway 
highlighted by a Kinexus™ protein array.  Interestingly, inhibiting the Src-pathway 
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stops PHB’s likely dephosphorylation event.  Accumulating previous data and data 
collected throughout this thesis, PHB up-regulation leads to cell cycle arrest through a 
direct interact of a key cell cycle regulator; E2F1.  Moreover, PHB was found to have an 
inhibitory effect on both the migration and adhesion of PC cells, potentially through the 
down-regulation of wnt genes.  Thus potentially, PHB up-regulation can inhibit the 
migratory potential of PC cells, stopping the progression of the disease.  
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1 Chapter I: General introduction 
1.1 The prostate gland 
The prostate gland is known as the largest male accessory gland, positioned inferior to 
the neck of the bladder and it surrounds the urethra (figure 1.1).  Structurally, a 
fibroelastic tissue layer encapsulates the prostate gland, forming a septum that 
subdivides the gland into five lobes (1).  These lobes are responsible for 
accommodating saccular glands, excretory ducts, stroma, blood vessels and nerves.  
Moreover, the prostate gland can be divided into zones, namely; central, peripheral, 
transitional and the stroma. The central zone is made of 20% glandular tissue that forms 
the majority of the prostatic base and surrounds the ejaculatory duct apparatus (1).   
The peripheral zone is made of 70% glandular tissue and is the most common zone for 
carcinomas to arise.   The transition zone is made of two small lobules where benign 
prostatic hyperplasia (BPH) usually arises (1).  The prostate gland is composed of two 
main cell types; luminal and basal that form the epithelial cell layer that is encapsulated 
by the stroma (2) (figure 1.1).  
Firstly, luminal cells are both polarised and columnar and carry out a secretory role 
within the lining of the prostate lumen.  The basal cells are elongated allowing the 
separation of the lumen and stroma and are also involved in proliferation (2).  Both 
these cells types are distinguishable by cell markers. For example, the luminal cells 
express the androgen receptor (AR), cytokeratin 8, 18, and CD57.  However, basal cells 
express a low level of the AR, CD44 and cytokeratin 14 (2).  Interestingly, a third cell 
type can be found with the prostate epithelium known as neuroendocrine cells.  This 
type of cell is very rare, post mitotic, is AR negative and secretes neuropeptides that are 
vital for the differentiation of the luminal epithelia (1).  In terms of stem cells within the 
prostate, little information is known about their role.  It has been thought that within 
the epidermis of the prostate resides a small population of stem cells that contribute to 
a growing population of prostate cells, which in turn differentiate into the luminal cells 
(3).   
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Figure 1.1. Structure of the prostate gland in the male human body (4), alongside the representation of 
the two major cell types within the prostate epithelium. 
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1.2 The function of the prostate gland 
The prostate gland carries out various functions.   Firstly, the mass and musculature of 
the prostate gland itself, aids the transmission of seminal fluid (5).   As it is known as an 
exocrine gland, it provides an array of molecules and enzymes such as coagulase and 
fibrinolysin that aid fertility.  The prostatic fluid also reduces the acidity of the urethra, 
protecting sperm viability.  The motility of sperm is enhanced by the prostate gland 
providing albumin and other proteins (5).  Finally, as an exocrine gland it participates in 
the rapid metabolism of the circulating androgen, testosterone to the more potent form; 
dihydrotestosterone (DHT). 
1.3 The development of the prostate gland 
In humans, the formation of the prostate gland is seen around week 11 of gestation. 
The formation begins with multiple outgrowths appearing from the urethral epithelium 
from both sides of the mesonephric duct.   Five epithelial buds mature into five internal 
prostatic lobes (5).  At 22 weeks, the stroma has significantly matured and continues to 
do so until birth. At birth, the anterior lobule reduces in size and loses its branches, 
regression of the gland is seen that then enters a quiescent phase at 12-14 years of age 
until puberty.  Maturation of the gland is seen during puberty (5). Figure 1.2 shows the 
pathway for androgen synthesis in the adult male prostate.  
1.4 Prostate Cancer 
Prostate cancer (PC) is an extremely complex and heterogeneous disease.  PC is the 
most frequent cancer in the Western male, particularly targeting men over the age of 65 
(6).  PC, when diagnosed at an early stage, is dependent upon androgen stimulation. If 
the cancer relapses to anti-androgen therapy, it becomes ‘castration resistant’ and in 
some cases, PC can become androgen independent. Androgen dependent PC relies on 
the androgen receptor (AR) signalling pathway, whereas AIPC is able to adapt to a low 
androgen environment and thus continue to progress to a more malignant state.  The 
transition from androgen dependence to androgen independence is poorly understood. 
Mechanisms establishing this transition will identify a more in-depth, understanding, 
vital for new therapeutic agents.  Supplemental figure 1 depicts the stages of PC 
progression.   
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1.5 Epidemiology of PC 
The diagnosis of PC has greatly improved over the last 50 years, leading to an increase 
in known cases. Approximately 40,000 cases per annum has been reported in the UK 
and PC is now the most common non-cutaneous cancer in men in the Western world 
(7).     Epidemiological studies based upon migrating populations uncovered that the 
environment and lifestyle choices play a vital role in the incidence of PC.  This being 
said, there is no inclusive risk factor that completely determines PC initiation (7).  Based 
on autopsy material, PC prevalence is highest among African American men and lowest 
in Chinese men (8).  Moreover, African American men tend to be diagnosed at a 
younger age with a more aggressive version of the disease (8).  The reasons behind the 
high incidence rate of PC in African men are still unknown, however a few factors such 
as socio-economic status, access to healthcare and delayed diagnosis may have some 
influence on the situation (8). In the United States, the number of diagnosed PC cases 
varied due to the introduction of the gold standard diagnostic test of the Prostate 
Specific Antigen (PSA) serum test in the early 1980s.  A rise in detection of PC is 
thought to be due to a rise in the number of biopsy cores taken and lowering of the 
PSA detection threshold (9). Table 1.1 shows the numbers of recorded PC cases 
worldwide. With regards to Europe, Tyrol in particular has a higher number of cases 
recorded for PC than the eastern parts of Austria.  This is due to an organised screening 
PC process being conducted in Tyrol (8).  Moreover, epidemiological studies of PC 
have identified that migrant Asian men adopting a western diet had an increased PC 
incidence due to dietary vitamin D.  Further, American men were identified to be 10 
times more likely to be diagnosed with PC than Japanese men, potentially due to 
Japanese men consuming a diet rich with fatty fish high in vitamin D (10).  
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Table 1.1. Numbers of recorded PC cases worldwide (9). 
 
Continent Country 
Incidence 
of PC (per 
100,000) 
 Africa 
Congo 29 
Kenya 16.6 
Senegal 7.5 
Uganda 38 
Zimbabwe 27.4 
   
North 
America 
Canada 78.2 
US 124.8 
Asia 
 
China 
 
1.7 
Taiwan 3 
Japan 12.6 
Korea 7.6 
Thailand 4.5 
  
Austria 71.4 
 Austria, Tyrol 100.1 
Europe 
Austria, 
Vorarlberg 
66.4 
France 59.3 
Hungary 34 
Iceland 75.2 
Norway 81.8 
Spain 35.9 
Sweden 90.9 
Switzerland 77.3 
UK 52.2 
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1.6 Risk factors 
Although there is not one specific risk factor that can lead to the onset of PC, there are 
several which can predispose an individual towards the disease.  Similar to breast and 
ovarian cancer, familial clustering of PC is a known risk factor (7).  For example, men 
who have first-degree relatives with PC incur a two-fold higher chance of developing 
PC than the rest of the general population (7). A meta-analysis of a Swedish population 
based cancer database highlighted 5,623 out of 26,651 men were familial cases, 
underlining that almost 5% of men with a familial case of PC will indeed be predisposed 
to the disease themselves (11).  For example, mutations in the BRCA1 and BRCA2 
genes are associated with high risk PC.  Men carrying the BRCA1 mutation have a 2-5-
fold increased risk of PC.   Moreover, men carrying BRCA2 mutations incurred a more 
aggressive form of the disease. Clinic-pathological analysis of men carrying BRCA1 and 
BRCA2 mutations displayed higher Gleason scores (> Gleason score 8) and metastasis 
was found at diagnosis.  A hindrance with this screening technique is reports of men 
with BRCA1 and BRCA2 mutations have been scarce (12).  
1.6.1 Ethnicity 
Asian men are less prone to developing PC but the aetiology is unknown.  On the other 
hand, African American men have a 60% higher occurrence than the American white 
population (11).   African-American men are also more than twice as likely to die of 
prostate cancer as white men. Lower cases of PC have been recorded in Asian-
American and Hispanic males than in non-Hispanic white males(11).   However, when 
Asian men migrate to the USA, their incidence is the same, thus there could be a dietary 
influence on PC incidence. The reasons for these racial and ethnic differences are yet to 
be identified. 
1.6.2 Age 
Age can greatly influence the onset of PC, for example the probability of developing PC 
in younger men is 0.005% which rises to 2.2% in men between 40 and 59 years of age 
(13). Unfortunately this percentage increases to 13.7% in men aged 60-79 years old (13). 
Worryingly, half of men aged between 70 and 80 years old age show malignancy upon 
histological analysis (13).  
Chapter I. General introduction 
8 
 
1.6.3 Single nucleotide polymorphisms (SNPs)  
Moreover, in terms of genetic predisposition, mutations can be potent and extremely 
rare or can be quite frequent with an intermediate effect (7).  Since 2005, 74 single 
nucleotide polymorphisms (SNPs) have been identified as a PC risk (7).   The first 
identified SNP at position 8q24 locus, found within the MYC gene, can give rise to 
oncogenic transformation and has had the most amount of independently associated 
variants (7). Likewise, SNPs have also been identified on chromosome 19, where genes 
encoding for the Kallikreins (KLK) family are found.  This family consists of the well-
known serine protease enzyme PSA also known as KLK3. Therefore SNPs within this 
region has been associated with altered expression levels of PSA (7).  Moreover, another 
identified SNP was located to the DNA mismatch repair (MMR) gene.  The SNP 
rs1799977 found in MLH1 gene was identified with a modest increase in overall PC 
risk, an increased risk in a more aggressive form of PC and PC recurrence. A similar 
pattern was seen with this SNP in breast cancer (14). Mutations in the MLH genes are 
damaging to microsatellites causing the failure of DNA repair during DNA replication.   
Therefore, ideally SNPs can be targeted for prognostic uses (7). In terms of 
distinguishing between aggressive and indolent disease, there is no known SNP that can 
do so at present.   
1.6.4 Mutations in tumour suppressor genes 
Mutations in the tumour suppressor P53 gene, leading to its inactivation, are the most 
frequent genetic alteration in human cancers.  Whether P53 mutations are associated 
with an increased risk in PC still needs to be further elucidated.  In around 1000 clinical 
samples carried out by Rivlin, et al, 2011, P53 mutations were screened.  The majority of 
P53 alterations identified by immunohistochemistry correlated with a higher Gleason 
grade.   Other studies suggest that nuclear accumulation of P53 correlates with poor 
prognosis, following radical prostatectomy, however this was contradicted by another 
study reviewed by Rivlin, et al., 2011 (15). This could be due to the small study number.  
It can be said that p53 mutations are associated with hormone refractory PC as it was 
confirmed that 94% of hormone refractory specimens had increased mutant P53 
protein expression, that has lost its tumour suppressor function and gained oncogenic 
functions (15). 16 mutant forms of the P53 gene were identified from an extensive 
functional analysis of PC.  LNCaP cells (wt p53) transfected with four gain-of-function 
P53 mutants (G245S, R248W, R273H, and R273C) were able to grow in the absence of 
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androgens, which is unique as LNCaP cells are characterized as androgen dependent 
cells (16). This could potentially link to how androgen dependent PC cells are able to 
survive and proliferate in an androgen-depleted environment.   
Another mutated tumour suppressor gene identified in primary PC is known as 
Kruppel-like factor 6 (KLF6). Its function still needs to be elucidated.  Analysis by 
(Narla, et al., 2001) (17) revealed that 77% of primary PC tumours had KLF6 deletions.  
Functional analysis observed that wt KLF6 significantly reduced proliferation and up-
regulated p21 activity, whereas tumour derived KLF6 mutants did not (17). This led to 
the assumption that KLF6 displays tumour suppressor activity in PC.  
Phosphatase and tensin homolog (PTEN) negatively regulates the PI3K/AKT pathway 
acting as a tumour suppressor gene and is often lost or mutated in cancers (18).  A study 
using a murine PTEN cancer model showed that the deletion of PTEN gene led to 
prostatic intraepithelial neoplasia (PIN) that progressed to invasive carcinoma, followed 
by metastasis (19).  
1.6.5 Mutations in oncogenes in PC 
Epidermal growth factor receptor (EGFR) is a tyrosine receptor kinase, and is involved 
in numerous signalling pathways such as Akt, MAPK and STAT.  Targeted inhibition of 
EGFR with microRNA28 resulted in an up-regulated apoptotic response in a PC 
tumour (20). Immunohistochemical studies showed that with increased PSA serum 
levels, there was an increased expression of EGFR.  Moreover, PC biopsies with a high 
Gleason grade (>7) were significantly more prone to be co-expressed with EGFR.  
Already there are EGFR-targeted therapies such as Geftinib that has been approved for 
the use of non-small cell lung carcinoma (NSCLC) (20)  In terms of PC, EGFR has a 
complicated interaction with the AR.  On the one hand, androgen stimulated AR was 
noted to increase the expression levels of EGFR mRNA. Anti -EGFR antibodies 
inhibited androgen-stimulated proliferation of PC cells.  On the other hand, another 
study suggested that androgen stimulation caused an increased EGFR degradation (20).  
Therefore further studies need to confirm the exact role EGFR has in PC.     
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Another oncogenic signalling pathway that is associated with the progression of PC is 
the Wnt signalling pathway. The canonical Wnt/βcatenin signalling pathway is 
associated with malignant PC (21). Inhibition of this pathway by a known Wnt 
inhibitor, WIF1, significantly reduced the size of PC tumours in a xenograft mouse 
model.  A transducer of the Wnt signalling pathway; CamKII amplified cell motility that 
could aid future tumour invasion (20). Interestingly, a non-canonical Wnt, known as 
Wnt-11 increases the invasiveness of both PC-3 and LNCaP cells when over-expressed 
(21). 
The fusion of 5’untranslated region of TMPRSS2 (21q22) to ERG (ETS-related gene) 
(21q22) has been identified in approximately 50% of PC cases, and this gene fusion has 
been seen in 90% of PC cases over-expressing ERG (22).  ERG is an oncogene 
belonging to the ETS family of transcription factors that plays a role in angiogenesis 
and haematopoiesis (23).  
TMPRSS2 is a bona fide androgen-regulated gene, and it was noted that androgen 
stimulation of PC cells resulted in an upregulation of the TMPRSS2-ERG gene fusion.  .  
Transgenic expression of TMPRSS2-ERG only resulted in PIN lesions, and additional 
genetic changes such as PTEN loss is needed to initiate carcinogenesis.  Over-
expression of this gene fusion has been associated with increased cellular proliferation 
and invasion (22). TMPRSS2-ERG gene fusion has had promising results as a PC 
biomarker in combination with the non-coding RNA PCA3 (24).  
1.7 Current biomarkers for PC 
As mentioned, PSA testing is the main diagnostic test used in clinics.  Normally PSA is 
secreted from the prostatic epithelium into the secretary ducts, then onwards into the 
seminal fluid (18). Upon PC initiation, the basal cell layer may become compromised, 
allowing PSA to leak into the circulation, causing a rise in its concentration in the blood.  
Unfortunately, PSA testing can be more sensitive than specific as it can be indicative of 
benign prostatic hyperplasia, prostatitis or altered due to certain medication.  More 
specifically PSA cannot distinguish between PC stages, or the metastatic state of the 
disease (18).  This causes implications regarding accurate therapeutic decisions, 
especially as PSA testing can give rise to false positives (18).  A concentration above a 
4ng/ml threshold is used as an indicator for a prostate biopsy to be taken. 40-50% of 
diagnosed cases, are classified as indolent cases (clinically insignificant PC), causing 
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unnecessary treatment. On the opposing hand, false negatives miss 20-30% of cancer 
cases (18).    
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There have been developments to incorporate the PSA serum test with different 
molecular versions of the protein and the rate by which it increases, to try and enable a 
more refined test. For instance, the rate of total PSA (tPSA) increases PSA velocity 
(tPSAV), that could hold some potential diagnostic value (18).  This holds importance 
in patients with a history of raised PSA blood concentrations, indicating prostate 
disorder. Again, this is not completely reliable as false negatives are mis-diagnosed.  The 
prostate health index (PHI) was approved for use in the United States, Europe and 
Australia (25).  This combines tPSA, free PSA and truncated PSA to aid in clinical 
decision-making  (18).  Recently, it has come to light that small non-coding RNAs such 
as micro RNAs (miRNAs) can have diagnostic and prognostic values. miRNAs can 
either be oncogenic or tumour suppressive, dependent upon the stimuli and type of 
cancer.  For example, members of the oncogenic microRNA family such as miR-21, 
miR-125b, miR-221 and miR-222 have been noted to be up-regulated in advanced PC 
(18).  As microRNAs are found in tissues and serum, they are stable against the 
degradation by RNases and freeze thawing, therefore they qualify as non-invasive 
biomarkers (26). 
1.8 Treatment options   
The AR is implicated in PC progression, thus therapies rely on targeting the AR 
signalling pathway.  Therapy that targets the AR signalling cascades is known as 
androgen ablation therapy (AAT).  Firstly anti-androgens such as Flutamide and 
Bicalutamide, both androgen receptor antagonists can be administrated (27). Anti-
androgens bind to the AR through competitive antagonism preventing interaction 
between androgens and the AR.  Anti-androgens hold the AR in an inactive state and 
recruit co-repressors of the AR such as nuclear receptor co-repressor 1(NCoR) and 
silencing mediator for retinoid and thyroid receptors (SMRT). These closely related co-
repressors work in synergy with histone deacetylases leading to condensing of the 
chromatin structure (27). Co-repressors mediate binding by extending LXXLL-like 
motifs located at the C terminal of both NCoR and SMRT, these are named co-
repressor nuclear receptor boxes (27).   
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Moreover, another anti-androgen therapy, Enzalutamide can inhibit the translocation of 
the AR towards the nucleus, inhibiting DNA binding and stops the recruitment of co-
activators.  This drug has proved to be successful in establishing anti-tumour activities 
irrespective of previous chemotherapy treatment (28).  
Though a highly used treatment option, anti-androgens do not eliminate the main 
circulating androgen, testosterone, thus Luteinizing hormone-releasing hormone 
(LHRH) agonists/antagonists are used in combination with anti-androgens to produce 
higher treatment efficacy.  They act as an agonist for the pituitary LHRH receptors 
initiating a rise in the luteinizing hormone (LH), follicle-stimulating hormone (FSH) and 
testosterone.  Constant activation of these receptors results in a castration level of 
testosterone.  With regards to LHRH antagonists, this signaling cascade is completely 
inactivated resulting in a faster inhibition of testosterone production (29). 
Often in some cases, use of anti-androgen therapy can promoter AR gene mutations, 
that can result in Flutamide stimulating the AR signalling pathway, causing a relapse in 
combination therapy, which is the case for a third of patients (30). Needless to say, 
these treatment options are simply targeted for the androgen dependent disease.  80% 
of patients undergoing androgen ablation therapy have a positive outcome, however if 
metastasis is present, after 12 months of AAT the disease progresses causing relapse 
and is resistant to further AAT therapy (30). 
 In terms of castration resistant PC (CRPC) there are a limited number of treatment 
options.  One breakthrough in CRPC treatment was the rediscovery of Abiraterone 
Acetate by the Institute of Cancer Research (31)  Abiraterone is an effective oral 
irreversible inhibitor of the CYP17 enzyme (32). This enzyme can be found in the 
endoplasmic reticulum (ER) of the testes, adrenal glands and ovaries and is responsible 
for the synthesis of cortisol and androgens (32).  The first use of Abiraterone in humans 
showed that a daily dose of 800mg was successful enough to reduce the levels of 
testosterone to undetectable amounts (32). The regulation of CYP17 is determined by 
cytochrome B5.  Usually a high ratio of CYPB5/CYP17 is found within the testes 
where production of androgens is high and low in the region of the adrenal glands (32). 
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Figure 1.2. Androgen biosynthesis.  Enzymes represented in red.  Image adapted from (33).  
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Patients that have relapsed with resistance to anti-androgen therapy are termed 
castration-resistant.  These patients are then treated with taxane-based chemotherapies.  
However, if patients then become resistant to taxane-based chemotherapies such as 
Docetaxel, an alternative is available, namely Cabazitaxel.  Phase I clinical trials 
demonstrated that not only did Cabazitaxel overcome cases of CRPC which had not 
been exposed to chemotherapy before but also Docetaxel pre-treated cases of CRPC.  
After Phase II and III of clinical trials, the US Food and Drug Administration (FDA) 
approved Cabazitaxel for advanced cases of PC (32). 
Recent advances propose that augmenting the immune response of the patient may be 
beneficial in terms of a valid therapeutic agent.  An array of immunotherapeutic 
methods is under investigation by clinical trials.  Either as a single vaccine, or in 
conjunction with chemotherapy and radiotherapy, agents aims to modulate the activity 
of T cells (34).  Sipuleucel-T was the first cancer vaccine to receive the FDA 
administration approval (34).  This was based on the evidence that Sipuleucel-T 
prolonged overall survival of men with CRPC.  Stages of Sipuleucel-T treatment begin 
with the removal of autologous cells via leukapheresis, these are then processed and are 
coupled with the vaccine target.  Following this, the product is intravenously 
administrated into the patient (34). Prostvac-VF is a viral vaccine made of two 
recombinant viral vectors that each encode for PSA, B7-1, intracellular adhesion 
molecule 1, and lymphocyte function-associated antigen 3.  Currently, Prostvac-VF is 
being assessed for CRPC in clinical trials (35). Immunotherapy remains to be further 
explored in PC, as the number of prostate tumour specific antigens are limited.  
1.9 Stage and Grade of PC 
Accurate staging of PC is essential for correct prognosis and treatment.  The tumour, 
node, metastasis (TNM) system is the most widely used clinical staging system for PC in 
deciphering the spread of cancer.  In terms of how well differentiated the PC tissue is, 
the Gleason grading system is the most widely used for pathological staging.   Donald 
Gleason formulated the PC grading system in 1966 (36). PC was unique in the way it 
was graded as it was solely based on the glandular epithelial architecture rather than 
cytology.   The five tier grading system ranges from 1 meaning well differentiated to 5, 
the most poorly differentiated pattern.  As different areas of the PC often have varying 
grades, a grade is allocated to the two areas that make up most of the cancer (36).  The 
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grade of these two areas is added together to formulate a Gleason score.  The lowest 
Gleason score a PC biopsy can have means it is well differentiated and less likely to be 
aggressive.  A high Gleason score, confers to a more aggressive and less differentiated 
cancer.      
1.10 Bone metastases from PC 
PC has a strong tendency to metastasise to the bones, evidenced by the majority of 
patients with advanced PC possessing skeletal metastases.  The tumour cells infiltrate 
the trabecular bone of the axial skeleton as well as the proximal ends of the femur.  One 
theory to why PC cells settle within the bone environment is based around the network 
of veins that receive blood from the prostate, the Batson plexus (37).   Between the 
Batson plexus and the vertebral column a large amount of metastatic PC cells are found 
in PC patients.  These cells form sinusoids, reducing the blood flow rate, facilitating 
entry of these cells into the bones.  PC cells in particular have a strong affinity to attach 
to the bone epithelium through the recognition of certain protein receptors such as 
integrins.  Tumour cells first bind to the bone-marrow endothelium-specific lectin with 
low affinity and then firmly adhere onto a bone marrow endothelium-specific integrin.   
Finally the tumour cells produce proteolytic enzymes to break down the basement 
membrane of the bone marrow microvessels, where they are able to colonize in the 
bone environment (37).  PC metastases almost always form osteoblastic lesions (with 
some osteolytic lesions) in the bone, producing a bone-forming phenotype that can be 
detected via radiographical and histological analyses (38). 
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1.11 The androgen receptor (AR) 
1.11.1 The AR 
The AR, a steroid hormone activated transcriptional factor belongs to the nuclear 
receptor superfamily. The AR gene locus maps to chromosome Xq12 and encodes for a 
protein with three main functional domains; the N terminal domain (NTD), DNA-
binding domain (DBD) and the ligand binding domain (LBD) (39) (figure 1.3).  Exon 1 
transcribes for activation function 1, exon 2 and 3 encode for the DBD and exon 4-8 
encodes for the LBD (40).  During embryogenesis, production of androgens by the 
male foetus causes an AR signalling cascade which is responsible for the male 
phenotype and is critical for prostate gland biology (39).  
1.11.2 The N-terminal domain (NTD) 
 Exon 1, in the AR gene encodes for the NTD, which is the least conserved out of the 
four domains (41). The NTD contains two polymorphic trinucleotides that encodes for 
poly-glutamine (Poly-Q) and poly-glycine (Poly-G) tracts.  Variations within these 
polymorphic regions are associated with altered AR transcriptional activity in vitro (42).  
Variations in the Poly-Q regions are responsible for degenerative neuromuscular 
diseases such as Kennedy Syndrome. The variation can be between 11-31 repeats and 
≤18 repeats has been associated with the onset of PC (42). The NTD allows the AR to 
recruit co-regulators stimulating androgen dependent transactivation of the AR.  The 
NTD possesses the activation function 1 (AF-1) element that differentiates it from 
other steroidal receptors that use the activation function 2 element (AF-2) found in the 
LBD (43). 
1.11.3 Mutations in the NTD 
Mutations found within the NTD accounts for a third of all mutations in the AR. Many 
of them are a result of androgen ablation therapy. Located with the ligand dependent 
TAU-1 region, two mutations at amino acid positions 142 and 221 were discovered in 
CRPC patients (41). At position 142, valine is substituted for glycine whereas at position 
221, aspartic acid is substituted for histidine. Shorter CAG repeats have a positive 
correlation with a higher PC incidence. Thus these mutations may contribute towards 
the initiation of the disease and its progression (41).  Mutations within the NTD can 
lead to heightened AR transcriptional activity.  
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1.11.4 The DNA-binding domain (DBD) 
Exons 2 and 3 encode for the two zinc fingers found within the DBD (41). The DBD 
carries out the responsibility of binding the AR to AR-specific DNA sequences situated 
within androgen responsive genes. Sequencing analysis of the AR DBD illustrated that 
it is comparable to the Glucocorticoid (GR), Mineralocorticoid (MR) and Progesterone 
receptor (PR), all members of the steroid receptor family (42).  Three α helices form 
two zinc fingers along with a C-terminal extension that creates the basic DBD structure.  
Situated within the first zinc finger is a P-box which is a conserved motif, allowing 
interaction between specific nucleotides and the DNA within the major groove.   The 
second zinc finger consists of a D-box where receptors are able to bind to and 
homodimerise (41).  
1.11.5 The ligand binding domain (LBD) 
The AR LBD found at the C-terminus binds specific ligands (androgens) such as 
testosterone and dihydrotestosterone (DHT) to the AR.  Therefore, this interaction 
holds immense importance in the androgen signalling cascade, as ligand bound AR 
increases AR stability and initiates its translocation towards the nucleus.  Without 
ligand, the AR is found in the cytoplasm of cells bound to heat shock proteins (HSP) 
and chaperones which hold the AR in an inactive state by association of cytoskeletal 
proteins (41).  
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Figure 1.3. The chromosomal location of the AR on the X chromosome.  The gene representation of the 
AR and how this gene transcribes into the AR protein.  NTD = N-terminal domain, DBD = DNA 
binding domain, LBD = Ligand binding domain.  AF= activation function.  Figure adapted from (44). 
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1.11.6 Transactivation of the AR 
The LBD of steroid hormone receptors fold into 12 helices that form the ligand 
binding pocket.  The folding over of helix 12 in the AR leads to the disclosure of a 
groove that binds a region of the NTD. Ligand activation of the AR induces its 
conformational change allowing the formation of AR dimers on androgen response 
elements (AREs).  To increase the rate of target gene transcription, co-activators are 
recruited, along with chromatin remodelling complexes.   Co-activators potentiate the 
interaction of the AR with basal transcriptonal machinery and also covalently modify 
histones.  Chromatin remodelling proteins ensure the accessibility of nucleosomal DNA 
to transcriptional factors (45).  
1.11.7 Co-activators of the AR 
The regulation of the AR transcriptional activity is highly regulated by both co-
activators and co-repressors.  The AR binding to chromatin occurs in competition with 
nucleosome histone proteins.  AR co-activators aid AR binding to the chromatin by 
recruitment of chromatin modifying enzymes (39).  Such co-activators of the AR 
include SRC/p160 family members, which bind to the DBD and NTD via TIF2 and 
carboxyl terminal domains of the AR. Characterisation of the SRC family of co-
activators includes an N-terminal tandem basic helix-loop-helix, a C-terminal glutamine 
rich region and three LXXLL motifs within the central portion of the protein (39).   
Two major functions are carried out that modulate AR activity.  Firstly, p300 a class I 
co-activator causes the recruitment of transcriptional machinery to nuclear receptors 
and secondly class II co-activators such as p160 proteins which recruit histone 
acetyltransferases (HAT), resulting in a more open chromatin structure (39).   
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1.11.7.1 p300 co-activator  
p300 is known to be an adaptable co-activator among steroid receptors such as the 
oestrogen and androgen receptor. Originally p300 was acknowledged to be bound to 
the adenovirus E1A and cAMP responsive element binding protein (CREB) (46).This 
transcriptional co-activator can regulate gene transcription through a manner of 
mechanisms.  Firstly, it can act as a scaffold between DNA bound transcriptional 
factors and the basal transcriptional machinery (47).  Secondly, p300 carries out histone 
acetyl transferase activity by transferring an acetyl group to the ε-amino group of a 
lysine residue on histones (48),  easing the chromatin structure allowing more 
accessibility for the transcriptional machinery (47).  Not only can p300 acetylate 
histones, it can acetylate proteins such as transcription factors.  This can  change 
protein-protein interactions, protein-DNA interactions or even the half-life of specific 
proteins (47).  In terms of activating the AR, p300 can do so under the influence of 
hormone induction, causing full ligand induced transcriptional activity of the AR and 
also influencing the growth of prostate cancer cells (47).  The exact acetylation of the 
AR by p300 occurs at a phylogenetic conserved motif found within the hinge region 
(46). p300 over-expression instigated heightened cell proliferation and a change in 
nuclear morphology causing the development of aggressive disease features in PC cells 
(49).   Moreover, it was also found that over-expression of p300 was found in other 
tumours such as colorectal and breast, indicating its more general role (49). 
Interestingly, it was shown that p300 was vital for the induction of AR activity by IL-6 
in the absence of androgen (49). This was identified through IL-6 induced activation of 
the PSA gene promoter in PC cells (49). Moreover, through the suppression of p300, 
IL-6 activation of the AR was disrupted.  Indeed, silencing p300 with siRNA reduced 
the proliferation of IL-6 induced PC cells.  This highlights the significance of p300 
working in synergy with IL-6 aiding the survival of cells in androgen independent PC 
(46).  
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1.11.7.2 P160-SRC co-activators   
The first cloned nuclear receptor (NR) co-activator was steroid receptor co-activator -1 
(SRC-1) (50).  SRC-1 interacts with an array of NRs in a hormone dependent manner, 
increasing their transcriptional activity.  Two other members of the SRC-1 family are 
identified as SRC-2 and SRC-3 and together they form the p160 SRC family, all 
possessing three structural domains.  Firstly the most conserved domain is the N-
terminal basic helix-loop-helix-Per/ARNT/Sim that partakes in protein-protein 
interactions.  The central domain contains three LXXLL motifs accountable for the 
interaction with NRs.  Lastly, the bHLH-PAS domain is responsible for the interaction 
with transcriptional factors such as myogenin ,MEF-2C and AR (50).  The C-terminus 
domain comprises of two transcriptional activation domains (AD1 and AD2).  AD1 
binds to the p300 histone acetyltransferase that is essential for SRC mediated 
transcriptional activation.  Further, SRC-2 interacts with histone methyltransferases. 
SRCs can also be co-activators for transcriptional factors such as E2F1, SMADs and 
STATs.  SRCs therefore regulate diverse physiological functions through both NRs and 
non-NR transcriptional factors.   
1.11.8 Co-repressors of the AR 
By definition, co-repressors of the AR are molecules that bind to the AR and cause the 
enlistment of chromatin modifying enzymes and repress its transactivation potential.  
However this is not the only mechanism by which these molecules repress the AR, as 
alternative mechanisms include inhibition of the AR N/C terminal interactions, 
inhibition of co-activator recruitment or disruption of nuclear translocation of the AR 
(51).  An overview of the mechanism involved in AR co-repression is given in (figure 
1.4).  
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Figure 1.4. Representation of the diverse co-repressor mechanisms (51). Mechanisms include (1) 
inhibition of the AR translocation, (2) inhibition of co-activator recruitment, (3) inhibition of AR binding 
to DNA, (4) inhibition of chromatin modification and the (5) inhibition of the AR N/C interaction. 
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Chromatin modifying co-repressors cause the recruitment of histone deacetylases 
(HDACs) to the DNA-bound AR complex. HDACs can prevent co-activators 
acetylating lysine residues on histone tails, causing DNA condensation, causing 
promoter inaccessibility (27). However HDACs cannot bind to DNA directly and need 
secondary molecules to activate their enzymatic activity. For instance, HDAC3 needs 
either NCoR or SMRT to aid in its function.  Furthermore, HDACs may promote 
alternative routes to administrate AR function.  One mechanism involves HDACs’ 
ability to counterbalance the AR hinge region acetylation by p300. Thus, although 
HDACs can condense chromatin with the aid of NCoR and SMRT, they can also elicit 
their function by modifying the AR itself or by interfering with AR co-activators (27). 
AR promoter or UTR mutations are rare in CRPC patients (52).  
1.11.8.1 Cyclin D1 as a co-repressor of the AR 
Cyclin D1 has a crucial role in the cell cycle as a vital component of the CDK4 kinase 
complex.  It binds CDK4 directly, causing the CDK4 mediated phosphorylation of 
retinoblastoma (Rb) (53). In terms of steroid receptor activation, cyclin D1 has been 
shown to bind to the oestrogen receptor (ER) causing the activation of its 
transactivation domain in the absence of ligand.   For cyclin D1 to carry this out this 
function, a leucine rich LXXLL-like motif is needed, that aids the link between steroid 
receptor and co-activators (53). Mutations within this LXXLL-like motif lead to the 
production of a protein that can bind to the ER but fails to recruit co-activators (53).   
However in PC, cyclin D1 has an opposing role whereby its interaction with the AR 
causes the repression of its transactivation.  The repression occurs by cyclin D1 binding 
to the N-terminal domain with high affinity, inhibiting AF-1 (53). Interestingly, ectopic 
expression of cyclin D1 in the LNCaP cell line reduced their proliferation capacity (53).   
The AR and cyclin D1 migrate between the cytoplasm and the nucleus in response to 
cellular signals.  In particular, cyclin D1 is exported to the nucleus in response to anti-
mitogenic signals through GSK-3β-mediated phosphorylation (53). As the AR 
translocates to the nucleus in response to ligand binding, it is thought that cyclin D1 
inhibits AR activity through cytoplasmic sequestering (53).  A nuclear cyclin D1 mutant 
protein, cyclin D1-T286A was found to be unable to be phosphorylated by GSK-3β, 
therefore was unable to be transported from the nucleus (53).   Interestingly, this 
mutant form of cyclin D1 was still able to repress AR activity.   
Chapter I. General introduction 
25 
 
To identify the site at which cyclin D1 is active, mapping studies were carried out by 
Petre at al., (53).   This determined the NTD of the AR as the main region where cyclin 
D1 binds, specifically between amino acids 1-502 (53).   On the other hand, according 
to Reuens et al,. (54) it was observed that cyclin D1 was able to bind to amino acids 633-
668 within the hinge region of the AR.  However, this interaction was only observed as 
a two-fold higher expression than that of the background level.  Therefore, this suggests 
that cyclin D1 can bind to the NTD of the AR that is highly relevant as this is the most 
common binding site for co-activators of the AR (24).  
1.11.8.2 SMRT and NCoR as co-repressors  
The silencing mediator for retinoid and thyroid hormone receptor (SMRT) and its close 
relative nuclear receptor co-repressor (NCoR) are homologous to one another, and 
both proteins are 270kDa in size (27).  The C-terminal of NCoR possesses three nuclear 
receptor interaction domains, whereas SMRT contains just two.  These nuclear receptor 
interaction domains aid with the interaction of SMRT and N-CoR with the LBD of 
nuclear receptors (27). The functional motifs of these interaction domains contain 
‘coRNR boxes’ with the consensus sequence L-X-X-I/H-I-X-X-X-L/I (L: leucine, I: 
isoleucine, X: any amino acids) (27). The regulation of the binding affinity is affected by 
any conformational change of the nuclear receptor in response to ligand.  Specifically 
binding of ligand to nuclear receptors induces the movement of helix 12 which is 
essential for the binding of SMRT/N-CoR to nuclear receptors (27). 
1.11.8.3 SMRT and NCoR, mechanism of action 
Both SMRT and NCoR have previously been identified to inhibit the transcriptional 
activity of antagonist bound progesterone receptor (PR) and ER (55).    In addition to 
steroidal nuclear receptors, SMRT/N-CoR can carry out a repressive function with 
other nuclear receptors such as RevErB and the orphan receptor DAX1.  The 
unrestrained activity of SMRT and N-CoR is also seen in an array of transcriptional 
factors involved in many cellular functions, such as Bcl-6 which plays a role in the 
suppression of inflammation (56). Despite there being accumulating evidence to suggest 
SMRT and N-CoR’s ability to repress nuclear receptors activity, less is known about 
their function involving the AR.  Moreover, the ability of SMRT and N-CoR to bind to 
steroid receptors is weaker than that of non-steroidal receptors (57).  However, it is 
interesting to note that Tamoxifen, the well-known ER antagonist enhances the 
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interaction between NCoR and the ER which is a contributing factor in aiding 
Tamoxifen’s ability to suppress the ER’s targeted gene expression (57).  
1.11.8.4 SMRT and NCoR interaction with the AR  
Previous studies evidence that a reduction of SMRT/NCoR may link to the ligand-
independent activation of the AR, leading to PC progression (27). However, the idea 
that these co-repressors are able to repress the activity of the AR is more complicated 
than thought.  This is due to studies over-expressing both SMRT/NCoR, failed to 
suppress the androgen responsive gene transcription in PC cell lines.  This refers to the 
fact that simply over-expressing these co-repressors does not represent what occurs 
under physiological conditions.  However, rather than effecting protein production of 
these co-repressors, post-translational modification of SMRT/NCoR was found to 
enhance ligand bound repression of the AR.  Specifically, protein kinase A (PKA) is 
capable of binding directly to the RD1 domain within NCoR, phosphorylating ser-70 
(27). This causes an increased nuclear localisation of NCoR where it can carry out its 
repressive function of the AR (27). 
1.11.8.5 Prohibitin (PHB) as a co-repressor of the AR 
PHB, a highly conserved 32kDa protein across all species, yeasts and plants displays 
tumour suppressor characteristics (58).  It resides within the inner membrane of the 
mitochondria, where it co-interacts with a similarly structured protein, BaP37 (PHB2).  
It has also been identified to reside within the nucleus of ovarian granulosa, breast 
epithelial and prostate epithelial cells.  Within the nucleus, it co-interacts with NCoR, 
HDAC1 and Rb (59). This interaction inhibits transcription of genes regulated by 
members of the E2F family.  Breast cancer cells treated with Tamoxifen, displayed 
inhibition of E2F activity through the recruitment of PHB.    PHB’s participation 
within a repressive complex of proteins, is thought to hinder growth within hormone 
sensitive cancer cells.  This is relevant to PC, as it was previously shown that androgen 
stimulation caused a repression of PHB mRNA and protein expression in the LNCaP 
cell line. This allowed progression of the cell cycle (58).   This implies that PHB plays a 
role in androgen-regulated cell cycle of PC cells which shall be discussed further on.   
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1.12 AR in the normal prostate gland 
Testosterone is the main circulating androgen produced by the testes, with less than 5% 
of androgen production being made by the adrenal glands. Other androgens include 
DHT that is a metabolite of testosterone and has a five-fold greater affinity for the AR 
than testosterone and is produced at target organs. Androgenic precursors such as 
androstenedione, are produced by the adrenal glands can either be converted to 
testosterone in the testes by dehydrogenation or converted to estrone (an estrogen) by 
aromatization (60). DHT is essential for the prenatal development of the prostate gland.  
The enzyme responsible for the production of DHT is known as 5α-reductase (isotype 
2 is the main enzyme found in the prostate gland).  In the absence of 5α -reductase the 
prostate gland can be undetectable during foetal development, suggesting 5α -
reductase’s crucial role in its development. Heinlein et al,. (61) showed the absence of 5α 
-reductase can cause a partial formation of the prostate gland in response to low levels 
of DHT, this emphasises that a certain threshold level of DHT must be reached for 
complete prostate morphogenesis. Models such as AR knockout (KO) mice, testicular 
feminised mice (TFM) and individuals who have succumbed to AR mutations rendering  
them androgen insensitive, validate that the AR is vital for the development of the 
prostate gland and other androgen regulated tissues (61).   
Prostatic bud formation is reliant upon a functional AR within the urogenital 
mesenchyme that allows interactions between the epithelium and stroma to commence.  
This highlights that is it the mesenchyme that secretes growth factors responsive to 
DHT that then act on the developing epithelium.   Androgens continue to regulate the 
prostatic epithelium throughout adulthood, and it is the epithelium that is transformed 
in prostate adenocarcinoma (61). 
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1.13 AR in the bone, muscle and immune system 
During the growth of a male adolescent, the production of androgens influences the 
skeletal size and shape. This is depicted by the misuse of androgen treatment, as often 
men self-administrate high doses of androgen for bodybuilding purposes (62).  During 
adulthood, production of androgens maintains bone homeostasis, as AR expression is 
seen in bone and bone marrow cells (63). Depleting androgen levels leads to bone 
remodelling and in some cases, bone loss.  Germline deletions of the AR in male mouse 
models displayed low bone mass with a high bone turnover as well as decreased 
trabecular and cortical bone volume.  This emulates androgen deficiency in humans 
(63).  
Androgens within muscle tissue increase both muscle mass and strength. This is in 
accordance with the withdrawal of testosterone causing muscle mass and strength to 
lessen.  During adulthood, androgens are essential for men to reach peak muscle mass, 
by influencing myogenic commitment.  Androgens also play a role in maintaining 
muscle mass through suppression of atrophy pathways.  Men undergoing androgen 
deprivation therapy (ADT) displayed reduced upper limb strength as opposed to lower 
limb strength, indicating androgens influence different anatomical regions.  However, 
there was no effect seen on muscle endurance with ADT, suggesting that slow twitch 
fibres are less responsive to androgen withdrawal (64).  
The AR-signalling pathway has also been identified to function within the immune 
system.  For example, the AR is consistently expressed in the neutrophil lineage from 
the proliferative precursors to the mature neutrophils.  Women suffering from 
polycystic ovary syndrome with hyper-androgenism have a higher neutrophil count, 
suggesting that androgens can promote neutrophil production.  Supporting this 
concept, AR knockout mice models demonstrated a 90% reduction in neutrophil count 
when compared to the wt mice.  In human cases, patients undergoing ADT, tend to 
have a mild reduction in neutrophil count, suggesting the AR has a more intense effect 
on neutrophils than androgens.  Moreover, restoring the AR in AR knockout mouse 
model resulted in macrophage progenitor cells salvaging neutrophil production, 
indicating the role the AR has in neutrophil differentiation (65). 
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1.14 AR in females 
The AR is primarily seen to play a role in the development of male-specific phenotypes.  
However the signalling cascade has also been identified in the development of female 
reproductive organs and their functions.  Specifically, the AR is expressed in the 
mammary gland, ovaries, uterus and the fallopian tubes of various mammalian species.  
Within the ovaries, testosterone is produced by theca cells in response to luteinizing 
hormone.  During early follicular development, androgens directly influence the 
function of the ovaries, however during late pre-ovulatory development androgens then 
serve as precursors for the production of oestrogens.   
In mammalian species, the AR is expressed in different cell types of the ovaries such as 
stroma, oocytes and granulosa.  Exposure of high serum androgen in women leads to 
the production of larger ovaries with increased numbers of antral follicles.  In mice, 
both testosterone and DHT promote follicular growth, and the ovulation rate in pigs 
was also enhanced with DHT treatment (66).   There is little evidence to understand 
how the AR influences the development and function of the uterus. However, in a 
porcine study, it was observed that the AR and ERα interact allowing the regulation of 
the uterine growth and endometrial gene expression (66).  
Interestingly, the secretion of testosterone seems to play a role in breast tissue 
development.  Activation of the AR by DHT is thought to suppress the growth of 
breast tissue.  The majority of breast cancer patients expressing the oestrogen receptor 
are also positive for the AR and progesterone receptor (PR), and have a longer disease 
free interval than patients negative for the PR, HER2, ER receptors (67).   However, 
whether the AR signalling pathway is beneficial or detrimental in breast cancer is yet to 
be discovered and will likely depend on the subtype of the cancer and the menopausal 
status of the patient (67).   
Premature ovarian failure syndrome is depicted by the decline of ovarian function.  
Knockout of AR (-/-) in 8 week old mice demonstrated a decrease in follicle numbers 
and a weakened mammary development. Also the number of pups per litter was halved 
when compared to control mice.  At 40 weeks old, the AR (-/-) mice display complete 
loss of follicles and therefore are infertile (68). 
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1.15 AR in PC 
Androgens are mediators in PC pathogenesis, evidenced by a positive correlation 
observed between AR expression, a high Gleason Grade and the vascularity of the 
tumour (41). Even upon AAT, the AR is expressed heterogenously and no change is 
seen in the pattern of heterogeneity.  Interestingly, mutations within the AR have been 
documented and could elude to how the AR signalling is still active in the absence of 
androgens. For example, AR mutations can consist of loss of function and gain of 
function mutations, both of which are associated with androgen insensitivity syndrome 
(AIS) and PC respectively (41).  Specifically within the AR gene, four main types of 
mutations have been established.  These consist of single point mutations, nucleotide 
insertions or deletions, complete or partial gene deletions and intronic mutations.  It is 
extremely infrequent for AR mutations to evolve in the earlier stages of PC with only 
10-30% of patients with CRPC carrying AR mutations (41).  There have been over 150 
mutations found within the AR in PC tissue, rather than germline mutations, somatic 
mutations have been noted consisting of single base substitutions. 45% of these somatic 
mutations arise in the LBD of the AR, whereas 30% arise in exon 1.  It is these gain of 
function mutations which may allow non-specific ligands found in the body such as 
oestrogen and adrenal androgens to activate the AR signalling pathway causing prostatic 
epithelial cells to grow in an castration resistant manner (41). Resistance to current 
therapies is a worrying dilemma, for example mutations in the LBD can cause resistance 
to Enzalutamide, allowing the AR to become active even in the presence of anti-
androgens (41). 
1.16 Pathogenesis of androgen independence 
It has been suggested that PC pathogenesis is predominantly AR regulated, thus termed 
‘androgen dependent’.  Upon androgen ablation therapy, the AR is no longer able to 
continue its signalling cascade, thus growth and progression of cancerous cells and 
androgen regulated cells is halted.  Unfortunately, in some cases the cancer initiates 
adaptation to the new environment in the absence of androgens and begins its own 
mechanisms of survival.  Thus ‘androgen independence’ occurs.   There have been 
numerous models to support how and why androgen independence arises (figure 1.5).  
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Figure 1.5. Image adapted from Saraon et al., (69). The various mechanisms of AR adaptive activation 
that have been theorised to date.   
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1.16.1 AR amplification 
25-30% of androgen independent PC (AIPC) cases have AR augmentation both at 
mRNA and protein level (69). Worryingly, AR gene amplification has not been noted in 
untreated PC cases, leading to the assumption that androgen ablation may lead to the 
onset of this phenomenon.  This AR over-expression initiates cancerous cells to 
become sensitized to a low androgen environment, promoting more proliferation and 
survival, ideal for cancerous cells to overcome hormonal therapies used in clinics.  In 
the absence of AR gene amplification, over-expression of the AR can still occur, 
indicating that elements such as epigenetics and miRNAs can regulate this event, 
independent of gene amplifications (69). 
1.16.2 AR mutations 
Further, it is particularly rare to find AR gene mutations in early onset PC cases (0-4%), 
however this percentage increases as the grade of the tumour also increases, especially 
in androgen independent cases.   Originally, the first described gene mutation was a 
mis-sense mutation at codon 877 of the AR mRNA causing a substitution of threonine 
to alanine in the LNCaP cell line.   This mutation causes the ligand-binding domain to 
reduce its specificity and allow non-specific ligands such as anti-androgens and other 
steroidal hormones to activate the AR.  Further ligand binding mutations include 
H874Y, V715M, L701H, T877A, and Y741C (69).   
1.16.3 AR splice variants 
A more novel insight to AIPC is splice variants that have been seen to be over-
expressed in AIPC cases.  It was discovered that three splice variants, namely AR3, AR4 
and AR5 are all ligand-binding domain deficient (70).  Without a ligand binding domain, 
the AR is no longer dependent on androgen binding to cause its translocation towards 
the nucleus and can do so independently. Interestingly, neither androgens nor anti-
androgens can activate the transcriptional activity of AR3.  AR3 was identified as the 
most abundantly and ubiquitously expressed splice variant to be seen across a panel of 
human PC tissues (70). However in normal prostate tissues, AR3 expression is seen in 
basal and stromal cells and is absent in luminal epithelial cells.  Guo et al,. (70) suggests 
that AF3 may play a role in androgen-insensitive regulation of the homeostasis found in 
the normal prostate gland. Although studies on these variants are still in their 
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preliminary stages, they could hold huge importance in unveiling how cancerous cells 
evade androgen ablation. 
1.16.4 Non-ligated AR activation 
Besides ligand activation, the AR can be activated by signalling pathways and can be 
induced by growth factors, cytokines and kinases in the absence of androgens.  
Firstly in terms of growth factor mediated AR activation, insulin like growth factor-1 
(IGF-1) is the most widely studied.  IGF-1 can influence the up-regulation of co-
activators such as TIF2, enhancing AR activity.  Moreover, epidermal growth factor 
(EGF) can also potentiate AR signalling in the absence of androgens. Over-expression 
of the EGF regulated SPINK1 protein was seen in aggressive PC cases negative for the 
ETS chromosomal rearrangements (69).  Both IGF-1 and EGF are ligands for receptor 
tyrosine kinases (RTKs) which are heavily influenced in the progression of PC.  The 
most notorious RTK is known as HER-2/neu, that when overexpressed in PC cells 
cause the activation of androgen responsive genes in the absence of androgens.  
However, unlike IGF-1, upon androgen ablation HER-2/neu is still able to carry out its 
signalling pathway suggesting its independence from the AR (69).   
1.16.5 Cytokines 
Cytokines have also been shown to activate the AR in AIPC cases, in particular the NF-
κB signalling pathway can regulate IL-6 and IL-8, which both can stimulate the AR and 
activate AR response genes in LNCaP cells (69).  Moreover, the canonical Wnt 
signalling pathway causes the activation and stabilisation of a β-catenin pool that can 
independently interact with the AR, modifying its function.  As well as activation of AR 
response genes, Wnt response genes can also be activated.  In vivo studies demonstrate 
that the AR and β-catenin co-localise and interact with one another in xenografts in 
castration resistant mice (69).    
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1.16.6 Bypassing the androgen receptor pathway 
All the mentioned mechanisms involve the AR one way or another.  However in terms 
of the outlaw mechanism, signalling pathways can become activated independent of the 
AR, thus completely bypassing this system.  This is known as ‘true androgen 
independence’. For example, an important pathway known as the PI3K/AKT/mTOR 
pathway plays a crucial role in cancers, especially in PC. The pathway is associated with 
cell growth and survival during cellular stress.   AKT can activate the AR via an outlaw 
mechanism, nevertheless it plays a vital role in the proliferation and apoptosis status of 
PC cells.  The key tumour suppressor within this signalling pathway PTEN, as 
mentioned before is often lost, causing unregulated cell proliferation, highlighting the 
importance of this pathway in AIPC (71).  Further, throughout androgen ablation, 
apoptotic signalling pathways are activated, thus anti-apoptotic factors must be released 
to circumvent cell death in AIPC.  For example Bcl-2 is a key anti-apoptotic protein 
which when expressed, aids PC cells to avoid apoptosis.  According to Lui et al,. (72) 
Bcl-2 detection was found in xenografts of castrated mice, upon targeting Bcl-2 with si-
RNA, a deferred onset of AIPC in these mice was observed.    
Both outlaw and bypass mechanisms can interact with one another to initiate the 
transition of androgen dependence to androgen independence. Further investigation is 
needed to verify the exact molecular mechanisms of this transition to depict the main 
mode of action to how this occurs.   
1.16.7 Epigenetic alterations 
Normal cellular development is regulated via epigenetic alterations. Hyper-methylation 
of the AR promoter is an example of an alteration that has been highly implicated in 
AIPC cases. It has been noted that 20-30% of AIPC cases do not express the AR, 
which is due to the promoter of the AR being hyper-methylated and is more prominent 
in severe cases than primary tumours (73). Genes that are often silenced in PC are 
involved in the cell cycle, cell invasion and DNA damage repair.  Such genes include 
cyclin-dependent kinase inhibitor 2A, CD44 and methylguanine-DNA 
methyltransferase (MGMT) tumours (73). This could lead to further research involved 
in aberrantly expressed genes in PC that can translate into prognostic or diagnostic 
value in clinics as biomarkers. 
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1.17 Introduction to Prohibitin 
An insight into unveiling mechanisms involved in AIPC could be due to the down-
regulation of the AR co-repressors. This thesis will study the role of PHB1 (will be 
referred to as PHB throughout the thesis) as a co-repressor of the AR.  
Ubiquitously expressed, PHB also known as B-cell-receptor-associated protein 32 (BAP 
32) and its homologue PHB2 (BAP 37) are evolutionally conserved proteins expressed 
in an array of eukaryotic organisms (74).  Remarkably, the sequence of PHB is 
extremely conserved across species spanning from yeast up to the rat species.  The 
mouse and rat’s PHB protein-coding sequence is virtually identical with the human 
sequence with a differing of one amino acid (75). The PHB gene was first identified in 
the 1980s by McClung’s research group, through a screening of potential tumour 
suppressor genes.  It was here that PHB was seen to carry out anti-proliferative 
functions and thus acknowledged as possessing tumour suppressor characteristics (76).  
Although the cellular functions of PHB have been recognised in aging, inflammation 
and obesity, the molecular functions of PHB in carcinogenesis is still to be fully clarified 
(77). Figure 1.6 shows a schematic representation of the PHB gene.   
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Figure 1.6. Image displaying schematic representation of the human PHB protein. N = N terminal, C = 
C terminal, adapted from: (78).  
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The PHB gene is located on chromosome 17q21 and consists of two alleles. One allele 
expresses an exon 6 associated single strand conformation polymorphism (SSCP) 
identified by cleavage at a polymorphic intronic EcoRI site.  The second allele is not 
similarly cleaved (76).  The PHB protein has molecular weight of 32kDa and comprises 
of 272 amino acid residues. PHB belongs to a family of proteins which have an 
evolutionary conserved prohibitin-like domain, otherwise known as band-7 family of 
proteins along with a transmembrane domain at the N-terminus and a coiled coil-
domain at the C terminus (76).  The structure of the PHB protein lacks motifs 
characteristic for signal transduction, nuclear localisation, ATP binding sites or 
transcriptional factors (76).   
1.18 Cellular location of prohibitin 
1.18.1 Mitochondrial prohibitin  
The role of PHB was first seen in the mitochondria in a C. elegans model, whereby loss 
of PHB resulted in fragmentation and disorganisation of the mitochondria when 
compared to control mitochondria, which appeared to be elongated and well structured. 
Indeed in mammalian cells the staining for PHB is predominantly mitochondrial, 
therefore is it often classified as a mitochondrial marker.  Correspondingly, PHB can 
also partake within the dynamics of the mitochondria.  For example, stomatin-like 
protein (SLP-2) can associate with PHB within the inner mitochondrial membrane to 
form specialised membrane micro-domains that are associated with optimal 
mitochondrial respiration (79, 80). Upon depletion of SLP-2 in HeLa cells, proteolysis 
of PHB1 and PHB2 ensued, suggesting PHB stability is dependent upon SLP-2 during 
mitochondrial stress [41] that is of particular relevance as SLP-2 holds importance in the 
biogenesis and activity of the mitochondria (81).  
The PHB protein complex found within the mitochondria embodies two subunits that 
physically associated with one another, namely PHB1 and PHB2 (74).  Both subunits 
share more than 50% identical amino acids (77). Upon deletion of PHB2 gene, PHB1 is 
also reduced suggesting that they are mutually dependent on one another for stability. 
The loss of PHB1 causes disruption of the mitochondrial structure, which is evidenced 
by the loss of PHB2 resulting in the deterioration of OPA1 (optic atrophy 1) (82). 
OPA1 has a specific function in governing the formation of mitochondrial cristae and 
resides with the inner mitochondrial membrane.  The interaction between PHB and 
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OPA1 was proved by PHB depleted MEF (mouse embryonic fibroblast) cells showing a 
highly similar fragmentation pattern which was also seen in OPA1 down-regulated 
MEF cells (82). The C-terminal coiled coil-domain is responsible for the interaction of 
the two subunits, PHB1 and PHB2, which together form heterodimers (83). These 
heterodimers organise into ring like structures that establishes the integrity of the 
mitochondrial structure and regulates mitochondrial function (76).  PHB1 and PHB2 
affix into the inner membrane of the mitochondria via hydrophobic stretches at the N-
terminal (77). In the yeast model, PHB1 transports into the mitochondria, combines 
with Tim8/13 complexes (translocase of the inner membrane proteins) allowing the 
biogenesis of transmembrane proteins in the intermembrane space of the mitochondria 
(78). Moreover, PHB functions as a chaperone for newly made proteins, which form 
parts of the mitochondrial complex 1 (84).  PHB can also act as a scaffold, enlisting 
membrane proteins into a lipid environment, essential for mitochondrial morphogenesis 
(82). The localisation of PHB within the mitochondrial membrane may hold importance 
in preventing apoptosis in yeast and mammalian cells, against metabolic stress (58).  
Accumulating evidence suggests that PHB1 also plays a role in preventing oxidative 
stress in an array of cell lines.  For example, oxidative stress occurring in the intestinal 
epithelial cells causes a drop in PHB1 levels and also in ex vivo lung tissue undergoing 
hypoxia (85). Further, knockdown of PHB1 in endothelial cells produced reactive 
oxidative species (ROS) in the mitochondria, as a result of blockade of the electron 
transport chain (86). Conversely, over-expression of PHB1 in cardiomyocytes served a 
protection against hydrogen peroxide induced injury and maintained the structure 
mitochondrial membrane (75). 
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1.18.2 Nuclear localisation of PHB 
Although the roles and location of PHB have been extensively defined in the 
mitochondria, PHB is also located in the nucleus, depending on cell types (75). 
A study showed that PHB was localised to the nucleus and cytoplasm of LNCaP cells 
(81). In the same study, PHB was consistently expressed in the nucleus of cultured 
human cells, interacting with E2Fs - suppressing their function and causing the 
recruitment of HDAC-1 and N-CoR (81). Further, data from this study suggested that 
PHB translocates from the nucleus towards the mitochondria in response to apoptotic 
signalling occurring in transformed cells as opposed to untransformed cells (81). The 
export of PHB out of the nucleus is slightly more complex, as it is usually bound to 
other proteins such as Rb therefore it is unable to undergo passive diffusion out of the 
nuclear membrane. Instead it exports via short amino acid stretches known as nuclear 
export signals. PHB has a well-defined nuclear export signal, similar to the most 
common type of export sequence seen in the HIV virus and type 1 rev protein (87). 
This sequence classically has a core of large hydrophobic amino acids that are 
recognised by the CRM-1 export receptor (88). This receptor aids the nuclear transport 
of PHB, as the removal of nuclear export signals stopped the transport of PHB out of 
the nucleus. PHB was shown to localise in the nucleus in breast cancer cells, and 
localise to the cytoplasm in camptothecin-treated cells (89). This may indicate that PHB 
undergoes transport out of the nucleus upon receiving apoptotic or stress signalling.   
This transportation of PHB out of the nucleus in response to camptothecin seems to 
eliminate its interaction with E2F1 in the nucleus (89). The ability of PHB to translocate 
to various subcellular locations in response to different signals, along with regulating 
E2Fs and P53 raises the idea that depending on the environment it is placed in, it can 
either initiate apoptosis or enhance cell proliferation, which is rather unique.    
Likewise, PHB studies in rat ovaries revealed that PHB translocates from the cytoplasm 
into the nucleus in atretic follicles, germinal vesicle-stage oocytes, zygotes and 
blastocytes. (Thompson et al., 2004) (90) suggests that PHB has a regulatory role in the 
nucleus of theca-interstitial cells in the ovum throughout follicular maturation. This 
could be linked to PHB interacting with steroid receptors such as the AR and ER.  
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Interestingly, the PHB gene is differentially expressed in the ovaries.  Within the ovary, 
PHB is localised to the granulosa cells and oocyte cells. PHB expression that was seen 
within these cell types was higher than when compared to proliferating-cell nuclear 
antigen (PCNA) expression during follicular maturation, suggesting the positive 
correlation with anti-proliferating cells and PHB expression (91).  Similarly, within rat 
testes, expression of PHB was not noted in the mitochondria of actively dividing 
spermocytes (91).   
1.19 PHB and the AR 
PHB is known to interact with proteins that regulate the cell cycle progression and can 
hinder DNA replication in numerous cell types. The role PHB has in PC via interaction 
with the AR is further discussed.  
Gamble et al,. (58), noted that 50% of PHB protein was diminished in LNCaP lysates 
(weakly metastatic), following androgen stimulation for 16 hours.  This was also seen, 
when the metastatic and androgen independent cell line PC-3 was stably transfected 
with the AR. Consequently after androgen stimulation, a 30% decrease was seen in 
PHB protein levels (58).  Moreover, to further demonstrate the interaction of the AR 
signalling pathway and PHB, a study carried out by (Fletcher, 2007) (92) highlighted that 
a decrease in PHB levels either via androgen stimulation or siRNA mediated knock 
down, triggered enhanced growth of xenografts in mice, due to increased AR activity.  
Further, it has to be noted that the down-regulation of PHB by androgens is only partly 
at the transcriptional level, and it is still not understood how this mechanism occurs.  
An alternative study (Ummani et al., 2008) (93) used proteomic analysis to identify 
significant changes in protein expression in needle biopsies of 23 patients diagnosed 
with high probability of PC.  Indeed this confirmed that PHB was recognised as a 
protein with altered expression in PC.  According to (Gamble et al,.) (58) stimulation of 
LNCaP cells transfected with a PHB expression vector with DHT failed to enter the 
cell cycle, with 97% of the cell population remaining in the G1 state, compared to 80% 
of cells entering the cell cycle that were not transfected (58). Further, the importance of 
PHB down-regulation was also assessed. Small inhibitory RNA (si-RNA) oligos 
complementary to either exon 1 of PHB or to the 3’UTR of PHB were designed and 
stably transfected into LNCaP cells. FACs analysis of cell cycle entry highlighted that 
cells with the PHB si-RNA had an increase in cell population entering the S/G2 M 
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phase. Specifically 2% of these cells were seen in this phase when compared to control 
cells, which increased to 10% after DHT stimulation.  
There are no specific DNA binding-motifs of PHB, however chromatin bound PHB 
has been seen.  This chromatin bound fraction, can be displaced upon androgen 
treatment in LNCaP cells, highlighting the dynamic opposing interaction between AR 
activation and PHB bound-chromatin (94). The dissociation of PHB from chromatin 
could either be due to androgen stimulation of the AR, or serum derived growth factors 
allowing the progression of the cell cycle.  PHB closely associates with HDACs and 
HP-1 proteins which are known chromatin modifying proteins.  Knockdown of PHB 
led to more AR-bound chromatin in LNCaP cells in response to DHT treatment.  
Over-expression PHB had the opposite effect, whereby less AR bound chromatin was 
seen  (94). As the down-regulation of PHB is implicated in the progression of the cell 
cycle, it could have a role in the onset and progression of PC, especially in cases where 
the cancer has sensitised to a low androgen environment. However, how the tumour 
acquires a decrease in PHB levels via androgen stimulation still needs to be understood 
(figure 1.7). Moreover, there may also be other mechanisms that completely bypass the 
AR signalling pathway, causing a down-regulation of PHB such as oncomiRs, which 
also needs to be elucidated.  
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Figure 1.7. Mechanism of action of PHB. A, schematic representation of PHB repressing the 
translocation of the AR-DHT complex towards the nucleus, thus transcription of androgen responsive 
genes is halted. B, chromatin bound PHB that usually associates with HDACs is dissociated from the 
chromatin in the presence of androgen.  
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1.20 Mouse PC models  
Further, a study entailing the knockout (KO) of PTEN in a mouse prostate specific 
model showed less PHB transcripts (figure 1.8A). This was envisaged through data 
produced by RNA-seq.  Data was available through personal communications. 
(D.Dart). 
This could unveil mechanisms involved in early PIN as PTEN knockout is the main 
characteristic of this phenomenon.  Figure 1.8B illustrates the quantitative analysis of 
the decrease seen in PHB gene expression in the KO PTEN mouse when compared to 
the wild type. 
Although the role PHB has within PC remains the main focus, it is essential to discuss 
the role PHB has within further cancers.  Thus allowing one to assess any similarities or 
differences PHB has within different cancers, in order to decipher its main mechanism 
of action, particularly in PC pathogenesis.  
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Figure 1.8. Knockout (KO) of PTEN in a mouse prostate specific model. A, PHB transcript for 
wild type and PTEN KO mouse. At each exon the expression of PHB is less in the PTEN KO mouse 
when compared to the wild type n=4. B, Relative PHB expression in wt and PTEN KO mice. Data 
provided by Dr.D.Dart. n=4, p <0.05*.  
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1.21 PHB, breast cancer and the estrogen receptor 
Breast cancer now holds the statistic for being the most common cancer in women 
worldwide (95), with world regions that previously had low breast cancer incidence 
showing increases.  The ER signalling cascade is implicated in more than 70% of 
primary breast cancer. The activation of the ERα by oestrogen intensely increases the 
proliferation and the metastatic potential of breast cancer cells (96). 
Firstly, the homologue of PHB, PHB2, can bind to ERα repressing its transactivation to 
the nucleus, also enhancing the effectiveness of Tamoxifen bound ERα (97). Tamoxifen 
inhibits the interaction between oestrogen and ERα, therefore PHB can enhance the 
function of the standard treatment for ERα positive patients. Within the same study, 
PHB was also identified as an ERα co-repressor in several cell lines such as CV1, MCF-
7 and T47D suggesting PHB’s role is not cell line specific (97). However, a regulator of 
the oestrogen/ ERα signalling pathway known as BIG3 was thought to co-localise with 
PHB2 in the cytoplasm rendering PHB2 unable to repress ERα transcriptional ability 
(98). However to overcome BIG3 repressing PHB2, a dominant negative peptide 
named ERAP was shown to competitively bind to PHB2, preventing its interaction 
with BIG3 thus allowing PHB2 to suppress ERα activity, leading to complete 
suppression of ERα positive breast cancer cell proliferation both in vivo and in vitro (98).  
Additionally, both PHB and PHB2 were shown to repress SRC-3 activation of ERα.  
This is extremely important, as SRC-3 is a known co-activator of ERα and is frequently 
amplified in breast cancer (50). To further confirm this, anti-sense PHB2 RNA causes a 
heightened fold increase in ERα transactivation, highlighting that endogenous PHB2 
dulls the stimulatory effect oestrogen has on ERα.  Although the mechanism to how 
PHB2 counteracts SRC-3’s function still needs to be defined, it is clear that PHB and 
PHB2 compete with SRC-3 for the ERα receptor, causing the recruitment of HDACs, 
suppressing ERα activation (98). To further highlight PHB’s role in oestrogen signalling 
co-repression, knock out of PHB displayed a hypoplastic uterus and impaired U2-
induced uterus proliferation (99). Moreover, during early pregnancy, mRNA levels of 
PHB found in the uterus of mice were heightened by 2-fold 2 days post coitum.   As 
blastocyst implantation occurred 4.5 days post coitum, this high expression of PHB 
prior to the implantation suggests its role in maintaining the implantation status of the 
blastocyst (99). Further, in the same study, treatment of ovariectomized mice with 
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oestrogen resulted in an increase in PHB mRNA transcripts in 6 hours (99). This 
suggests that PHB is a probable target of oestrogen in the uterus.  Overall, there are 
clear results indicating that PHB is an oestrogen regulated gene both in vivo and in vitro.  
1.22 PHB, irritable bowel syndrome and Stat3 
PHB has also been seen to exhibit its function in inflammatory diseases that often lead 
to cancer development (100), especially as it is associated with oxidative stress.  A 
known transcriptional factor Stat3 (Signal transducer and activator of transcription 3) is 
activated via various ligands in an array of tissues. Interestingly, data collected from 
Han, et al., (101) suggests that there is a link between mitochondrial Stat3 and PHB in 
the intestinal epithelium.  It is thought that this interaction prevents mitochondrial 
dysfunction and it is this process that is disrupted in the pathogenesis of Irritable bowel 
syndrome (IBS).  Phosphorylation of Stat3 occurs at serine 727 (S727) that is necessary 
for the mitochondrial function of Stat3 (102). To ensure phosphorylation of Stat3 is 
needed for PHB interaction, a co-immunoprecipitation assay was carried out (101). This 
assay determined that PHB interacts with pS727-Stat3 in the mitochondria of cultured 
intestinal epithelial cell lines and in vivo in mouse colonic epithelium (101). This PHB-
pS727-Stat3 interaction is lowered throughout mitochondrial stress in response to TNF-
α by the means of lowered PHB expression.  However, upon PHB overexpression, 
PHB-pS727-Stat3 interaction is preserved during TNF-α induced stress (103). It has 
been recognised that PHB expression levels are lower in inflamed epithelia of IBS 
patients when compared to healthy controls, signifying that down-regulation of PHB 
may be an event in the early onset of pathogenesis rather than a downstream effect of 
the disease (101). A transgenic model over-expressing PHB in intestinal epithelial cells 
demonstrated an up-regulation of protection against experimental colitis and there was 
notably less oxidative stress present in the colon (101). As previously mentioned, 
mitochondrial dysfunction is a familiar feature seen in cancers due to ROS (104) and 
loss of mitochondrial chaperones such as PHB (figure 1.9).   A recent report showed 
that loss of PHB led to the onset of dysplasia during ulcerative colitis (101). Moreover, 
PHB protein expression found in colonic mucosa was decreased after mice were 
induced with experimental colitis-associated cancer and vis versa (101). Thus it is 
theorised that PHB could potentially prevent the onset of tumours by aiding 
mitochondrial stability.  By targeting Stat3, PHB’s function could be enhanced to 
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regulate mitochondria function that could theoretically aid intestinal epithelial cells 
homeostasis during colitis where PHB is lost.  
  
Chapter I. General introduction 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Schematic representation of the interaction between PHB and pS727-Stat3, stopping stress 
signalling pathway activation.  
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1.23 PHB and cell cycle machinery components in multiple cancers 
There is a complex combination of factors / proteins which regulate the progression of 
the mammalian cell cycle. Members of the Rb family and their downstream targets such 
as members of the E2F family are examples of proteins which are heavily involved in 
the progression of the cell cycle (105). Mis-regulation of these proteins have been 
influenced in the onset of multiple types of cancer (106).  Rb and its family members; 
p107 and p130 repress the G1/S phase transition, however cyclin D phosphorylates Rb 
preventing Rb from binding to E2F, allowing the transition to the S phase to take place 
(105). Studies showed that PHB can bind to all three family members of the Rb family; 
Rb, p107 and p130 with robust efficiency (107). Even though PHB lacks the canonical 
LXCXE motif which most Rb binding proteins have.  However, unlike other Rb 
binding proteins such as cyclin D, PHB does not have a negative effect on Rb’s 
function, instead it heightens its function much like Brg1 protein.   The study also 
found that PHB can bind to the E2F family members 1,2,3,4 and 5 unlike Rb which can 
only bind to E2F1,2,3 (107). This suggests that PHB binds to a domain that is alike 
amongst all the family members of the E2Fs.  It was also shown that PHB could 
suppress the transcriptional activity of E2F1 in T47D cells (107). Furthermore, this 
suggests that PHB binding to Rb is only one mechanism of action, and there is potential 
for mechanisms independent of Rb that allows the suppression of E2Fs by PHB.  
Interestingly, the suppression of E2Fs via PHB cannot be reversed when the adenovirus 
E1A protein is added, however, this is the case with regards to Rb’s suppression of 
E2Fs (107). With regards to Rb, E1A can disrupt the interaction of Rb and E2Fs in the 
activation domain, allowing E2F to be uninhibited.  It is likely that PHB prevents E1A 
from carrying out this function, thus suppression of E2Fs is enabled even in the 
presence of E1A.  Overall, there is an established relationship between PHB, Rb, E2Fs 
and cell proliferation (107). This is supported by evidence showing that PHB lacking an 
Rb binding domain cannot suppress E2Fs nor cellular proliferation.  Specifically, E2F1 
inhibition via PHB occurs through a putative coiled-coil domain, and it is this region 
alone that could hinder the transcriptional activity of E2F1.    
Further studies on PHB could unveil mechanisms associating PHB and the regulation 
of the cell cycle that is vital in uncovering information regarding the initiation of cancer 
(figure 1.10). 
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Figure 1.10. Schematic representation of where PHB binds to E2Fs and Rb, causing the recruitment of 
HDACs.  
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1.24 PHB and miRNAs 
1.24.1 PHB-untranslated region (3’UTR) and miRNAs 
The coding region is 95-100% similar in the PHB gene across species, however the 
3’UTR of the highly conserved PHB gene shows high variability across mammals (table 
1.2). 
Figure 1.11 demonstrates the percentage similarities between species along with the 
genetic differences between them. The variations in the 3’UTR region of PHB across 
species and the multiple miRNA target sites suggest it is widely and variably regulated, 
however this is not the case for the PHB protein, although the UTR could regulate ‘fine 
tuning' of the PHB protein. 
Alignment analyses of PHB’s 3’UTR across mammals indicate there is variation 
amongst mammals (figure 1.11). 
The human PHB 3’UTR gene has an array of miRNA targets with some similarity to 
that of the mouse and rat species (Micro-RNA.org).  
Many of these miRNA targets on PHB’s 3’UTR are classified as oncogenic such as 
miR-27a (108) (figure 1.12). Therefore, theoretically, administration of the PHB-3’UTR 
absent of the PHB protein could act as a miRNA ‘sponge’ (109). 
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Table 1.2. Similarities of PHB-3’UTR sequence across mammalians. 
 
Species Species 3’ UTR 
Similarity (%) 
Coding 
sequence 
similarity (%) 
human chimp 98.93 100 
human mouse 71.44 100 
human rat 68.66 100 
human dog 75.05 100 
human horse 80.36 99.99 
human cow 78.52 100 
human chicken         49.17         99.98 
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Figure 1.11. Phylogram of 3’PHB-UTR genetic differences between mammalian species. Image adapted 
from: (NCBI, aligned in ALGGEN).  
human 0.00302 
chimp 0.0077 
Mouse 0.0555 
rat 0.05 
chicken 0.35419 
dog 0.12072 
horse 0.08206 
cow 0.1191 
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Figure 1.12. miRNA targets within PHB’s UTR in humans, mice and rats. Similar targets are indicated in 
red.  Dissimilar targets indicated in black. miR-27a is androgen regulated, showed to be up-regulated in 
PC (92).  However, miR-205 is down-regulated in PC (110). 
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1.24.2 MicroRNAs and PHB 
MicroRNAs are small noncoding strands of RNA, usually around 25 nucleotides long, 
and can control gene expression by mRNA degradation or inhibition of protein 
production.  Interestingly, microRNA gene locations are often found in cancer 
associated regions or in fragile sites, making them vulnerable to SNPs, thus can acquire 
either oncogenic or tumour suppressive characteristics. It is therefore no surprise that 
microRNAs can become aberrantly activated during prostate carcinogenesis and their 
acquiring of oncogenic characteristics (OncomiRs).   In particular an oncomiR known 
as MiR-27a located on chromosome 19 position p13.1, is encoded by a intergenic 
cluster along with both miR-23a and miR-24-2 (92).  The expression of this particular 
cluster has been modified in numerous cancers such as leukaemia and ovarian cancer. 
Remarkably, its’ function can have opposing effects, for example in hepatocellular 
carcinoma, up-regulation of this cluster can hinder TGFα’s ability to suppress tumour 
growth.  On the other hand, in human embryonic kidney cells, it can up-regulate 
apoptosis. It is probable that post- transcriptional modification plays a role in these 
clusters’ alternative functions within different cellular environments and also on 
differing gene targets (92).  With regards to miR-27a, it was shown by Fletcher, et al., 
2012 (92) that this microRNA upon androgen stimulation down-regulates PHB 
expression, allowing target gene expression and PC cell growth.  It was predicted that a 
binding site for miR-27a was found within the highly conserved 3’ UTR of the PHB 
gene.   This was confirmed by a luciferase assay, which confirmed down-regulation of 
this UTR in response to androgen treatment, suggesting this region’s susceptibility to 
androgen-regulated miRNAs that attach to this position, hindering its activity.  Silencing 
of the AR, resulted in increased PHB activity. It was indeed established by (92) that 
PHB down-regulation was due to miR-27a binding to the 3’UTR PHB region. The 
mechanism behind this was said to be due to degradation of the PHB gene transcript 
rather than post-transcriptional inhibition. To demonstrate that miR-27a possesses 
characteristics of an oncogene, manipulation of miR-27a caused an upsurge in androgen 
responsive genes such as PSA and TMPRSS2 (92).  Several other targets of miR-27a 
have been identified such as the tumour suppressor gene FOXO1, ZBTB10, a repressor 
of the Sp family of transcriptional factors and Wee-1 a vital regulator of cyclin B.  This 
highlights the potent oncogenic attribute that miR-27a does indeed have.  It is likely that 
miR-27a only fine tunes PHB protein expression rather than causing complete 
reduction, and it is likely that miR-27a targets other genes associated with cell 
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proliferation resulting in growth stimulation (92). Mechanisms understanding the 
androgen regulation of miR-27a were established by Fletcher et al,. 2012 (92).  Firstly, 
the expression cluster region of the primary transcript primiR-23a27a24-2 was shown to 
rise quickly after androgen treatment and then fall, signifying androgens initially 
stimulate a high amount of primiR levels.   
1.25 PHB in other cancer types  
PHB has been showed to have an implication in PC and breast cancer, a functional role 
has also been noted in ovarian and bladder cancer.  Firstly, in line with PHB aiding 
apoptosis, it was noted that up-regulation of PHB was seen in normal ovarian cells 
undergoing apoptosis in the presence of gonadotropin releasing hormone (GnRH) 
(111).  As this was seen in the mitochondria, this emphasises that PHB is maintaining 
the mitochondrial integrity and loss of PHB may be associated with defective apoptosis 
in ovarian cancer.  This may be the reason why PHB accumulation was seen in the peri-
nuclear and cytoplasmic regions in the epithelial cells in papillary serous ovarian tumour 
cells (111).  On the other hand, in bladder cancer PHB up-regulation was shown to be 
associated with the proliferation of bladder cancer cells through PHB1’s 
phosphorylation at thr258 by AKT (112).  In the same study it was also observed that 
up-regulation of PHB, at both a transcriptional and translational levels, in bladder 
cancer tissue were associated with poorer bladder cancer prognosis when compared to 
normal adjacent urothelial tissue (112). PHB phosphorylation has also been observed in 
response to insulin signalling causing PHB to interact to a lesser extent with PIP3 (113).  
This may disrupt PHB’s ability to attenuate the PI3K pathway, which often is aberrant 
in cancers (113). 
As there is an accumulating amount of evidence to suggest that the down-regulation of 
PHB could be a mechanism involved in androgen independent PC, this thesis will focus 
on unveiling the mechanism involving PHB in PC.  
 
 
 
Chapter I. General introduction 
57 
 
1.26 Post-translational modifications of PHB 
1.26.1 Phosphorylation sites of PHB 
Phosphorylation is an essential process involved in post-translational modification. 
However, improper phosphorylation such as hyper-phosphorylation and de-
phosphorylation due to aberrant phosphorylation cascades can lead to the onset of 
carcinogenesis.  Interestingly, PHB1 and its homologue PHB2 were found to be 
phospho-proteins via orthophosphate labelling in T lymphocytes. Further, Ande et al,. 
2009 (114) showed that PHB was found to be serine phosphorylated, whereas PHB2 
was both tyrosine and serine phosphorylated.  Tyrosine phosphorylation of PHB2 was 
mapped to Tyr248.  As these studies demonstrate that PHB and its homologue PHB2 are 
phosphorylated at different residues, this may relate to their differing functions that they 
carry out (114).   Table 1.3 summarises the phosphorylation sites of PHB. Figure 1.13 
illustrates phosphorylation sites of both PHB and PHB2 within different cell types.  
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Table 1.3. Summary of phosphorylation sites of PHBs (114).  
 
Context Protein Phosphorylation 
site 
Known kinase Function 
C2C12 PHB 
Tyr114, Tyr259 
 
Receptor tyrosine 
kinase 
Cell signalling 
MiaPaCa-2 PHB Thr258 AKT Regulation of 
PHB function 
T cells PHB Ser (specific site not 
known) 
Not identified Mitochondrial 
homeostasis and 
survival of T cells 
T cells PHB2 Ser(specific site not 
known) 
Not identified Mitochondrial 
homeostasis and 
survival of T cells 
Granulosa cells PHB Not identified Not identified Cell proliferation 
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Figure 1.13.  Sequence alignments of PHB and PHB2 from human, rat, mouse and Drosophilia 
demonstrating tyrosine residues in the PHB protein are highly conserved across species.  A, illustrates 
that PHB and PHB2 are highly conserved in humans. B, illustrates that all four Tyr residues are highly 
conserved across all species.  Bold letters indicate probable phosphorylation sites (114). 
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Further investigation of the tyrosine residues that were phosphorylated in response to 
insulin was carried out using Human Protein Reference Database (HPRD) server (114).  
This revealed that it was Tyr114 as insulin and EGF receptors kinase motif. NetPhosK 
1.0 server also identified this residue as a probable phosphorylation site by insulin 
receptor kinase. Further studies revealed insulin stimulation causing Tyr114 
phosphorylation on the PHB protein causes the recruitment of the Shp1 protein (114).  
This is an interesting signaling cascade that necessitates further investigation.   
1.26.2 Ubiquitination of PHB 
Research has suggested that some proteins in the mammalian sperm mitochondria are 
tagged with ubiquitin, a proteolytic peptide that could initiate the destruction of sperm 
mitochondria inside the fertilised oocyte.  A higher molecular weight isoform of PHB 
was identified in mammalian spermatozoa, along with PHB transcripts’ being present in 
rat spermatogenic cells that were no longer present by the time that spermiation was 
completed in the testis.  This could be due to the degradation of PHB by ubiquitin.  
Evidence to support this theory includes the accumulation of ubiquitinated PHB in 
immotile sperm fractions.  This suggests ubiquitin-degradation of defective 
spermatozoa in the epididymis (115).    PHB could be tagged with ubiquitin, within the 
testes, epididymis and in the oocyte cytoplasm.  Ubiquitin tagged sperm mitochondria 
may be hidden by a disulphide bond present during epididymal passage.  However, this 
can then be uncovered by disulfide bond reduction activities during fertilization (115).  
Therefore, exposed ubiquitin-tagged mitochondria may be able to destroy sperm 
mitochondria or aid further poly-ubiquitination of other mitochondrial substrates.  
Ubiquitin-tagged PHB could initiate the signal given during the degradation of sperm 
mitochondria by the oocyte proteolytic degradation system.  Further research into the 
mechanism of PHB ubiquitination in sperm mitochondria could unveil explanations to 
male infertility (115).  
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1.27 The cell cycle 
1.27.1 Overview of the cell cycle  
Requirements of cell division include DNA replication and the segregation of replicated 
chromosomes into two distinct separate cells (116). Cell division can be divided into 
mitosis and interphase.  Interphase is then further subdivided into several stages known 
as G1, S, and G2. The G1 phase precedes the S phase where preparation of DNA 
synthesis occurs (116). The G2 phase follows on where the cell prepares for mitosis to 
begin.   Interestingly, cells that are in G1 are able to exit the cell cycle and to enter the 
G0 phase instead of continuing with DNA replication.  The majority of non-
proliferating cells in the body remain in this phase (116). 
1.27.2 Regulation of the cell cycle 
Revolutionary studies in yeast have provided the key elements that regulate the cell 
cycle.   In yeast, a single cyclin dependent kinase (CDK) controls the cell cycle, 
specifically cdc28 in Saccharomyces cerevisiae and Cdc2 in Schizosaccharomyces pombe (116). 
Through the process of evolution, the number of cyclins and CDKs identified has 
increased.  On the contrary, only a few key cyclins and CDKs are responsible for the 
regulation of the cell cycle (figure 1.14).  
 The ‘classical’ model of the cell cycle states that specific CDK-cyclin complexes are 
responsible for events to take place during interphase in a methodical order (116).  
Firstly, mitogenic signals are received by D-type cyclins that favourably bind CDK4 and 
CDK6 causing their activation in the G1 phase.  The G1 phase is responsible for the 
preparation of DNA synthesis.  The activation of these complexes causes the partial 
inactivation of pocket proteins such as Rb and RbL1 (116).  This allows the expression 
of E-type cyclins such as cyclin E1 and cyclin E2 that bind to CDK2 causing its 
activation.  This stable complex of cyclin E-CDK2 subsequently causes the complete 
inactivation of pocket proteins.   The expression of E-type cyclins is restricted to the 
early phase of DNA synthesis (116). This leads to the assumption that CDK2-cyclin E 
complexes are essential for the G1/S phase transition.  Further in the later stages of 
DNA replication, CDK2 is next activated by cyclin A2 driving the S/G2 phase. To end, 
CDK1 is activated by A-type cyclins to aid the onset of mitosis, during nuclear envelope 
breakdown, A-type cyclins are destroyed, allowing the formation of CDK1-cyclin B 
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complexes.  These CDK1-cyclin B complexes are the driving force for the remainder of 
mitosis (116). 
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Figure 1.14. Each stage of the cell cycle is regulated by a specific cyclin-CDK complex.  M=mitosis. G1-
G2=interphase.  Image adapted from (44).  
 
  
The cell cycle 
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1.27.3 Cell cycle inhibitors 
The activity of CDKs can be hindered by certain cell cycle inhibitory proteins known as 
CDK inhibitors.  There are two well-defined groups of these inhibitors namely; the 
INK4 family and Cip/Kip family (116). The INK4 family compromises of p15, p16 and 
p18 that target CDKs by preventing the binding of cyclins involved in G1 only.  
Whereas the Cip/Kip family include p21, p27 and p57, that all share a conserved N- 
terminal domain. They inhibit the G1 CDKs and to a lesser extent CDK1-cylin B 
complexes.   p21 is also known to constrain DNA synthesis by binding to the PCNA 
(116). p21 contains a binding site for p53 in its promoter region.  p21 is therefore under 
the transcriptional control of p53, the well-known tumour suppressor that is inactivated 
in more than half of all sporadic cancers (117).  In contrast to p21, p27 expression is 
usually higher in mitogen starved cells and is quickly destroyed as the cell cycle proceeds 
(118).    
1.27.4 The cell cycle and cancer 
There is an extensive amount of literature that confirms the deregulation of the cell 
cycle in cancer biology.  Through an accumulation of numerous mutations, tumour cells 
can acquire a resistance to anti-proliferation signals, resulting in unrestrained 
proliferation activity.  Moreover, most tumours gain genomic instability (GIN) that 
leads to further mutations and chromosomal instability (CIN) (116). Altogether, un-
regulated proliferation, GIN and CIN all lead to the deregulation of the cell cycle. These 
factors in some way are mediated by the disruption of CDKs.     
1.27.5 E2Fs 
Accumulating evidence has led to the discovery that E2Fs are involved in cell cycle 
control.  E2Fs are a large family of transcriptional factors that contain one or more 
conserved DBD.  These DBDs are responsible for targeting promoters and regulating 
expression of certain genes.  The Rb pocket protein and its close relatives p107 and 
p130 are able to directly interact with E2Fs, suppressing their ability to promote gene 
expression. Evidence of RB inactivation in numerous transgenic animal models has 
shown unregulated control of E2F activity that stimulated aberrant cell proliferation 
(119).     
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Since the discovery of the founding member of the E2F family, E2F1, seven more 
genes have been identified in mammals. The unearthing that over-expressing E2F 
activators led to cells in G0 phase entering G1 phase led to the idea that E2Fs play a 
role in cell cycle progression and target genes involved in DNA replication (119).   
Members of the E2F family contain both transactivation and repression domains, thus 
are able to carry out both activation and repression functions.  For example, in order for 
the activation of transcription, E2Fs are able to form complexes with histone acetyl 
transferases (HAT), whereas when bound to pocket proteins such as Rb, E2Fs can carry 
out a repressive activity by interacting with HDACs (120).   
There are at least three subtypes of E2Fs.  Firstly activating E2Fs: E2F1-3 are well 
described as promoting progressing of the cell cycle through the S phase when Rb is 
inactivated.  Second repressing E2Fs; E2F4-5 that cause the inhibition of E2F 
responsive genes by forming a complex with Rb family members.  Finally, E2F6-8 work 
independently of Rb causing the inhibition of the transcription of E2F target genes.   
Further, it has been found that E2F7-8 are able to form heterodimers and homodimers 
with one another suppressing the activity of E2F1 (119). 
E2F1-6 are able to bind to DNA by forming heterodimers by interacting with a 
dimerization partner such as DP-1/DP-2 (119).The newer members of the family, 
E2F7 and E2F8 do not need to bind to either DP-1 or DP-2 (119). There is 
controversy to suggest that E2F1-3 are solely activators as they are able to bind to Rb, 
suppressing gene transcription.  Especially as E2F1 was first identified to associate with 
Rb (119). Therefore, one should not distinctly characterise E2Fs into repressors and 
activators as there appears to be some cross over.  However there seems to be a clear 
difference in the structure between the two groups.  For example, E2F1-3 contain their 
own nuclear localisation signals.  On the other hand, E2F4-5 carry nuclear export 
signals and reside in the nucleus when bound to pocket proteins (119). Figure 1.15 
shows how E2Fs are able to progress once the AR causes PHB to dissociate from E2Fs 
alongside Rb.  
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Figure 1.15. The release of PHB when the AR signalling pathway is activated with hormone, allowing 
transcription of E2Fs, leading to cell cycle progression. 
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1.27.6 Transcriptional targets of E2Fs 
Several microarray studies have demonstrated that E2Fs can regulate a variety of genes 
involved in many cellular processes such as metabolism and differentiation (121). 
Interestingly, they have also been identified to regulate the transcription of genes 
involved in DNA repair, mitosis and the spindle checkpoint.  Moreover, E2Fs are able 
to regulate genes involved in apoptosis and DNA damage checkpoints (121). The 
simple model of the Drosophilia fly has made an ideal system to analyse the genome wide 
targets of the E2F and Rb protein.  Interfering RNA (RNAi) was used to knockdown 
one activating E2F and one inhibitory E2F. Surprisingly, very few genes were affected 
by this, suggesting that genes are mostly affected by increasing activating E2F, or 
decreasing repressing E2Fs as a single event rather than in synergy (121).  Genes found 
to be regulated by decreasing the activating E2F were largely involved in the cell cycle, 
DNA replication, mitosis and chromosome segregation.   Assessing genes regulated in 
the repression of inhibitory E2Fs were found to be involved in cell development as 
opposed to cell cycle, including male and female specific genes (121).  Table 1.4 displays 
various gene targets of E2Fs.   
1.27.7 Rb 
It is well known that Rb is critical in hindering the progression of the G1 and S phase, 
acting as a tumour suppressor thus playing a pivotal role in cell proliferation.  The 
activity of Rb can act independent or dependent of E2Fs (121). Recently, it has been 
noted that Rb can send signals from damaged DNA machinery to cell cycle machinery 
to prevent proliferation in the presence of DNA damage (121).   
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Table 1.4. E2F gene targets in the G1, S/G2 and DNA synthesis and replication stages  
(122). 
 
 CELL CYCLE 
STAGE 
DNA SYNTHESIS AND REPLICATION 
 
 
CCDND1 
ASK 
  
 CCND3  CDC14B   
G1 JUN  CDC45L   
 MYC  CDC6   
 MYCN  CDC7L1   
  
  
  
G1/S CCNE1  DCK   
 CCNE2  DHFR   
 CDC25A  DUT   
 CDK2  LIG1   
 E2F1  MCM2   
 E2F2  MCM3   
 E2F3  MCM4   
 NPAT  MCM5   
 MYB  MCM6   
 MYBL2  MCM7   
 TFDP1  ORC1L   
S/G2   PCNA   
 AURKB  POLA   
 CCNA1  POLA2   
 CCNA2  POLD1   
 CDC2  PRIM2A   
 CDC20  RFC1   
 CKS2  RFC2   
 HEC  RFC3   
 KI-67  RFC4   
 KIF4A  RPA1   
 KNSL4  RPA2   
 PLK  RPA3   
 PRC1  RRM1   
 SMC2L1  RRM2   
 SMC4L1  TK1   
 STK12  TOP2A   
   TYMS   
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1.27.8 Regulation of G1/S phase  
Throughout G1, the expression of Rb varies; in the earlier stages of this phase p130 and 
p107 are highly expressed and associate with E2Fs.   For gene expression during the S 
phase, the Rb family of proteins recruit chromatin remodelling factors such as HDACs 
and the SWI/SNF chromatin remodelling complex (121).  It is known that high levels 
of cyclin E are found during the G1-S transition, therefore Rb is needed to recruit 
HDACs in cyclin E transcriptional initiation sites.   Rb can also bind to other chromatin 
remodelling proteins such as Brg1/Brm that are ATP dependent helicases (121).  Rb 
can cause the enlistment of Brg1 to cyclinA promoters stopping its interaction with 
E2Fs.   Regulation of E2F activity by Rb can also be mediated by Rb forming a 
complex with DNA methyltransferase 1, resulting in the methylation of chromatin 
(121). Dissociation of Rb occurs during the end of the G1 phase as cyclinD/CDK4 
endorses the hyper-phosphorylation of Rb family members, causing the dissociation of 
Rb from E2Fs permitting the progression of S phase (121).   Working independent of 
E2F, Rb can associate with genes involved in DNA replication such as MCM7, 
enhancing the idea that Rb plays a role in DNA replication (121). 
Finally, Rb is implicated in senescence.  Under cellular stress, levels of p16 are 
increased, heightening the function of Rb. This results in irreversible repressive 
heterochromatin due to chromatin reorganisation at loci containing E2F targets causing 
exit from the cell cycle (121).   
1.27.9 MCMs 
Minichromosome maintenance (MCM) proteins were discovered in the 1980s as being 
necessary for DNA replication and gene targets of E2Fs.  They carry out helicase 
activity essential for replication elongation.   They also participate in other chromosomal 
activities such as chromatin remodelling, transcription and genome stability (123).  The 
MCM family comprises of 7 members MCM2-8 and are a subgroup of the AAA 
ATPase family.   The structure of MCM family members consists of an ATPase domain 
and a MCM box that spans around 200 residues.  Within the MCM box, two ATPase 
consensus motifs are found, namely walker A and walker B (123). Walker A consists of 
a P-loop as an active site with a lysine residue found in all ATP-binding proteins.  
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However walker B possesses hydrophobic stretches and takes part in ATP hydrolysis.  
Besides the MCM box, there is little similarity between members of the MCM family 
(123). 
1.27.10 Control of DNA replication  
DNA replication is an extremely controlled mechanism that is controlled by members 
of the MCMs gene family (figure 1.16). The ring structure that MCM proteins form has 
a central pore that accommodates DNA.  In the initial stages of the S phase, MCMs are 
dispersed onto un-replicated DNA, where it is thought MCMs fasten to the nuclear 
matrix during the S phase, acting as rotating molecular pumps.  As DNA replication 
advances, CDKs phosphorylate MCMs, freeing them from DNA.  The free MCMs 
continue to reside in the nucleus and remain so until early mitosis (124).  They are able 
to re-bind to chromatin during late M/G1 phase ready for the next G1 phase.  The 
expression of MCMs proteins remains constant throughout the cell cycle in the nucleus.  
Their recruitment to the chromatin is regulated by CDK activity.  The origin 
recognition complex proteins (ORC) aid both CDC6 and CDT1 (MCM loading factors) 
that resides on the chromatin to form a pre-replication complex.  As the S phase 
proceeds, CDC6 and CDT1 are phosphorylated causing their displacement from the 
chromatin.   CDC6 is exported to the cytoplasm whereas CDT1 is degraded in the 
nucleus (124).   
1.27.11 MCMs as cancer biomarkers 
As the cell cycle is often deregulated in cancer, MCMs are being analysed as biomarkers 
of cancer.  For example, the appearance of MCM positive cells in pre-invasive cervical 
lesions was higher with increasing histological grade (124).  Moreover, disruption of 
MCM expression was also noted in a range of other malignancies such as colorectal and 
ovarian cancer (124).  So far, Ki67 is used as a proliferation marker, however is 
ineffective in a clinical setting as it is not as sensitive as MCMs at detecting cells in cycle.  
MCMs may work better as a biomarker as they are easily stained as their localisation 
remains in the nucleus, are more abundant and their expression during the cell cycle is 
unvarying (124).   Interestingly, immunohistochemical staining of MCMs has become a 
useful tool in deciphering survival in patients with breast and prostate cancer (124).  
Moreover, microarray analysis has identified genes that encode for MCMs to be up-
regulated in malignant cancers (124).  These genes have also been associated with poor 
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clinical outcome for breast cancer and mantle cell lymphoma.  However, there is not 
one single MCM that is being overexpressed, rather a few members such as MCM2, 
4,5,6 that all work together to form a ring like structure (124).   
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Figure 1.16. Initiation of DNA replication involving ORCs and MCMs, image taken from Tabancay, et 
al., 2006 (125). 
 
  
 
  
Chapter I. General introduction 
73 
 
1.28 Summary of key points 
PC if diagnosed at an early stage has a good prognosis. However, in many cases patients 
relapse with anti-androgen treatment currently used in clinics.  The cancer usually 
relapses with a more aggressive phenotype that has sensitised to a low androgen 
environment, thus is no longer dependent on androgens. This is where current 
treatment fails, as the cancer is able to survive in the apparent absence of androgen.  
Aberrant AR pathway activation is essential for the progression and survival of PC.  As 
down-regulation of PHB is seen in more aggressive and metastatic PC, this allows the 
AR’s activation threshold to lower, resulting in minimal androgen stimulation required 
to stimulate the cascade. Moreover, non-specific androgens such as adrenal androgens 
are capable of activating the AR.  This can progress the cancer from an indolent stage to 
a metastatic stage.   
PHB has been identified to increase the efficacy of breast cancer treatment by 
increasing the amount of Tamoxifen bound to ERα.  This highlights PHB’s ability to 
hold steroid receptors in an inactive state.  Moreover, PHB was able to directly repress 
E2F1 in breast cancer cells, depicting PHB’s role in rendering the cell cycle inactive.  
Therefore it was further investigated if PHB was able to carry and the same repressive 
role on E2Fs and E2F downstream targets such as MCMs in PC cells.  This could aid 
eluding a mechanism that explains how PC transitions from androgen dependence to 
androgen independence.   
This leads onto my aims and hypothesis.   
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1.29 Aims and hypothesis 
1.29.1 Hypothesis 
Androgen activation of the AR rapidly causes PHB to dissociate from the chromatin, 
leading to PHB’s downregulation, allowing cell cycle progression in PC cells.  
1.29.2 Aims 
 To understand the mechanism of PHB induced cell cycle arrest. 
 To understand the dynamics of AR:PHB interaction. 
 To understand how the rapid actions of androgens affect PHB.  
 To understand how activation of the AR is causing PHB to dissociate from the 
chromatin.  
 To provide a preliminary mechanism to how PHB’s tumour suppressive 
function is lost in aggressive PC.
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2 Chapter II. Materials 
2.1 Cell culture 
The parental LNCaP cell line was obtained from the American Type Culture Collection 
(ATCC CRL-1740).  The LNCaP cell line was cultured in RPMI medium (Sigma), 
supplemented with 10% (v/v) FBS (Clontech) and 1% (v/v) antibiotics (penicillin-
streptomycin 10,000U/mL (Sigma)). The LNCaP cell line modified to over express 
PHB under the influence of tetracycline (Doxycycline) (10 mM) (LNCaP/TR2/ PHB) 
was developed by Dr Alwyn Dart (58). Refer to figure 3.2 for how the cell line was 
made.  The LNCaP/TR2/ PHB cell line was cultured in RPMI supplemented with 10% 
(v/v) tet-free FBS (Clontech) and 1% (v/v) antibiotics. The PC3 cell line (ATCC CRL-
1435) and VCaP cell line (ATCC CRL-2876) were obtained from the American Type 
Culture Collection. COS-7 cells (ECACC 87021302) were obtained from the European 
Collection of Authenticated Cell Cultures. PC3, VCaP and COS-7 cells were cultured in 
DMEM media supplemented with 10% (v/v) FCS and 1% (v/v) antibiotics (penicillin-
streptomycin 10,000U/mL).  Bicalutamide-resistant LNCaPs (developed by Dr Dart) 
were made by growing wt LNCaP cells for 6 months in varying concentrations of 
Bicalutamide (0, 10, 20, 30 μM) until growth was established.  20 μM was the chosen 
concentration as cells were not healthy with the highest concentration (30 μM).    
2.2 Primers 
Primer sequences used for the SYBR® Green Q-PCR are shown in table 2.1. In cases 
where the entire coding sequence was amplified, the primer sequences are shown in 
table 2.2. All primers used were obtained by Sigma-Aldrich and diluted according to the 
datasheet provided and were stored at -20˚C.   
2.3 Antibodies  
Primary antibodies used are described in table 2.3. Secondary antibodies used were 
either horseradish peroxidase (HRP) conjugated anti-mouse (A9044) or anti-rabbit 
(A0545) IgG antibodies (Sigma-Aldrich).   
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2.4 Standard reagents and solutions 
2.4.1 General laboratory used materials 
0.05% DEPC water (Diethylpyrocarbonate)  
250 μL of DEPC was added to 500 mL of distilled water, left for 24 h and then 
autoclaved. 
PBS (phosphate buffer saline)  
A 10X stock of PBS (Sigma-Aldrich) was diluted to a 1X stock in distilled water.  This 
was then autoclaved and aliquoted accordingly.  
2.4.2 Materials used for cell culture 
Trypsin-EDTA  
10X Trypsin-EDTA (Sigma-Aldrich) was diluted to a 1X solution with PBS.  
Antibiotic antimycotic solution  
100X antibiotic antimycotic solution containing 10,000 units penicillin, 10 mg 
streptomycin and 25 μg of amphotericin B per mL was diluted to 1X using distilled 
water (Sigma-Aldrich). 
Charcoal stripped RPMI 
In experiments entailing the serum starvation of cells, 25 mL of charcoal stripped FCS 
(Clontech) was added to 500 mL of phenol-red free RPMI (Sigma-Aldrich) 
supplemented with 5 mL of antibiotics.    
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TET-free FBS 
The tetracycline inducible cell line; LNCaP/TR2/ PHB was cultured with 50 mL of 
tetracycline-free FBS (Clontech) in 500 mL of RPMI supplemented with antibiotics.   
2.4.3 1D and 2D-western blot materials  
Lysis buffer 
For 100 mL:  0.61 g 50mM TRIS base + 0.19 g 5mM EGTA + 0.87 g 150mM NaCL + 
1 mL 1% Triton X-100 (Melford Laboratories, UK). Upon use, a protease inhibitor 
cocktail tablet (Roche) was added and the solution was aliquoted and stored at -20˚C.  
10% APS (ammonium persulphate) 
1 g of APS (Melford Laboratories Ltd, UK) was dissolved in 9 mL of distilled water and 
stored a 4˚C. 
TBS (Tris buffered saline)  
10X TBS (Sigma-Aldrich) was diluted to 1X using distilled water. 
Running buffer 
1 L of 10X Tris Gycline SDS buffer (Sigma-Aldrich) was added to 9 L of distilled water. 
Transfer buffer 
1 L of 10X Tris/Glycine concentrate buffer (Sigma-Aldrich) was added to 2 L of 
methanol (Fisher Chemical) and 7 L of distilled water.  
0.01% TBS-T (TBS-Tween20) 
For the washing solution, 500 μL of Tween20 (Melford Laboratories Ltd, UK) was 
added to 500 mL of 1X TBS and thoroughly mixed.  
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10% SDS (sodium dodecyl sulfate) 
10 g of SDS (Melford Laboratories Ltd, UK) was dissolved in 100 mL of distilled water.   
Rehydration buffer 
19.82 g urea and 3.81 g thiourea was dissolved in 25 mL of distilled water.  Then 0.02 g 
of CHAPS (Sigma Aldrich) was added to 1 mL of this solution and kept at room 
temperature.  
Reducing solution 
0.5 mL of 10X NuPAGE Sample reducing agent (Invitrogen) was added to 4.5 mL of 
1X NuPAGE LDS sample buffer (Invitrogen). 
Alkylating solution 
116 mg iodoacetamide (Sigma Aldrich) was dissolved in 5 mL of 1X NuPAGE LDS 
sample buffer (Invitrogen). 
MOPS running buffer 
40 mL of 20X NuPAGE SDS- MOPS buffer (Invitrogen) was added to 760 mL of 
distilled water to make 800 mL of 1X MOPS buffer.  
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2.4.4 Materials for bacterial transformation  
LB-broth 
8 g LB broth (low salt granulated) (Melford Laboratories Ltd, UK) was added to 400 
mL of distilled water and autoclaved.  400 μL of 100 mg/mL ampicillin (Sigma-Aldrich) 
was added to the autoclaved broth to give a 10 mg/mL ampicillin solution.  
LB-agar amplicillin plates  
LB broth was made according to 2.6.4 with the addition of 6 g of agar (Melford 
Laboratories Ltd, UK).  Once the broth had cooled, the broth was poured in 10 cm2 
dishes to produce LB-agar amplicillin plates.   
2.4.5 Materials for immunoprecipitation and cell fractionation 
IPH buffer 
For 50 mL: 1.88 mL 4M NaCL,  2.5 mL 1M Tris (pH 8), 500 μL 500 mM EDTA,  50 
μL 1 mM DTT, 2.5 mL 10% NP40 and a protease inhibitor cocktail tablet (Roche). 
Buffer A 
For 10 mL: 100 μL 10 mM HEPES (pH7.9), 33 μL 10mM KCL,  15 μL 1.5mM MgCl2, 
1.16 g (0.35M) sucrose, 1 mL 10% glycerol, 10 μL 1mM DTT, and a protease inhibitor 
cocktail tablet (Roche). 
Buffer B 
For 10 mL: 60 μL 3mM EDTA, 4 μL 0.2mM EGTA, 10 μL 1mM DTT, and a protease 
inhibitor cocktail tablet (Roche).  
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2.5 Inhibitors, hormones and anti-androgens 
Src-inhibitor-1 (4-(4’-phenox-yanilino)-6,7-dimethoxyquinazoline) (Sigma-Aldrich) was 
used at a working concentration of 10 nM (stock concentration 10 mM diluted in 
DMSO).  MDV3100 (Enzalutamide) was used as a working concentration of 10 μM. 
Bicalutamide (CDX Sigma-Aldrich) was diluted in DMSO to produce a stock 
concentration of 10 mM, and used at a working concentration of 10 μM.  R1881 ((17b)-
17-hydroxy-17-methyl-estra-4,9,11-trien-3-one) (Sigma-Aldrich) was diluted in 100% 
ethanol to produce a stock concentration of 10 μM.  The working concentration used 
was 10 nM.  Ethanol (100% v/v) was used as the vehicle.    
Chapter II. Materials and Methods 
82 
 
Table 2.1. Primer sequences used for the SYBR® Green Q-PCR. 
 
Oligo 
Name 
Sequence (5’-3’) 
MCM2F TGCTATGGCGGAATCATCGG 
MCM2R GAGGTGAGGGCATCAGTACG 
MCM3F AGTCATCCTGGGAACCTCCA 
MCM3R TGTTCAGAAGCCTCGTCGTC 
MCM4F CCAGACGCCTCGGAGTGA 
MCM4R TTGGCATCGGCTGCAACT 
MCM5F CACCAAGCAGAAATACCCGGA 
MCM5R GCGAGTCCATGAGTCCAGTG 
MCM6F AGTAAAACGGGGTGTCCTGC 
MCM6R TCCTCCACGTGCTTGAGAAAT 
MCM7F CAGGAGCAAGACCTCTGAGC 
MCM7R ACCTTTTCCTTCTCTAGCGCGT 
MCM8F TGAAGAAGCACAGGAGAGATGA 
MCM8R CCTGAGAAGTTCCCACCACC 
MCM9F GGATCCTGGCACAGGGAAAT 
MCM10F TCCCCTGTAGAGAAGTCTCCC 
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PHB F GGCTGAGCAACAGAAAAAGG 
PHB R GCTGGCAGGTAGGTGATGTT 
PSA F GTG TGTGGACCTCCATGTTATT  
PSA R ATATCGTAGAGCCGGTGTGG       
GAPDH F TGC ACC ACC AAC TGC TTA CG 
GAPDH 
R 
GGC ATG GAC TGT GGT CAT GAG 
RPL19 F AGC GAG CTC TTT CCT TTC G 
RPL19 R GAG CCT CTT CTG AAG CCT GA  
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Table 2.2. Primers sequences used for amplification of the coding sequence. 
 
Oligo 
Name 
Sequence (5’-3’) 
E2F1 F ATGGCCTTGGCCGGGGCC 
E2F1 R GCCCTGTCAGAAATCCAGGG 
PHB F TGT CAT CTT TGA CCG ATT CCG 
PHB R CTG GCA CAT TAC GTC GTC GAG 
 
Table 2.3. Antibodies used. 
 
Antibody Code Company Dilution 
Prohibitin mouse 
monoclonal IgG 
II-14-10 ThermoScientific 1 in 200 
Prohibitin rabbit polyclonal  
IgG 
28259 Santa-Cruz 1 in 200 
Androgen receptor rabbit 
polyclonal IgG 
816 Santa-Cruz 1 in 200 
E2F1 rabbit polyclonal IgG 193 Santa-Cruz 1 in 200 
GAPDH mouse monoclonal 
IgG 
32233 Santa-Cruz 1 in 2000 
MCM5 rabbit polyclonal IgG 22780 Santa-Cruz 1 in 200 
Polyclonal goat anti-rabbit 
Immunoglobins/Biotinylated 
E0432     Dako           1 in 1000 
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2.6 Methods for cell culture 
2.6.1 Cell culture maintenance 
All cell lines were incubated at 37˚C, 95% (v/v) humidified atmosphere at 5% (v/v) 
CO2 in either a 25cm
2 or a 75cm2 flask.  Media on cells was changed every 3-4 days. All 
cells were regularly checked for mycoplasma contamination using the EZ-PCR 
Mycoplasma Test Kit (Biological Industries, Israel). Gene expression of PSA was 
carried out the LNCaP cell line in starvation media using the SYBR® Green Q-PCR 
technique described in 2.8.3 to validate their androgen responsiveness.    
2.6.2 Detachment of adherent cells and cell counting 
Adherent cells were detached from the plastic using either 1-2 mL of Trypsin-EDTA 
(0.01% trypsin and 0.05% EDTA in PBS buffer).   Cells were left to detach in an 
incubator at 37˚C, until detachment of cells were seen under a light microscope.  5-10 
mL of serum containing media was added to the cell suspension to quench the trypsin.  
10 μL of cell suspension was added to a 0.100mm depth haemocytometer (Neubauer).  
Cells were counted in four separate squares and averaged.   
2.6.3 Freezing cells    
Stocks of cells of a low passage number were stored in liquid nitrogen.  Cells were 
trypsinised according to the protocol shown in 2.7.2.  The cells were centrifuged at 
12,000g for 4 minutes and the cell pellet was resuspended in 1 mL FCS + 10 %DMSO 
(Sigma-Aldrich). This was placed into a Cyro-tube (Grenier Bio-one) that was then 
wrapped in protective paper and stored at -80˚C for 24 hours.  The vials were then 
transferred to a liquid nitrogen tank for long term storage.  
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2.6.4 Resuscitation of cells 
Revival of cells was carried out by thawing cell vials from liquid nitrogen in a warm 
water bath at 37˚C.  The cells were then transferred to a sterile universal tube where 
fresh FCS-containing media was added.  The universal tube was centrifuged at 1,000g 
for 7 minutes.  The supernatant was removed and the cell pellet was resuspended in 5 
mL of fresh FCS-containing media.  The cells were transferred to a 25cm2 flask where 
they were left to seed at 37˚C within the incubator.   
2.6.5 Mycoplasma test (Biological Industries) 
Media from cultured cells was centrifuged at 250 g for two minutes. Next the 
supernatant was centrifuged for 15000 g for ten minutes.  The supernatant was 
decanted and the pellet was resuspended in 25 μL of Buffer solution.  This was then 
heated to 94˚C for three minutes and stored at -20˚C. A PCR was carried out with the 
cycling conditions shown in table 2.4.  The PCR products were then run on a 0.8% 
(w/v) agarose gel to visualise DNA products.  
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Table 2.4. Cycling conditions for mycoplasma PCR. 
 
Stage Temperature   
(˚C) 
Time 
Holding  94˚C 30 seconds 
Cycling (35 cycles) 94˚C 30 seconds 
 60˚C 120 seconds 
 72˚C 60 seconds 
Holding                 94˚C 30 seconds 
                 60˚C 120 seconds 
                 72˚C 5 minutes 
  
Chapter II. Materials and Methods 
88 
 
2.7 Methods for molecular biology 
2.7.1 RNA extraction 
Cells for RNA extraction were lysed in 1 mL of TRI reagent (Ambion) and were 
scraped down into a sterile Eppendorf tube.  0.2 mL of chloroform (Sigma-Aldrich) was 
added and the lysates were thoroughly mixed and left to stand for five minutes.  The 
Eppendorf tubes were centrifuged for 15 minutes at 12000 g.  The top aqueous layer 
containing the RNA was removed and placed into a separate sterile Eppendorf tube.  
0.5 mL of 2-propanol (Sigma-Aldrich) was added to the aqueous solution and shaken.  
Samples were left to stand at room temperature for 15 minutes.  Eppendorf tubes were 
then centrifuged at 12000 g for ten minutes to pellet the RNA.  The supernatant was 
decanted and the RNA pellets were washed in 75% (v/v) ethanol and were centrifuged 
for five minutes at 7500 g.  The ethanol was then decanted and the pellet was left to air 
dry. Once the pellet had dried, the pellet was dissolved in DEPC treated water. The 
samples were measured on an Implen nanophotometer (UK) to determine the RNA 
concentrations (ng/μL).  Samples were either stored at -80˚C or were immediately 
reversed transcribed.  
2.7.2 Reverse transcriptase reaction (RT) 
500 ng of RNA was reverse transcribed (RT) into cDNA with the following protocol: 
OligodT primer (ABI) (1 μL) was added to RNA and water (total 9 μL).  This was 
heated to 65˚C for 5 minutes.  Next 10 μL of the RT mix (ABI) was added.  This was 
heated to 42˚C for 20 minutes followed by 75˚C for 10 minutes.  The cDNA was then 
diluted accordingly.  
2.7.3 Quantitative SYBR® green PCR (Q-PCR) 
Reactions were plated using MicroAmp Applied Biosystems 96 well plates.  Each 
reaction consisted of 2 μL of the desired cDNA and 8 μL of a master mix.  The master 
mix consisted of 5 μL of Sybr® Green PCR master mix (Applied Biosystems), 1 μL of a 
primer mix containing both the forward and reverse primers (2.5pmol/μL) and 2 μL of 
PCR water. Cycling conditions for Quantitative SYBR® green PCR are shown in table 
2.5.  Gene expression was normalised to housekeeping genes (GAPDH, RPL19).  
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2.7.4 Quantitative Molecular beacon PCR (Q-PCR) 
Reactions were plated using MicroAmp Applied Biosystems 96 well plates.  Each 
reaction consisted of 1 μL of the desired cDNA and 9 μL of a master mix 
(Primerdesign).  Table 2.6 illustrates the contents of the master mix.  Table 2.7 
illustrates the cycling conditions. All samples were normalised to GAPDH and RPL19 
gene expression.    
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Table 2.5. Cycling conditions for Quantitative SYBR® green PCR. 
 
Stage Temperature 
(˚C) 
Time 
Holding  95˚C 10 minutes 
Cycling (40 cycles) 95˚C 15 seconds 
 60˚C 60 seconds 
 
Table 2.6. Contents of Quantitative Molecular beacon PCR master mix. 
 
Reagent Amount 
1pM Z reverse primer  0.3 μL  
10pM forward primer  0.3 μL 
Uniprobe 0.3 μL 
Master mix 5 μL 
H2O 3 μL 
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Table 2.7. Cycling conditions for the molecular beacon Q-PCR. 
 
Stage Temperature 
(˚C) 
Time  
Holding  95˚C    10 minutes 
Cycling (100 cycles) 95˚C     10 seconds 
 55˚C      35 seconds 
 72˚C 10 seconds 
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2.8 Methods for proliferation, adhesion and migration assays 
2.8.1 Crystal Violet Proliferation assay 
96 well plates were plated with the desired cell number and left to adhere overnight.  In 
the case of the doxycycline dose dependent curves, the cells were cultured with fresh 
medium with the specific concentrations of doxycycline.  Plates were left for either 24 
hours or 48 hours.  At the specific time point, the media was removed from the wells 
and replaced with 4% (v/v) formalin (Sigma Aldrich) to fix the cells for an hour.  The 
formalin was then washed off gently with tap water and replaced with 0.5% (v/v) 
Crystal Violet solution (Sigma Aldrich) and left for 30 minutes.  The Crystal Violet was 
then washed off gently with tap water and plates were left to dry.  The dye was then 
dissolved in 10% (v/v) acetic acid (Sigma Aldrich). Absorbance was read at 540nm 
using an ELx800 plate reading spectrophotometer (BioTek, VT, USA). 
2.8.2 Scratch assay 
Cells were seeded onto a 24 well plate until a confluent monolayer was formed.  Prior to 
a scratch formation using a p10 pipette tip, the media for each well was changed (1 mL 
each) with and without doxycycline (10 μM) for 24 hours.  In the case of no 
doxycycline, PBS was added as a control.  Once the scratch was made, an image was 
taken of each well to mark time-point zero.  To ensure the same area of the wound was 
being imaged at every time point, several marks were made underneath the plate as a 
point of reference.  Images were taken every hour using a Leica DMI1 microscope.  
Semi-quantification of the wound area was measured using Image J software (National 
Institutes of Health, NY, USA).  
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2.8.3 Transwell filter migration assay 
Cells (500,000) were seeded onto the upper chamber of a 8 μM pore size ThinCert™ 
insert (Greiner-Bio one) in 500 μL of 1% (v/v) FCS RPMI.  The lower chamber of the 
24 well plate contained 1 mL of 10% RPMI FCS to create a chemoattractant gradient.  
Cells were left to migrate for desired time points.  At the correct time point, filters were 
washed with PBS and placed onto a fresh 24 well plate.   An enzyme free cell 
dissociation solution (Millipore) (350 μL) made with calcein AM (Thermo Fisher 
Scientific) (ratio of 1.2 μL: 1 mL) was placed in the lower chamber of the 24 well plate 
and left to incubate at 37˚C for one hour.  The solution was transferred to a black 96 
well plate and Fluorescence was measured using the Glomax multi-detection system 
(Promega) at an excitation and emission wavelengths of 495/515 nm.    
2.8.4 FACS (Fluorescence-activated cell sorting) 
Cells were fixed with 10 mL of 70% (v/v) ethanol and kept at 4˚C.  Cells were stained 
with a propidium iodide/Ribonuclease A (PI/RNase A) solution for 30 minutes.  PI 
was used at a concentration of 50μg/mL and RNase A (Sigma Aldrich) was used at a 
concentration of 100𝜇g/mL. The samples were then run on a FACSCanto II machine 
(BD Biosciences).  Analysis of the data was carried out using FCS Express 4 Flow 
research. Gating for live cells was carried out using the FSC-A (forward scatter area) 
and SSC-A (side scatter area).  FCS-A measures the cell size whereas SSC-A measures 
the cell granularity.  Next gating for single cells was carried out by using the FSC-A and 
FSC-W (forward scatter height) to eliminate doublet cells (figure 2.1).  From this gate, 
the cell cycle histogram was made using the fluorochrome channel PerCP-CY5-5-A 
against cell count.  From here the percentage of cells in G1, S and G2 phase could be 
calculated.  
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Figure 2.1. Gating on FACSDiva version 6.1.3 for fixed cells stained with propidium iodide (PI).   
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2.8.5 Adhesion assay 
In order to create a surface for the cells to attach to, matrigel was set onto wells of a 96 
well plate.  Matrigel was made at a working concentration of 5 μg/100 μL in serum free 
media (stock concentration 9.1 mg/ml). The matrigel was coated onto the wells of the 
96 well plate and left to set at 50 ˚C for 2 hours.  The matrigel was then rehydrated in 
media for 30 minutes, after 30 minutes the media was aspirated off and cells were 
seeded onto the matrigel (45,000 cells/well).  The cells were left at 37˚C in the incubator 
for the desired amount of time.  The media was gently removed and the cells on the 
matrigel were then fixed with 4 % formalin for 30 minutes.  The cells were then stained 
with 0.5 % crystal violet solution for 20 minutes.  The cells were gently washed with tap 
water and left to air-dry overnight.  The cells were visualised using a Leica light 
microscope and pictures were taken using the LAS (Leica Application Suite) 4.4.  Each 
well had 6 pictures taken and the cells seen in the field of view were counted.   
2.9 Method for RNA-sequencing 
2.9.1 mRNA isolation and cDNA synthesis 
The initial stage of RNA sequencing was to isolate polyA mRNA from total RNA, 
using the Dynabeads mRNA DIRECT kit (Life Technologies).  To ensure ribosomal 
RNA was still intact, any degradation of 18S and 20S (ribosomal peaks) in the RNA 
samples was identified using a Bio-analyser-2100 (Aligent). Next, the isolated mRNA 
samples were fragmented using RNAse III and purified to produce a 150-200bp library, 
using the Total RNA-seq kit (Life Technologies).  These fragments were ligated to 
adaptors to allow cDNA synthesis to occur.  The amplified cDNA was carried out using 
the IonXpress RNA-seq 5’ and 3’ barcoded primers. Amplified cDNA was then 
purified and quantified using the Bio-analyser 2100 (Aligent).   
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2.9.2 Template preparation and RNA-seq 
In order to clonally amplify the cDNA library onto Ion Sphere Particles (ISP’s) for 
sequencing, an emulsion PCR was carried out using on an Ion OneTouch2 system and 
the PI template OT2 200 kit (Life Technologies). Template positive ISP’s were 
recovered using an ion torrent machine (Life technologies) and streptavidin Myone 
beads.  Further, the template positive ISP’s were processed using the Ion Proton 200 
sequencing kit and loaded onto a P1 chip.  This chip was then sequenced on an Ion 
Proton (Life Technologies).  The following parameters were used; single end, forward 
sequencing.  Samples were aligned to the human genome (version Hg19). The torrent 
Suite version 3.6 (Life Technologies) was utilised for base calling, adaptor trimming, 
barcode deconvolution, bowtie and cufflinks using STAR aligner.  Data analysis was 
carried out with the Partek Genomic Suite 6.6 (2017 Partek Incorporated).  
Normalisation was carried out via the RPKM normalisation method (126) along with a 
1-way ANOVA test for differential gene expression (n=2).  The procedure is displayed 
in 2.10.3.  
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2.9.3 Overview of RNA sequencing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AAAAA
A 
TTTTT
T 
AAAAA
A 
A 
1) mRNA is captured using polyT beads 
2) mRNA is then fragmented and 5’ and 3’ 
adaptors are ligated to fragments 
3) RT primer binds and cDNA is synthesised 
4) cDNA is amplified and an optional 
barcode primer (green square) is added to 
distinguish between samples 
5) cDNA is captured and amplified on microbeads 
during an emulsion PCR 
6) Captured DNA is now ready to be 
sequenced from the A end to the 
microbead 
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2.10 Methods for protein detection 
2.10.1 Protein extraction 
Cells desired for protein extraction were washed with ice-cold PBS.  For a T75 flask of 
confluent cells, 600 μL of the lysis buffer was added to the cells and left on ice for 10 
minutes.  The cells were then scraped down into a 1 mL Eppendorf tube.  The cell 
lysate was then centrifuged at 20,000g for 20 minutes.  The supernatant containing the 
protein was then transferred to a clean sterile Eppendorf tube ready to be quantified.  
2.10.2 Protein quantification (BSA assay) 
Quantification of protein samples for loading onto a SDS-PAGE gel, was carried out 
using the BioRad DC Protein Assay kit (BioRad Laboratories) against a BSA (bovine 
serum albumin) standard curve. Firstly, a serial dilution of BSA was made, starting with 
the highest concentration of 10 mg/mL down to 0.15625 mg/mL. Each dilution (5 μL) 
was pipetted into a 96 well plate.  Reagent S (20 μL) was added to each mL of reagent A 
(Biorad). This solution (25 μL) was added onto the 5μL of standards and protein 
samples.  Reagent B (200 μL) (Biorad) was then added to each well and left to stand 
until a blue colour developed.   Absorbance was read at 630 nm using an ELx800 plate 
reading spectrophotometer (BioTek, VT, USA). Excel was used to calculate protein 
concentrations using the generated standard curve.  The proteins were diluted to a 
concentration of 20 μg/μL with lysis buffer.  This was then further diluted with 2X 
Llaemeli sample buffer concentration (Sigma-Aldrich) at a ratio of 1:1. The samples 
were then denatured at 95 ˚C for 3 minutes, before loading onto the SDS-PAGE gel.  
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2.10.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The percentage of the gel used was dependent on the size of desired protein to be 
detected. For a 10% resolving gel, table 2.8 depicts the components and volumes used.  
For the 5% stacking gel, table 2.9 depicts the components and volumes used.  Gels were 
set between two glass plates held in place by a loading cassette. Once both the resolving 
gel had set, the stacking gel was prepared according to the guidelines set in table 2.9 and 
a well-forming Teflon comb was inserted and the gel was allowed to polymerise.  The 
loading cassette was then placed into a gel electrophoresis tank filled with running 
buffer.  The comb was removed and the appropriate amount of heat-denatured protein 
was loaded (concentrations of protein determined via BSA assay). 5 μL of a BLUeye 
prestained protein ladder (Geneflow) was loaded as a marker. Samples were 
electrophoresed at 120V for 90 minutes.   
2.10.4 Transfer of proteins onto polyvinylidene fluoride (PVDF) membrane 
Once the SDS- PAGE was complete, a wet transfer was carried out to transfer the 
proteins onto an Immobilon®-P PVDF membrane (Merck Millipore, MA, USA).  Prior 
to transfer, the PVDF membrane was activated in methanol for 5 minutes.  The 
resolving gel was gently removed and placed in transfer buffer, alongside filter papers.  
On the negative side of the ‘sandwich’ cassette, two filter papers were placed onto a 
sponge, the resolving gel was placed onto the filter papers.  This was followed by the 
activated PVDF membrane alongside two more filter papers and a sponge.  Electro-
blotting was carried out at 250mA for 2 hours.  Once transfer was complete, 
membranes were incubated at room temperature in 5 % (w/v) blocking buffer (5 g of 
milk powder (Marvel) in 100 mL of TBS) for 1 hour to ensure non-specific binding of 
the primary antibody.  Membranes were kept on a rolling platform (Wolf Laboratories).  
Chapter II. Materials and Methods 
100 
 
2.10.5 Immuno-blotting of proteins 
The primary antibody was diluted in 5 % blocking solution according to table 2.3. 
Membranes were incubated overnight with the primary antibody at 4˚C with constant 
rotation.  Membranes were then washed three times (5 minutes each) with 0.1 % (v/v) 
TBS-T at constant rotation. The HRP-conjugated secondary antibody secondary was 
diluted 1 in 1000 in 5% blocking solution and incubated with the membranes for 1 hour 
at room temperature with constant rotation. Membranes were washed twice with TBS-
T and the final time with TBS.  Development of membranes was carried out by mixing 
a 1:1 ratio of EZ-ECL solution A and solution B (Biological Industries) and incubating 
this solution on the membrane for 5 minutes.  Images were processed using the G-
BOX by Syngene. Semi-quantitative analysis of protein expression was carried out using 
Image J software (National Institutes of Health, NY, USA).   
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Table 2.8. Volumes and components for a 10% resolving gel. 
Solution Component volume (mL) 
H2O  5.9 
30% acrylamide mix 5.0 
 1.5M Tris (pH 8.8) 3.8 
 10% SDS 0.15 
 10% ammonium persulfate 0.15 
TEMED 0.006 
 
Table 2.9. Volumes and components for a 5% stacking gel. 
 
Solution Component volume (mL) 
H2O  3.4 
30 % acrylamide mix 0.83 
 0.5 M Tris (pH 6.8) 0.63 
10 % SDS 0.05 
10 % ammonium persulfate 0.05 
TEMED 0.005 
  
Chapter II. Materials and Methods 
102 
 
2.10.6 2D western blot  
In order to assess both the molecular weight and the isoelectric point of proteins, a 2D 
western blot assay was carried out. Firstly, a 2D clean up procedure (GE healthcare) 
was carried out to remove interfering contaminants such as salts and lipids.  To 100 μL 
of protein sample, 300 μL of precipitant was added and left on ice for 15 minutes.  Next 
300 μL of co-precipitate was added and the sample was centrifuged at 12,000g for five 
minutes.  The supernatant was removed and 40 μL of co-precipitant was added to the 
pellet.  The sample was then left on ice for five minutes.  The sample was centrifuged at 
12,000g for 5 minutes and the supernatant was discarded.  Next 25 μL of dH20 was 
added onto the pellet and vortexed to disperse the pellet. 1 mL of chilled wash buffer (-
20˚C) was added with 5 μL of wash additive.  This was vortexed every ten minutes for 
half an hour.  Next, the sample was centrifuged at 12,000g for five minutes and the 
pellet was left to air-dry once the supernatant had been discarded.  The pellet was 
resuspended in 116 μL of rehydration buffer, 1 μL of bromophenol blue, 2 μL of IPG 
buffer and 6.25 μL of Dithiothreitol (DTT).   
Next the total sample was loaded onto a coffin (Amersham Biosciences). An 
Immobiline DryStrip (IPG) pH 3-10, 7 cm (GE healthcare Life Sciences) was placed on 
top of the sample with the anode facing the positive end of the strip.  The sample and 
IPG strip was covered with 0.5 mL of DryStrip cover fluid.  The coffin was then placed 
onto the isoelectric focusing unit (IPGPhor Pharmacia Biotech).  The protocol was as 
follows; 
Rehydration: 12 hours at 20˚C 
Step 1: Step and hold 500V for 1 hr 
Step 2: Gradient 1000V for 2 hr 
Step 3: Step and hold 1000V for 1 hr 
Step 4: Gradient 8000V for 2 hr 
Step 5: Step and hold 8000V for 8 hr 
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Once the isoelectric focusing was complete the IPG strip needed to be equilibrated.  
First the IPG strip was placed in 5 mL of reducing solution in a Falcon tube and placed 
on a rolling platform for 15 min.  The reducing solution was then decanted and 
replaced with 5 mL of alkylating solution and left to rotate for 15 min.  The IPG strip 
was then placed into the IPG well of NuPAGE 4-12% Bis-Tris Zoom Gel (Invitrogen).   
1X MOPS running buffer was added to the centre chamber and external chamber.  The 
gel was electrophoresed at 200V for 5 min and then 150V for 55 min. The transfer of 
proteins onto PVDF membrane and immunoblotting of the membranes were carried 
out following the guidelines in 2.11.4 and 2.11.5.  
2.10.7 Cell fractionation and chromatin isolation  
Cells were seeded at a specific cell number and hormonally starved for 72 hr.  Cells were 
either treated with R1881 (10 nM) or the vehicle (100% ethanol). Cells were washed in 
PBS once and scraped down in PBS. Cells were pelleted and resuspended in 400 μL of 
hypertonic buffer A and 50 μL of 1% (v/v) Triton-X100 (Melford Laboratories UK).  
Cells were left on ice for five minutes.  Next cells were centrifuged at 1300g for four 
minutes to isolate the cell nuclei.  The supernatant was collected into a separate tube as 
the cytoplasmic fraction.  The pellet was resuspended in 200 μL of buffer B and left on 
ice for ten minutes to lyse the nuclei.  This was then centrifuged at 1700g for four 
minutes to isolate the chromatin.  The supernatant was collected as the soluble nuclear 
fraction.  The pellet was resuspended again in buffer B and centrifuged at 1700g for 
four minutes.  The pellet was collected as the chromatin fraction. All fractions were 
diluted in 2X Laemmli sample buffer.   The fractions for each condition; +/- R1881 
was then electrophoresed on an SDS PAGE gel and immunoblotting was performed 
for desired proteins as described in 2.11.5.   
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2.10.8 Immunoprecipitation  
Once the nuclear fraction of the cell lysate had been isolated as described in 2.11.7, the 
pellet was resuspended in IPH buffer.  Next 50 μL of the lysate was mixed with 450 μL 
of IPH buffer.  The primary antibodies (3 μg) were added to each sample. As a control, 
a polyclonal rabbit (or monoclonal mouse) anti-rabbit IgG antibody (3 μg) was added to 
each sample, depending on the species of the primary antibody used. Samples were left 
on a shaker for two hours at 4˚C.  The required amount of Dynabeads® protein G 
(Invitrogen Life technologies) were placed on a DynaMay2 magnetic stand (Life 
Technologies) and the supernatant was removed.  The beads were then resuspended in 
IPH buffer.  Dynabeads® (15 μL) were added to each sample and left on a shaker for 
one hour at 4˚C.  Samples were placed onto a magnetic stand, supernatant was removed 
and Dynabeads® were washed three times with 200 μL of washing solution.   Antigen-
antibody complexes were eluted off the beads in 20 μL of elution buffer.   Elutes were 
mixed with 2X llaemmli sample buffer and a western blot was carried out as described 
in 2.11.3.   
2.10.9 Kinexus protein array 
LNCaP cells were hormonally starved for 72 hr.  Cells were treated with R1881 (10 nM) 
or ethanol as a vehicle control.  Cells were lysed with 300 μL of lysis buffer and 
centrifuged at 20,000g for twenty minutes.  The samples were then sent to Kinexus 
(Canada) where both total protein changes and phosphorylated proteins were recorded.  
The array consisted of 518 pan-specific antibodies and 359 phosphosite-specific 
antibodies in duplicate. Data was received as an Excel spreadsheet. The fold change was 
calculated from the z score of the vehicle and R1881 treatment.  The full Kinexus 
antibody microarray contains 877 antibodies. Kinexus provided both semi-quantitative 
and qualitative analyses of expression of signalling proteins and also their 
phosphorylation status.  The signal strength of each antibody spot was measured by its 
size and also its density.  The fluorescent signal was quantified and presented in 
duplicates in a Microsoft Excel spreadsheet, alongside the average percentage change 
from control, Z scores and fold change ratios.    
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2.11 Methods for bacteriology  
2.11.1 Cloning 
The desired coding sequence for a gene or DNA sequence of interest was amplified 
from its original plasmid or cDNA using the components and volumes shown in table 
2.10. The cycling conditions are shown in table 2.11. The amplified gene was then 
purified and cloned into desired plasmids as described in 2.12.3 and 2.12.4. 
2.11.2 DNA gel extraction  
DNA fragments were electrophoresised on an agarose gel and were excised, weighed 
and solubilised using the gel solubilisation solution (Sigma Aldrich).  1X volume of 
Isopropanol (Sigma Aldrich) was then added to the gel volume and mixed until 
homogenous in colour.  The solubilised gel mixture was loaded onto a prepared binding 
column and centrifuged for one minute.  The flow through was discarded and the 
column was washed with wash solution (diluted from Wash solution Concentrate G) 
and centrifuged for one minute.  Any residual wash solution was removed by another 
centrifugation step.  The DNA was then eluted, by adding 25 μL of the elution solution 
onto the binding column and centrifuging for one minute.  All centrifugation steps were 
carried out at 12000 g.  
Insertion of DNA into the pEF6/V5-His TOPO vector was carried out in compliance 
with table 2.12. Contents were incubated for five minutes, then place on ice, ready for 
transformation of competent cells. 
2.11.3 Transformation of competent cells 
One vial of One-Shot® TOP10 chemically competent E.coli (Invitrogen) was thawed on 
ice (25-50μL).  E.coli was aliquoted for each plasmid.  The DNA plasmid and insert (0.5 
μL) was placed directly into the middle of the cells.  The contents of the tubes was 
flicked to mix and left on ice for thirty minutes. As a positive control, the pUC19 
plasmid was added another aliquot of cells.  The cells were then heat shocked for 30 s at 
42˚C and then placed on ice.  Pre-warmed S.O.C medium (Invitrogen) (250 μL) was 
added to each tube.  The tubes were incubated at 37˚C on a shaking platform for one 
hour.  Each transformation was spread onto a pre-warmed selective plate and incubated 
overnight.   
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Table 2.10. PCR reactions.  
 
Components                Amount (μL) 
GoTaq®G2 green master mix 12.5  
PCR water 12  
cDNA template 2  
Forward primer 0.25  
Reverse primer 0.25  
 
Table 2.11. Cycling conditions for PCR. 
 
Stage Temperature 
(˚C) 
Time  
Holding  95˚C 5 minutes 
Cycling (25 cycles) 95˚C 30 seconds 
 55˚C 30 seconds 
 72˚C 180 seconds 
Extension 72 ˚C 10 minutes 
 4 ˚C Until taken off machine 
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Table 2.12. Components for ligation of DNA into the pEF6 vector. 
 
Component Amount 
DNA 3μL 
Salt solution 1μL 
Vector (pEF6/V5-His TOPO)  1μL 
water 1μL 
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2.11.4 Colony selection and overnight culture 
Once the LB-ampicillin agar plates had been incubated overnight with E.coli, colonies 
were picked and inoculated with 5 mL of LB media and left overnight with constant 
shaking at 37˚C.    
2.11.5 Plasmid purification  
Once recombinant E.coli cultures were grown overnight in liquid LB media, 2 mL of the 
culture was centrifuged at 12,000g. The pellet was resuspended in 200 μL of 
resuspension solution until cells appear homogenous.  The cells were then lysed using 
200 μL lysis solution.  The solution was immediately mixed.  Neutralisation solution 
(250 μL) was added and centrifuged for ten minutes at 12000g.  The lysate was then 
loaded onto a prepared Miniprep binding column and centrifuged for 30 s.  The flow 
through was discarded and 750 μL of diluted wash solution was added to the column 
and centrifuged for one minute.  The columns were further centrifuged to remove any 
excess liquid. The DNA was eluted by adding 50 μL of elution solution.  The DNA 
concentration was measured using the spectrophotometer.  To ensure the plasmid has 
taken up the DNA insert of interest, a single and double restriction digestion was 
carried out according to table 2.13. Each reaction was incubated at 37˚C for one hour.  
Alternatively a PCR reaction was carried out. The kit used for plasmid purification was 
GenElute® Plasmid Miniprep kit (Sigma-Aldrich). 
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Table 2.13. Single and double restriction enzyme digestions. 
 
                      Single Digest (BamH1) Double digest (BamH1 and EcoRV) 
(Sigma-Aldrich) 
DNA                       5 μL 5 μL 
Buffer (x10)             3 μL 3 μL 
Enzyme                 0.5 μL 0.5 μL + 0.5 μL 
PCR water             21.5 μL 21 μL 
 
Table 2.14. Ligation reaction. 
 
Ligation reaction Amount 
10X DNA T4 DNA ligase buffer with 
10mM ATP 
5 μL 
Desired vector X 
Insert X 
T4 DNA ligase  1 μL 
Water Up to 10 μL if reaction is less 
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2.11.6 Ligation of vector and insert 
The ligation of the desired insert into a linearized plasmid was carried out using 10X 
DNA T4 DNA ligase buffer with 10mM ATP (New England Biolabs) and a T4 DNA 
ligase enzyme (New England Biolabs).  
The equation used for the ligation reaction was: 
 (ng of vector x kb of insert)/ kb of vector x ratio =ng of insert (x3) 
This formula gave the ng of insert needed for a 1:1 ratio of vector to insert.  However 
the preferred ratio is 3:1, therefore the final number was multiplied by three to increase 
the likelihood of ligation. The reaction was left at 16-18˚C for two hours to ligate.  The 
ligation reaction was then transformation into E.coli.  Table 2.14 demonstrates the 
contents for each ligation reaction. Ligation controls consisted of reactions with no 
enzyme, no insert and no insert or enzyme.  Sequencing of plasmids was carried out in 
house at CBS (Central Biotechnologies Services).  
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2.11.7 Lipofectamine Transfection 
In order to transfect plasmids of interest into cell lines, Lipofectamine 2000 
(ThermoFisher Scientific) was the transfection agent used.   Firstly, DNA up to 500 ng 
was diluted in 25 μL of serum free media.  Next 2 μL of Lipofectamine 2000 was 
diluted in 25 μL of serum free media.  Each tube was left to stand for 5 minutes.  The 
two tubes were then mixed together and left to stand for twenty minutes.  The DNA-
lipid complex was then added to the cells dropwise and left for 48-72 hours.  
2.11.8 Luciferase assay 
Cells were seeded in a 24 well plate and transfected with specific luciferase reporter 
plasmids.  Cells were lysed with 1X sample buffer, diluted in PBS from the 5X reporter 
lysis buffer (Promega) and were left to freeze at -20˚C. Each lysate (15 μL) was 
transferred to a white microfluor 96 well plate.  Bright-Glo™ luciferase assay substrate 
(Promega) (15 μL) was added to each sample and mixed.  The luminescence was read 
on a glomax multi detection system (Promega).  
2.11.9 β-galactosidase assay 
β-galactosidase transfection assay (Invitrogen) was used following a luciferase assay as a 
control for transfection efficiency.  In any transfection assay a bos-β-galactosidase 
plasmid was transfected into the cells. At the end of the experiment, half of the lysate 
was used for the luciferase assay and half for the β-galactosidase assay.  β-galactosidase 
assay 1X cleavage (50 μL) buffer with β-mecaptoethanol was added to each lystate (30 
μL) along with 17μL of ONPG.  The plate was left at 37˚C for one hour, until a yellow 
colour developed.  The reaction was stopped by the addition of 125 μL of stop buffer 
to each well.  Absorbance was read at 405nm using an ELx800 plate reading 
spectrophotometer (BioTek, VT, USA). 
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2.12 QuikChange lightening Site-directed mutagenesis 
2.12.1 Primer design 
First primers were designed for mutating targeted gene of interest using ORF finder 
(NCBI, U.S.A).  ORF finder (Open Reading Frame Finder- NCBI) was used to analyse 
specific codons for different amino acids. Amino acid codons for specific serine or 
tyrosine residues were then single nucleotide substituted for codons for alanine.  
Primers were synthesised by Eurofins Genomics and were diluted according to the 
datasheet. Sequences for primers designed for the mutagenesis of PHB and the E2F 
binding site in the promoter region of MCM6 are shown in table 2.17.  
2.12.2 Mutant strand synthesis reaction 
Components from the QuikChange lighting Site-directed mutagenesis kit (Agilent 
Technologies) were used.  Firstly, mutant strand synthesis reaction involved both a 
positive control reaction and target gene reaction.  Components of both reactions are 
shown in table 2.15. QuikChange lighting enzyme (1 μL) was added to each reaction 
that were then put in a thermocycler with the cycling conditions shown in table 2.16.  
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Table 2.15. Mutant strand synthesis reactions.  
 
Control reaction Sample reaction 
2.5 μL 10X reaction buffer 2.5 μL 10X reaction buffer 
2.5 μL pWhitescript 4.5Kb control 
plasmid 
100ng of dsDNA template 
0.625 μL oligonucleotide control primer 
1 
125ng of oligonucleotide primer 
0.625 μL oligonucleotide control primer 
2 
0.5 μL dNTP mix 
0.5 μL dNTP mix 0.75 μL QuikSolution reagent 
0.75 μL QuikSolution reagent H2O up to 25 μL 
17 μL H2O  
Table 2.16. Cycling conditions for mutant strand synthesis reactions.  
Segment Cycles Temperature (˚C) Time (seconds) 
1 1 95 120 
2 18 95 20 
60 10 
68 30/Kb of plasmid 
length 
3 1 68 300 
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Table 2.17. Primer sequences for the mutagenesis of PHB and the promoter of MCM6. 
 
Oligo Name Primer sequence (5’-3’) 
MCM6 promoter 
mutation 1  
CCAGAAGGGCTTTGCA 
MCM6 promoter 
mutation 2 
GTTCATTGGTCAGGGTAG 
PHB S82 GTAATGTGCCAGTCATCACTGGTGCCAAA 
PHB T91 CAGAATGTCAACATCGCACTGCGCATCCTCTTC 
PHB S101 TTCCGGCCTGTCGCCGCCCAGCTTCCTCGCATCTT 
PHB S213 GGCGGCCATCATCGCTGCTGAGGGCGACT 
PHB S106 CGCATCTTCACCGCCATCGGAGAGGACTATGA 
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2.12.3 Dpn I digestion of amplication products 
Dpn I restriction enzyme (1 μL) was added directly to each amplification reaction and 
immediately incubated at 37˚C for five minutes to digest the parental DNA strand.  
2.12.4 Transformation of XL10-Gold Ultracompetent cells  
The XL10-Gold Ultracompetent cells (Agilent Technologies) were thawed on ice.  For 
each control and sample reaction, 22 μL of cells were aliquoted.  To each aliquot, 1 μL 
of β-Mercaptoethanol (β-ME) was added and incubated on ice for two minutes.   
Following this, 2 μL of the Dpn I treated DNA from the control and sample reactions 
were transferred to each aliquot of the competent cells.  The samples were mixed and 
left on ice to transform for thirty minutes.  The samples were heat pulsed at 42˚C in a 
water bath for thirty seconds.  The samples were then placed on ice for two minutes.  
To each sample, 0.5 mL of SOC media was added and the tubes were incubated at 37˚C 
for one hour, shaking at 225 rpm.  
An appropriate volume of each transformation was then plated onto a pre-warmed LB-
agar ampicillin plate.  
2.13 Methods for cytotoxicity assays 
2.13.1 MTT assay 
Cells were seeded into a 96 well plate and treated with increasing concentrations of 
doxycycline for 24 hr. Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma Aldrich) 
solution was made by diluting 100 mg of MTT in 20 mL of PBS and was filter sterilised 
through a minisart 0.2 μm sterile filter (Sartorius Stedim Biotech) to produce a working 
concentration of 5 mg/mL. 100 μL of the MTT solution was added to 900 μL of media 
to produce a 10% solution.  The cells were incubated for 4 hr at 37˚C in the incubator.  
At the end point, the media was aspirated off gently, and the cells were mixed with 200 
μL of acidifed isopropanol.  Absorbance was read at 540 nm using an ELx800 plate 
reading spectrophotometer (BioTek, VT, USA).   
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2.13.2 RealTime-Glo™MT Cell Viability assay 
LNCaP/TR2/ PHB cells were seeded onto a white microplate 96 well and treated with 
increasing concentrations of doxycycline for 24 hr.  The RealTime-Glo™MT Cell 
Viability assay kit was used (Promega).  First, the 2X RealTime-Glo™ reagent was made 
by diluting the MT cell viability substrate and NanoLuc® Enzyme in cell culture media.   
An equal volume of the 2X RealTime-Glo™ reagent to the media on the cells was 
added to each well.  The cells were incubated for 60 minutes in an incubator ay 37˚C.  
The luminescence was read on a glomax multi detection system (Promega), once the 
Photomultiplier Tube (PMT) had been activated for 5 minutes.   
2.13.3 CellTox™Green Cytotoxicity Assay 
LNCaP/TR2/ PHB cells were seeded onto a white microplate 96 well and treated with 
increasing concentrations of doxycycline for 24 hr.  The CellTox™Green Cytotoxicity 
Assay (Promega) was used.  The CellTox™ Green reagent was made diluting the 
CellTox™ Green dye in the assay buffer (1:500). 100 μL of the CellTox™ Green 
reagent was added to each well and mixed on an orbital shaker for 1 minute.  The plate 
was incubated for 15 minutes at room temperature, shielded from light.  The 
fluorescence was measured at 485-500nmex  on a glomax multi detection system 
(Promega).  
2.13.4 CellTitre-Glo®Luminescent Cell Viability Assay 
LNCaP/TR2/ PHB cells were seeded onto a white microplate 96 well and treated with 
increasing concentrations of doxycycline for 24 hr.  The CellTitre-Glo®Luminescent 
Cell Viability Assay (Promega) was used.  First an equal volume of CellTitre-Glo® 
reagent to the media in the well was added, and the contents were left to shake on an 
orbital shaker for two minutes to induce lysis.  The plate was equilibrated at room 
temperature for 10 minutes to stabilise the luminescent signal.  The luminescence was 
read on a glomax multi detection system (Promega), once the Photomultiplier Tube 
(PMT) had been activated for 5 minutes.   
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2.14 Checkmate ™ Mammalian two-hybrid assay  
In order to assess protein-protein interaction, a Checkmate ™ Mammalian two-hybrid 
assay was carried out.  The assay contained two primary plasmids, pBIND and pACT. 
The pBIND plasmid contains the yeast Gal4 DNA binding domain upstream of a 
multiple cloning site.  The pACT plasmid has the herpes simplex virus VP16 activation 
domain that is upstream of a multiple cloning site.  The genes of interest (PHB and 
E2F1) were cloned into these vectors to produce fusion proteins with the DNA binding 
domain of Gal4 and VP16 respectively (refer to 2.12).  The fusion constructs were 
transfected alongside pGL5 into mammalian cells (refer to 2.12.8).  pGL5 has five 
GAL4 binding sites upstream of a TATA box, that is upstream of the firefly luciferase 
reporter gene.  In the absence of protein interaction, there is a background level of 
luciferase production.  However, upon protein-protein interaction, an increase in 
luciferase production is seen above the threshold limit.  Cells were left to transfect for 
up to 48 hours and then lysed.  The amount of luciferase was measured as compared to 
the negative controls. The luminescence was read on a glomax multi detection system 
(Promega).  Two positive control plasmids were provided.  pBIND-ID and pACT-myo.  
They both expressed proteins that are known to interact in vivo.  
2.15 Statistical analysis 
GraphPad Prism (GraphPad Software, Inc., CA, USA) for used for all statistical 
analysis.  Each experiment was repeated a minimum of three times (n=3), to give three 
independent biological repeats, unless otherwise stated.  Error bars represent the 
standard deviation or standard error of mean of all three experiments which is stated in 
each figure legend.  An unpaired student T test, or a one way ANOVA test was used to 
test statistical significance on data that was normally distributed.  On non-normal data, a 
Kruskal–Wallis one-way statistical test was carried out.  Asterisk (*) notation was used 
to denote p values; *<0.05, **<0.01,***<0.001.
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3 Chapter III: Characterisation of the LNCaP cell lines used in this study. 
3.1 Introduction 
As this thesis is focusing on PC, the main cell lines used were derived from PC patients.  
The first step was to identify that the cell lines used throughout this thesis were verified 
for their hallmark characteristics and their AR responsiveness.  The main cell model 
used in this project was the parental cell line, LNCaPs.  Table 3.1 describes its main 
features.  
The LNCaP cell model was first isolated from a human metastatic prostate 
adenocarcinoma found in a lymph node.  The original cell line is androgen responsive 
and is positive for both gene and protein expression of prostate specific antigen (PSA) 
and the androgen receptor (AR).  Although LNCaP cells are androgen sensitive, they 
harbour a mutation within the ligand binding domain of the AR, allowing non-specific 
ligands to activate the AR, thus are beginning to become less androgen dependent.    
This is the T877A mutation, that gives the cell line its unique promiscuous binding 
affinity for a broad range of steroids such androgens as well as adrenal androgens (127). 
Expression of EGF/TGF-α-R and IGF-1-R are seen.   Inactivation of both PTEN and 
P53 are seen in this cell line, along with the expression of cytokeratin 8, 18 and 20.  
Xenografts using this cell model have a 80% success rate with a tumour doubling time 
of 86 hours when implanted with Matrigel™ in nude mice (127).    
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Table 3.1 Characteristics of wt LNCaP cells. 
 
 Description 
Organism Homo sapiens, human 
Tissue prostate, derived from metastatic site: left 
supraclavicular lymph node 
Disease carcinoma 
Age 50 years old 
Gender male 
Morphology epithelial 
Growth properties adherent, single cells and loosely attached 
clusters 
AR                          Positive 
PSA                                                               Positive  
Chapter III. Results 
121 
 
3.2 Methods 
 Cell culture of LNCaPs and LNCaP/TR2/PHB cells (refer to 2.1). 
 SYBR® green Q-PCR (refer to chapter 2.8.3). 
 Western blot (refer to chapter 2.11.1-2.11.5). 
 Cell cycle FACS analysis (refer to chapter 2.9.4). 
 Crystal violet proliferation assay (refer to chapter 2.9.1). 
 Cell cytotoxic assays (MTT assay, RealTime-Glo™MT Cell Viability assay and 
CellTox™Green Cytotoxicity Assay).  Refer to chapter 2.14.1-2.14.3.   
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3.3 Results 
3.3.1 Verifying the characteristics of the parental LNCaP cell line 
To confirm that the cell line LNCaP was androgen responsive and that the methods of 
hormone manipulation used were robust, we verified the androgen sensitivity and 
responsiveness of the cells.  
Firstly, the LNCaP cell line was plated at a cell number of 250,000 cells (in a 6 well 
plate) and left to adhere. The cells were washed with PBS and the media was then 
replaced with 1 mL of charcoal stripped media and the cells were left to hormonally 
starve for 72 hr.  Cells were then treated with either R1881 (10 nM) as a synthetic 
androgen or ethanol (vehicle) and left for 24 hr.  The RNA was then extracted, reverse 
transcribed and SYBR® green Q-PCR was used to analyse the fold increase in the AR 
regulated gene; PSA (KLK3). Figure 3.1 illustrates a 286 fold increase in PSA expression 
when compared to ethanol treated cells.  
It has also previously been reported that androgen treatment downregulates PHB at the 
RNA level.  Figure 3.1 illustrates a 6 fold decrease in PHB expression in cells treated 
with R1881 (10 nM).  This confirms that the wt LNCaP cell line is in accordance with 
characteristics such as production of PSA gene expression upon AR stimulation (with 
the addition of R1881) and a decrease in PHB expression as previously published (128).   
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3.3.2 Verifying characteristics of the LNCaP/TR2/PHB cell line 
The LNCaP cell line was used to derive a doxycycline-inducible cell line over-expressing 
PHB cDNA that was carried out prior to the beginning of this project and published 
(129).   
Firstly, an introduction into the production of the LNCaP/TR2/PHB cell line. The T-
REX system by Invitrogen Life Technologies was adopted according to the 
manufacturer’s guidance.  The pcDNA6/TR expression plasmid was transfected in 
LNCaP cells to express the Tet repressor. Successful transfection was identified by 
Blasticidin (12 mg/mL) selection.  Positive colonies were expanded and a luciferase 
assay was used to determine doxycycline (dox) inducibility using a control 
pcDNA4/TO/luc plasmid (tet-inducible luciferase). Choosing a sub clone was 
dependent on being highly inducible with non-leaky expression of luciferase (129).  
Following this, LNCaP/TR2 cells were stably transfected with pcDNA4/TO/PHB (tet-
inducible PHB cDNA). Now only in the presence of doxycycline, the cell line produces 
ectopic PHB cDNA. The schematics of how this system works is shown in figure 3.2. 
Validation of the hallmarks of this doxycycline inducible cell line was carried out using 
Q-PCR, western blot and FACs.   
Firstly in order to verify that the inducible cell line used was producing an ectopic over-
expression of PHB cDNA only in the presence of doxycline (dox). The cells (250,000 
cells per well in a 6 well plate) were treated with 10 μM of dox for a minimum of 16 hr 
in TET-free RPMI media.  PBS was used as the vehicle. The RNA was extracted, 
reverse transcribed and SYBR® green Q-PCR was carried out to assess gene 
expression.  Figure 3.3 demonstrates that with the addition of dox there is a significant 
increase in PHB gene expression.  
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Further, the expression level of PSA was also assessed in the LNCaP/TR2/PHB cell 
line.  The cells were hormonally starved for 72 hr (charcoal stripped FBS), R1881 (a 
potent synthetic androgen 10 nM) was then added to the cells for 24 hr.  Ethanol was 
used as the vehicle control.  Figure 3.3 shows that in the absence of dox and with the 
addition of R1881 there is a 16 fold increase in PSA expression when compared to 
ethanol.  However, with the addition of dox, there is no androgen induction of PSA 
expression. Figure 3.3 illustrates no difference in PHB expression with and without 
R1881 in the absence of dox.  However, when dox is added, the expression of PHB 
increases, indicating the dox inducibility of PHB, and with the addition of R1881 the 
PHB expression decreases in the presence of dox but is not statistically significant.  
As a control to ensure dox was not inducing an increase in PHB on its own in the 
absence of the inducible plasmid, the LNCaP cells (250,000 cells in a 6 well plate) were 
also treated with 10 μM of dox for a minimum of 16 hr.  Figure 3.3 demonstrates no 
significant change in the expression of PHB in the presence of doxycycline.  This 
signifies that dox is only producing PHB cDNA over-expression in the inducible cell 
line.  
The protein expression of PHB was also assessed in the LNCaP/TR2/PHB cell line.  
Figure 3.4 demonstrates that there is a 6 fold increase in PHB protein expression in the 
presence of doxycycline.  Indicating that doxycycline (16 hr) induced etopic PHB 
cDNA is being translated into a functional protein. 
3.3.3 PHB over-expression halts the cell cycle 
Previous reports have identified that PHB has a repressive role on the cell cycle (128), 
thus further investigations were taken forward. FACs analysis was carried out to identify 
at what cell cycle stage PHB’s over-expression was having an effect.  Cells were left to 
seed to 70% confluency and incubated with 10 μM doxycycline for two time points, 24 
hr and 48 hr. Significance was seen at the 48 hr time point. Figure 3.5 shows PHB over-
expression increases the cell population in the G1 phase and decreases the cell 
population in the S phase and G2/M phase.  This confirms that PHB carries out a 
repressive role in the cell cycle by halting the cell population in the G1 phase.  In 
synergy with this experiment, a proliferation assay was carried out at the same time 
points, 24 hr and 48 hr using the crystal violet assay on the LNCaP/TR2/PHB cell line 
(figure 3.6).  Different concentrations of doxycycline were used to identify the optimum 
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concentration.  Significance was seen at 10 μM of doxycycline at 24 hr and at 2.5 μM, 5 
μM and 10 μM at 48 hr.  This again confirmed that PHB suppressed the proliferation of 
the LNCaP cells.  
 As PHB has an important role in the mitochondrial membrane, supporting proteins 
involved in the electron transport chain, it was important to verify that PHB over-
expression caused only cell cycle arrest and not cell death or mitochondrial dysfunction 
that could have halted the cell cycle. Various assays were used to assess mitochondrial 
activity, membrane integrity and number of live cells (Figure 3.7).  Firstly, an MTT assay 
was carried out on the LNCaP/TR2/PHB cell line treated with various concentrations 
of doxycycline (0 μM, 0.312 μM, 0.625 μM, 1.25 μM, 2.5μM, 10 μM) for 24 hr.  The 
MTT assay indicated there was no significant effect on mitochondrial activity with 
increasing concentrations of doxycycline, suggesting ectopic PHB over-expression was 
not causing cellular stress.  Further, a CellTox Green assay was carried under the same 
experimental conditions.  The assay showed no changes in cell membrane integrity - 
disruption of membrane integrity is indicative of cell death.  Next, the cell Titer-Glo 
assay determined the number of viable cells based on ATP production, an indicator of 
metabolic activity.  Increasing concentrations of doxycycline had no significant effect on 
the amount of ATP produced suggesting cells are still viable at the highest 
concentration of doxycycline.  Finally a RealTime-Glo™ MT Cell Viability assay was 
carried out.  This assay depends on the reducing ability of cells that in turn depicts 
metabolic activity.  Increasing concentrations of doxycycline had no significant effect on 
the luminescence produced, suggesting metabolism within the cells were unaffected 
with the presence of PHB over-expression.   
Further, cells pre-treated with doxycycline (16 hr) were then washed with PBS and left 
to grow for either 48 hr or 72 hr in full media.  The cell population in the S phase was 
measured via FACs analysis.  After 96 hr, slowly the cell population began to re-enter 
the S phase.  This suggests that PHB over-expression is causing a temporary 
suppression of the cell cycle and not permanent quiescence. Accumulating these assays 
together, PHB over-expression is only causing cell cycle arrest. This is also confirmed 
by the FACS analysis showing no apoptotic cell population (figure 3.5).  
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Figure 3.1. Characterisation of the LNCaP cell line.  A, SYBR green Q-PCR results of PSA (KLK3) gene 
expression.  The LNCaP cells were grown in charcoal stripped media (72hr) and then treated with 10 nM 
of R1881 or vehicle (ethanol) for 24hr.   Fold increase is shown compared against cells treated with 
ethanol. B, SYBR green Q-PCR results of PHB gene expression.  LNCaP cells were grown in charcoal 
stripped media (72hr) and then treated with 10 nM of R1881 or vehicle (ethanol) for 24hr. p value 
<0.05*, <0.01**.  n = 3.  Fold decrease is shown compared against cells treated with ethanol. Data was 
normalised to housekeeping genes; RPL19 and GAPDH.  Error bars depict the SEM.  
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Figure 3.2. Schematic representation of how a tetracycline inducible cell line works.  Image adapted from 
the protocol of life technologies T-REx™ System. A Tetracycline-Regulated Expression System for 
Mammalian Cells. 
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Figure 3.3. Characterisation of the inducible cell line LNCaP/TR2/PHB by analysing gene expression of 
PHB and PSA (KLK3). A, PHB expression in LNCaP/TR2/PHB cells grown in TET free media with and 
without 10 μM of dox (16hr). Fold increase compared against cells with no dox (PBS). B, PSA gene 
expression in  LNCaP/TR2/PHB cells grown in charcoal stripped media (72hr) with and without 10 nM 
of R1881for 24hr and with and without 10 μM of dox.  Fold increase compared against cells with ethanol 
and cells without dox. C, PHB gene expression in LNCaP/TR2/PHB cells in charcoal stripped media 
(72hr) with and without 10 nM of R1881 for 24hr and with and without 10 μM of dox.  Fold increase is 
shown compared against cells treated with ethanol and cells without dox. D, PHB gene expression in wt 
LNCaP cells. No significant difference in PHB expression in LNCaP cells treated with and without 10 
μM of dox (16 hr). Data was normalised to housekeeping genes; RPL19, GAPDH and βactin. p value 
<0.05*, p value <0.001***. n=3. Error bars represent SEM.  
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Figure 3.4. Protein verification of PHB expression with dox in LNCaP/TR2 /PHB cells. A, western blot 
analysis showing PHB expression in LNCaP/TR2/PHB cells treated with dox (16hr, 10 μM).    B, a bar 
graph illustrating the densitometry values of the bands shown in A.  Values were normalised to GAPDH 
values.  Approximately a 7-fold increase in PHB protein expression is seen with dox. n=1.  
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Figure 3.5. Cell cycle analysis of LNCaP/TR2/PHB cells treated with and without doxycycline (10 µM) 
for 24 hr and 48 hr. A, bar graph indicating number of cells in each phase, measured by FACs in 
LNCaP/TR2/PHB cells treated with dox (24hr). B, bar graph indicating number of cells in each phase, 
measured by FACs in LNCaP/TR2/PHB cells treated with dox (48hr).   % of cell population in each 
phase of the cell cycle is seen below each respective graph (± standard error of mean) and was calculated 
using FlowJo® analysis.  C, histogram showing the number of cells in each phase measured by FACs in 
LNCaP/TR2/PHB cells treated with dox (24hr). The blue line represents cells with no PHB over-
expression.  The red line represents cells with ectopic PHB over-expression (dox). p<0.05* n=3.    
C 
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Figure 3.6. Crystal violet proliferation assay. A, Proliferation of LNCaP/TR2/PHB cells treated with 
increasing concentrations of dox for 24 h (0.312 μM - 10 μM). B, Proliferation of LNCaP/TR2/PHB 
cells treated with increasing concentrations of dox for 48 h (0.312 μM - 10 μM). p<0.05*, p<0.01** n=3.  
Absorbance was read at 540nm.    
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Figure 3.7. Cytotoxicity assays on the LNCaP/TR2/PHB cell line. A, MTT assay, mitochondrial activity 
of LNCaP/TR2/PHB cells treated with increasing concentrations of doxycycline. B,  CellToxGreen 
assay, cell membrane integrity of LNCaP/TR2/PHB cells treated with increasing concentrations of 
doxycycline. C, Realtime-Glo MT assay on LNCaP/TR2/PHB cells treated with increasing 
concentrations of doxycycline n=2.  As a control for cell cytotoxicity, cells were lysed. D, bar graph 
showing % of LNCaP/TR2/PHB cells that re-enter the S phase after doxycycline was washed off and 
left for 48 hr and 72 hr.  n=1.  
Chapter III. Results 
133 
 
3.4 Discussion 
Accumulating both data presented here and previous literature, it is clear that PHB is a 
repressor of the AR. This was due to a strong repression of PSA gene expression seen 
in the presence of PHB ectopic over-expression. Both the AR and PHB are in dynamic 
opposition in controlling androgen-mediated gene activation in prostate cancer cells.  
According to(130),  androgen stimulation of LNCaP cells led to a down-regulation of 
PHB protein expression, allowing progression of the cell cycle.  However, the over-
expression of PHB led to a repression of AR signalling and cell cycle arrest.  This agrees 
with data from Gamble, et al,. (130), whereby transfection of LNCaP with a PHB 
expression plasmid led to the failure of cells entering the cell cycle, even in the presence 
of the potent androgen; DHT.  It was verified that the cell cycle arrest was not due to 
cell death, as various cell cytotoxicity assays indicated that PHB over-expression had no 
effect on mitochondrial activity or function, alongside no change in membrane integrity. 
This is of particular importance as mitochondrial dysfunction plays a key role in 
activating apoptosis in mammalian cells, especially as mitochondria are essential for cell 
viability (131).  Mitochondria undergo structural and functional changes upon apoptotic 
initiation.  First mitochondria incur a decrease in their membrane potential followed by 
membrane permeability.   Moreover, the cytotoxicity assays assessed the metabolism of 
viable cells.  If nutrients in the cell environment are lacking, metabolic checkpoints are 
activated leading to the intrinsic apoptotic pathway through the activation of the Bcl-2 
family of proteins (132).   As PHB over-expression showed no effects on the 
metabolism of the cells, the apoptotic pathway was not activated.  Further evidence that 
PHB has no role in activating cell apoptosis, FACs analysis showed no sub G0/G1 
population left to the G1 peak, indicating no DNA fragmentation or apoptotic cell 
population.  Additionally when doxycycline-induced PHB was removed, cells began to 
re-enter S phase of the cell cycle, indicating no permanent damage or quiescence. Thus, 
PHB over-expression was having a prominent effect on arresting the cells in the G1 
phase. There is an array of genes or proteins that PHB could be interacting with to 
cause cell cycle arrest that will be further investigated.   
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3.5 Conclusion 
To summarise, characterisation of the predominantly used cell lines throughout this 
project were validated prior to further experiments. Data collected supported that PHB 
over-expression repressed the AR and led to a halt in the cell cycle that in turn led to 
reduced cell proliferation.  This was not a result of cellular stress, apoptosis or cell 
death.  Therefore, PHB mediated cell cycle arrest is specific and further experiments 
were set out to investigate this mechanism.  
3.6 Summary points 
 Validation of the androgen responsive LNCaP cell line was confirmed by 
assessing the androgen responsive gene; PSA when cells were treated with a 
synthetic androgen (R1881). 
 Validation of the LNCaP/TR2/PHB cell line was confirmed as in the presence 
of doxycycline, an increase in ectopic PHB cDNA and protein expression was 
seen.   
 PHB expression is down-regulated in LNCaP cells stimulated with hormone 
(R1881). 
 PHB has a significant repressive role on the cell cycle – this in turn significantly 
decreased the proliferation of the LNCaP/TR2/PHB cells. 
 PHB causes cell cycle accumulation in the G1 phase.  
 PHB’s repressive role on the cell cycle is not due to causing cellular stress or cell 
death.   
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4 Chapter IV: The repression of E2Fs is mediated through PHB binding to 
MCMs’ promoter region. 
4.1 Introduction 
Chapter III showed that PHB halted the cell cycle by increasing the cell population in 
the G1 phase whilst decreasing the cell population in S phase.    From previous 
literature, it has been identified that PHB is able to repress the cell cycle through 
interactions with genes that progress the cell cycle.  Gene families that are known to 
regulate and progress the cell cycle include cyclins, CDKs, and E2Fs.  Cyclins and 
CDKs work together to form complexes that are essential for the regulation of 
interphase during the cell cycle.  E2Fs are a family of transcriptional factors that have 
one or more conserved DNA-binding domains that play a role in the progression of the 
cell cycle.  E2Fs are regulated by the Retinoblastoma (Rb) proteins and are often 
deregulated in carcinogenesis (133).  Numerous E2F targets have been identified, such 
targets include c-jun, myc, POLA and MCMs. Members of the MCM and POLA gene 
family are responsible for DNA replication.  Interestingly, PHB has been shown to 
interact with E2F1 by binding to Rb, rendering E2F’s function inactive.  This led to the 
inhibition of the cell cycle. This interaction was established in a breast cancer cell line; 
T47D.  Moreover, PHB is a strong gene repressor (e.g. the AR gene) and can recruit 
histone modifying proteins such as HP1 and HDAC to the chromatin. Previous 
evidence of PHB’s repressive mechanism on the cell cycle is limited and not fully 
understood in PC.   
The aim was to identify a mechanism by which PHB arrests the cell cycle.  We 
investigated if this repression was regulated through major cell cycle pathways such as 
E2F, CDKs or PI3K or whether any other novel pathways could be found.   To assess 
how PHB’s over-expression mediated cell cycle arrest in PC cells, a RNA sequencing 
(RNA-seq) experiment was carried out as PHB has a strong role in repressing gene 
expression.  Therefore gene repression could indicate a novel mechanism. This allowed 
the analysis of the entire transcriptome that was affected by PHB over-expression.  
Methods used to carry out these aims included an unbiased analysis of the RNA 
sequencing database through bioanalysis platforms and   biased data mining into the 
RNA sequencing database. Q-PCR was also carried out to validate gene expression 
alterations seen with PHB over-expression, from targets identified in the RNA-seq.  
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Key genes that were significantly altered with PHB over-expression were then isolated 
for further study and a hypothesis was proposed as how PHB causes cell cycle arrest.   
4.2 Methods 
 RNA sequencing (refer to chapter 2.10). 
 SYBR® Green Q-PCR (refer to chapter 2.8.3). 
 Metacore, IPA-Ingenuity and DAVID gene ontology analysis.  Here a gene list 
from the RNA-seq database was created using genes that had a significant fold 
change (<0.05) with a fold change >-2/2.  This gene list was inputted into 
online programs to assess for associated networks, pathways and transcription 
factors.  
 Luciferase reporter assay (refer to chapter 2.12.8).  
 Western blot (refer to chapter 2.11.1-211.5). 
 Site-directed mutagenesis (refer to chapter 2.13).  
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4.3 Results 
4.3.1 Gene expression changes in response to PHB over-expression in the 
LNCaP/TR2/PHB cell line 
In order to identify how PHB over-expression in the LNCaP/TR2/PHB cells affected 
gene expression, an unbiased RNA-seq experiment was carried out.  Firstly, the total 
RNA samples from LNCaP/TR2/PHB cells (+/dox, 10μM, 16 hr) were assessed for 
their quality and integrity using a Bio-analyser.  Next, isolation of polyA mRNA from 
total RNA using polyT beads was carried out (figure 4.1A).  The mRNA was then 
fragmented by RNaseII digestion, purified and again run on a Bio-analyser to confirm the 
fragmented mRNA was within the correct base pair size region (figure 4.1B). Purified 
fragmented mRNA was then amplified to cDNA fragments, 150-300bps long (figure 
4.1C) these were then amplified onto Ion Sphere Particles (ISPs) by an emulsion PCR.  
Next ISPs were loaded onto a P1 chip and sequenced on the Ion Torrent Proton 
sequencer. Figure 4.2A illustrates the percentage of ISP loading onto the chip (88%).  The 
total number of reads sequenced was 68,303,495 as the final library (figure 4.2B) per 
experiment of four samples. Each read length was in the correct base pair size region (50-
200) as shown in figure 4.2C. 72% of reads were aligned to the human genome 19 as 
shown in figure 4.3 with a mean raw accuracy of 96.6%.  The reason why the software 
used had Bowtie and Cufflinks integrated with automatic settings.   Data output was in 
the form of a BAM file format.  
Analysis of the RNA-seq data with Partek Genomics suite software was carried out 
using a workflow as shown in figure 4.4. Firstly, A RPKM (reads per kilobase million) 
normalisation step was carried out to account for sequencing depth and gene length of 
the two replicates for no dox vs dox.  The final step was a one way ANOVA analysis of 
the untreated sample vs the doxycycline treated sample, that produced a transcripts list 
of significantly differentially expressed transcripts in each sample set.  The list produced 
contained transcripts that either had no change, or an increase or decrease in expression 
in response to doxycycline.    
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Firstly, to ensure the inducible cell line was producing an over-expression of ectopic 
PHB cDNA in the presence of doxycycline, the location of the PHB gene was analysed.  
Figure 4.5 depicts the chromosomal location of PHB (chromosomal location 17q21.33) 
and its exons.  Two replicates can be seen of the histogram of read pile-ups.  Within 
each replicate, at each exon there is an increase in PHB transcript pile-ups in cells 
treated with doxycycline when compared to untreated cells.  As the software is unable 
to detect the PHB cDNA is from an exogenous source (an integrated plasmid), the pile 
ups are seen on the hg19 chromosomal location was seen. Therefore, as the two 
replicates show, PHB cDNA was being ectopically over-expressed in the presence of 
doxycycline and the cell line LNCaP/TR2/PHB was working accordingly, as previously 
described. Q-PCR analysis was carried out to verify that PHB was being over-expressed 
in the presence of doxycycline (n=3) (figure 4.5).  
Partek software was used to create a heatmap, clustering genes from both replicates in 
order of log2 expression (p value <0.05).  The parameters used were; each gene 
expression was normalised to zero with a standard deviation of 1.  Genes that were 
unchanged were displayed as a grey colour with a value of zero, down-regulated genes 
were displayed as blue with a negative value, whereas up-regulated genes were displayed 
as red with a positive value.  Around 2000 genes were significantly altered in the 
presence of PHB over-expression (figure 4.6).  The top ten most significantly up-
regulated and down-regulated transcripts from the RNA-seq database are shown in 
figure 4.7. 
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Figure 4.1. RNA-library preparation.  A, an example of an electrogram from total RNA extracted from 
LNCaP/TR2/PHB cells provided by a Bioanalyser. RIN (RNA integrity) number is 9.8, highest RIN 
number a sample can get is 10. (FU = fluorescence, nt=nucleotides, bp = base pairs, RIN= RNA 
integrity number).  B, Bioanalyser results showing fragmented mRNA after RNAse II digestion.  C, 
Purified amplified cDNA with a base pair range of 150-300. 
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Figure 4.2. Run report summary for the RNA-sequencing experiment.  A, 88% of the P1 chip was 
successfully loaded with the ISP beads as shown by ISP density.  B, 100% enrichment of successfully 
loaded beads, with a 83% final library including 68,303,495 total sequencing reads. C, illustrates a 
histogram of global read lengths, reads had a mean length of 116 base pairs.  
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Figure 4.3. Alignment report summary for the RNA-sequencing experiment.  A, alignment to Hg19 
genome. 72% of bases were successfully aligned to the human genome version Hg19. B, illustrates 
alignment was successfully achieved with a 96.6% mean raw accuracy.  C, shows the number of reads per 
sample (LNCaP/TR2/PHB (+/- dox, 10μM, 16 hr). 
C 
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Figure 4.4. Partek Genomics suite software RNA-seq workflow.  A, Screenshot of the workflow.  B, 
description of the main steps resulting in a final gene list. 
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Figure 4.5. Identification that doxycycline is producing ectopic PHB cDNA in the RNA-seq data. A, 
Histogram of transcript pile-ups on chromosome 17 where the PHB gene is found.  At each exon there is 
an increase in transcript pile-ups in the presence of dox when compared to no dox.  B, RNA-seq data 
showing PHB expression is increased in cells treated with dox. C, Q-PCR validation showing PHB gene 
expression is significantly increased when dox is added to LNCaP/TR2/PHB cells, values normalised to 
GAPDH and RPL19. n=3 p<0.001***.  
A 
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Figure 4.6. Significantly altered genes identified by Partek software and organised into hierarchical 
clustering and log2 transformed (p <0.05) with PHB over-expression in the LNCaP/TR2/PHB cell line. 
n=2.  
 
 
 
 
dox 
No dox 
Expression log2 change 
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Figure 4.7. Top ten significantly altered transcripts from the RNA-seq data. A, top ten most significantly 
up-regulated transcripts from the RNA-seq database. B, top ten most significantly down-regulated 
transcripts from the RNA-seq database. 
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4.3.2 Metacore analysis for gene ontology  
From the list produced by Partek software with approximately 42,000 transcripts, all 
transcripts with a p value > 0.05 were removed.  This left 2327 transcripts.  Of these, 
transcripts with no change in expression in response to doxycycline were removed.  
Further, the fold change of 2 was deemed to be within error and any fold change in 
expression 2/-2 was removed.  This left 1208 transcripts that were p<0.05 and a fold 
change in expression >2/>-2.   
To further analyse the data retrieved from the RNA-seq data, a pathway analysis 
program, Metacore was used.  Metacore is an integrated software suite for the 
functional analysis of RNA-seq or expression data. The program searches for shared 
biological pathways within the gene list.  It carries this out utilising a database made of; 
transcriptional factors, receptors, ligands, kinases, drugs and endogenous metabolites.  
Finally, signalling pathways were embodied onto maps and networks. Firstly, the excel 
spreadsheet consisting of transcripts that had a significant p value <0.05 and a fold 
change higher than or equal to 2/-2 was saved as a tab-delimited text file and imported 
into Metacore.  Annotation statistics showed if any errors occurred during the upload 
and how many transcripts were correctly identified in the transcript list.  
Figure 4.8 shows the data from the RNA-sequencing interpreted into biological 
processes, pathways and networks by Metacore. The pathways illustrated are a two-
dimensional representation of the data as it links genes together, rather than just a 
transcript list.  The cell cycle, regulation of the cell cycle and cell cycle progression 
appear within the top ten biological processes associated with PHB over-expression. 
Interestingly, cell cycle G1-S growth factor regulation, cell cycle G2-M and cell cycle 
meiosis are within the top 10 biological networks.  This emphasises that PHB has an 
effect at each stage of the cell cycle.  This agrees with the FACs analysis, showing that 
PHB causes a decrease in cell population within the S and G2 phase, whilst increasing 
the cell population in the G1 phase.  Figure 4.9 shows insight into the cell cycle network 
through a multi-dimensional analysis of the data.  Here it depicts PHB over-expression 
has a repressive role on the E2F/Rb pathway.  Further, the top most up-regulated 
process showed by Metacore was cellular metabolic processes. Moreover, the Wnt-
signal transduction pathway was also within the top ten altered processes, alongside 
Chapter IV. Results 
148 
 
integrin-mediated cell adhesion, these processes will be discussed in proceeding 
chapters.   
4.3.3 DAVID analysis of gene ontology 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
pathway analysis is a platform where a large gene database can be analysed such as 
RNA-seq data, however DAVID does not take into account fold change.   It discovers 
enriched functional-related gene groups and biological themes. The gene list from 
RNA-sequencing was also inputted into this system.  Figure 4.10 illustrates that E2F3 
and E2F6 were in the top ten functional related genes list.  This agrees with the 
Metacore analysis that members of the E2F family are associated with PHB over-
expression. Moreover, cyclin H and forkhead box E transcriptional factor were within 
the top most functional related genes with PHB over-expression.  Cyclin H plays a role 
in progression of the cell cycle, whereas forkhead box E is involved in cellular 
proliferation and growth.  These are all key pathways involved in PC progression.   
4.3.4 IPA analysis of gene ontology 
Finally, a third platform was used to analyse the gene list, namely Ingenuity® Pathway 
Analysis (IPA). IPA is a software designed for the analysis and interpretation of data 
retrieved from ‘omics experiments such as RNA-seq but is compiled by human 
knowledge.   Figure 4.10 illustrates the top 5 associated networks with the imported 
gene list.  Interestingly, the cell cycle appears at the top of the list. This agrees with the 
Metacore and DAVID analysis.  Moreover, cellular growth and cancer were found 
within the top five networks associated with PHB over-expression, highlighting PHB’s 
impact on tumorigenesis.  All three bioanalysis platforms conclude that PHB over-
expression is associated with cell cycle regulation and progression, and this could be due 
to regulation of key genes from the E2F transcription factor family.   
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Figure 4.8. Pathway analysis of RNA-sequencing data by Metacore. A, a list of the top 10 biological 
processes influenced by PHB over-expression produced by Metacore analysis. B, Describes the top ten 
networks produced by Metacore.  Cell cycle regulation, cell cycle G2-M phase transition and meiosis all 
are shown within the top ten.  
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Figure 4.9. Network analysis of RNA-sequencing data drawn by Metacore.  Network shown is of the cell 
cycle regulation.  Highlighted in red depicts inhibitory pathways.  Members of the Rb family; Rb, p107 
and p130 inhibit E2F4/DP1 functions.  Highlighted in green depicts activation pathways.   
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Figure 4.10. DAVID and IPA bioanalysis of the gene list derived from the RNA-sequencing experiment.  
Screenshots describe top 5 associated networks and top 9 functionally related genes. A, DAVID 
bioanalysis platform describes the cell cycle and development and cell growth to be in the top 5 network 
functions. B, IPA bioanalysis platform describes E2F3 and E2F6 to be in the top 9 functionally related 
genes.  
 
  
A 
B 
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4.3.5 RNA-seq identifies PHB over-expression represses genes involved in the 
cell cycle and in DNA replication  
The Bioanalysis programs confirmed that PHB over-expression strongly influences 
genes involved in the regulation and progression of the cell cycle, which correlates to 
the data shown in chapter III.  Selection of genes to be assessed was carried out by 
previous literature stating PHB’s role in interacting with E2Fs, consequently causing cell 
cycle arrest. Therefore, gene families involved in t cell cycle regulation, alongside DNA 
synthesis and DNA replication were assessed via the RNA-seq database as a biased 
analysis (figure 4.11).  Interestingly, cyclin-dependent kinases (CDKs) that were down-
regulated with a fold change higher than 2 in response to PHB over-expression included 
CDK1, CDK2, CDK14, CDK17, CDK20.  As it has already been established that PHB 
has a unique inhibitory interaction with certain E2Fs (107), data also pertaining to E2Fs, 
were retrieved from the RNA sequence database. E2F1,2,7,8 were all down-regulated in 
response to PHB over-expression.  Although figure 4.10 describes E2F3 as the top 
transcriptional factor to be affected by PHB’s over-expression, the E2F1 gene was 
taken forward for further analysis as it is a representative of the ‘activating E2Fs’ and 
often there is interplay and redundancy between E2F1 and E2F2/3.  Moreover, figure 
4.12 shows Metacore analysis depicting E2F1 within the top transcriptional factors 
altered by PHB over-expression.  Previous data has established an interaction between 
E2F1 and PHB in breast cancer, thus the same interaction was investigated in PC.  
Similarly, members of the MCM family MCM2,4,5,6,7,10 that play a vital role in DNA 
replication, were down-regulated with PHB over-expression.  This suggests PHB also 
has a repressive role in DNA replication.  Further, the cell cycle inhibitor known as 
CDKN1A (p21/WAF/CIP1) showed opposite regulation and was seen to be up-
regulated in response the PHB over-expression.  As the RNA-seq was n=2, SYBR ® 
Green Q-PCR was carried out in triplicate to validate the expression changes in key 
members in the gene families of interest.  Screening of all the members of the E2F and 
MCM family were carried out.  A significant decrease was seen in E2F1 and E2F4 with 
PHB over-expression and MCM2,3,4,6,7 (figure 4.13).  Q-PCR validation was also 
carried out for the cell cycle inhibitors CDKN1A (p21) and CDKN1B (p27).  Both cell 
cycle inhibitors showed a significant up-regulation in the presence of PHB over-
expression.  
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4.3.6 PHB represses MCM5&6 promoter activity 
Previously data collected from a low density array screen (through personal 
communications, Dr Dart) showed that members of the MCM gene family, TK1 and the 
CDK gene family were down-regulated with PHB over-expression. However, p21, p27, 
and GADD45a were all up-regulated with PHB over-expression.  TK1 is a DNA 
biosynthetic precursor gene, and plays a role in DNA replication. Therefore this data 
suggests that PHB over-expression down-regulates genes involved in DNA replication, 
an essential step in the S phase of the cell cycle.  Both p21 and p27 are cyclin dependent 
kinase inhibitors, stopping cell cycle progression.  This agrees with the data produced 
from the RNA-seq. Q-PCR was carried out to valid these targets (figure 4.13).    
Previous literature states that E2F binding sites are located in MCM promoter regions 
and thus potentially, MCMs are E2F-regulated (134) (135).  In particular, promoter 
activity of MCM5 and MCM6 were seen to be regulated by E2F by its binding to 
multiple E2F recognition sites in their promoter regions (136).  This was also confirmed 
by previous work carried out by Dr Alwyn Dart, entailing the transfection of LNCaP 
cells and COS-7 cells with an E2F1-overexpression construct, resulting in an increase in 
MCM5&6 gene expression (figure 4.16D) (137).  This suggests that MCM5&6 are 
regulated by E2F1. It was thought that potentially, PHB is able to bind to E2F1, 
repressing E2F1 from interacting with DNA binding sites within the promoter regions 
of MCM5&6. Thus the promoter activity of both MCM5&6 were assessed in the 
presence of PHB over-expression.  
Previously, 1Kb of the promoter sequence of both MCM5&6 was cloned into pGL4-
luciferase plasmids to produce reporter plasmids by Miss Georgia Economides (figure 
4.14). 1 Kb of the proximal promoters was chosen as the E2F binding sites were found 
within this DNA sequence via in silico analysis (-40, -56, -118). Firstly, COS-7 cells were 
transfected with either 400 ng of pGL4-MCM5 luciferase plasmid or pGL4-MCM6 
luciferase plasmid.  The pSG5-PHB plasmid was also transfected into COS-7 cells at an 
increasing concentration (0-400 ng).  In the absence of pSG5-PHB, a pSG5-empty 
plasmid was transfected into the cells as a control in an equal quantity.  In both cases, 
increasing concentrations of the pSG5-PHB plasmid led to a significant decrease in the 
promoter activity of MCM5&6 (figure 4.15).  This was monitored by luciferase 
production.   A constitutively active Bos-β-galactosidase plasmid was transfected into 
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the COS-7 cells alongside the reporter plasmids to control for transfection efficiency.  
The β-galactosidase assay results were used to normalise the luciferase values. 
The same experiment was also carried out in the LNCaP/TR2/PHB cell line. However, 
instead of transfecting the pSG5-PHB plasmid into the cells, doxycycline was used at 
increasing concentrations to produce PHB over-expression. 0,2.5,5 and 10 μM of 
doxycycline was used with 400 ng of both MCM5&6 reporter plasmids.  The cells were 
left to transfect for 48 hr rather than 24 hr as transfection in LNCaP cells is less 
efficient. Data retrieved agreed with the COS-7 cell transfections, and PHB was shown 
to have a repressive function on both the MCM5&6 promoter regions.   
4.3.7 Mutating a predicted E2F binding site in the MCM6 promoter region 
In order to identify if PHB was repressing E2F directly at the MCM promoter, one-site 
directed mutagenesis was carried out.  In silico analysis highlighted no predicted E2F 
binding sites in the mutated sequences. Interestingly, transfection of COS-7 cells with 
the mutated MCM6 reporter plasmid, abolished the repression of the promoter with 
increasing concentrations of the pSG5-PHB plasmid, when compared to the wild-type 
MCM6 reporter plasmid (figure 4.16).  A similar experiment was carried out on the TK1 
promoter by mutating predicted E2F binding sites by Dr Alwyn Dart. PHB repression 
of the TK1 promoter was abolished upon base changes within the predicted E2F 
binding sites. This mirrors the same effect seen in the mutated MCM6 promoter. 
ALLGEN in silico analysis showed no significant E2F1 potential sites in the mutated 
sequences (supplemental figure 2). Accumulating this data together, PHB is able to 
repress the activity of E2F-regulated genes such as MCMs, through a mechanism that is 
discussed in proceeding chapters.  
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Figure 4.11. RNA-sequencing data analysis.  The down-regulation of CDKs,MCMs,E2Fs with PHB over-
expression in LNCaP/TR2/PHB cells.  A, The down-regulation of CDK1, CDK2, CDK14, CDK17 and 
CDK20 with PHB over-expression.  A cell cycle inhibitor known as CDKN1A (p21) was up-regulated 
with PHB over-expression. B,  MCM2,4,5,6,7,10 showed downregulation with PHB over-expression.  C,  
E2F1,2,7,8 were down-regulated with PHB over-expression.  n=2.   
 
 
Chapter IV. Results 
156 
 
 
Figure 4.12. A screenshot of the transcription workflow report from Metacore showing E2F1 and the 
AR within the list of transcriptional factors affected by PHB over-expression.  
 
 
No
Key 
network 
objects
GO Processes
1 CREB1
macromolecule metabolic process (61.2%), metabolic process (74.1%), cellular 
metabolic process (65.6%), cellular macromolecule metabolic process (55.1%), 
primary metabolic process (66.0%)
2 c‑Myc
regulation of primary metabolic process (64.5%), regulation of cellular metabolic 
process (65.1%), regulation of metabolic process (69.9%), cellular metabolic 
process (78.5%), regulation of macromolecule metabolic process (62.4%)
3 SP1
positive regulation of cellular metabolic process (49.6%), positive regulation of 
cellular process (62.2%), positive regulation of metabolic process (52.8%), 
positive regulation of biosynthetic process (37.8%), positive regulation of 
biological process (65.4%)
4
ESR1 
(nuclear)
negative regulation of nucleic acid‑templated transcription (30.2%), positive 
regulation of cellular process (60.3%), negative regulation of RNA biosynthetic 
process (30.2%), negative regulation of cellular process (56.9%), positive 
regulation of cellular metabolic process (46.6%)
5 p53
positive regulation of cellular process (62.9%), positive regulation of cellular 
metabolic process (47.4%), positive regulation of biological process (64.7%), 
positive regulation of nucleobase‑containing compound metabolic process 
(35.3%), positive regulation of cellular biosynthetic process (36.2%)
6 Oct‑3/4
regulation of metabolic process (70.6%), positive regulation of cellular metabolic 
process (45.0%), regulation of primary metabolic process (63.3%), positive 
regulation of cellular process (57.8%), regulation of cellular metabolic process 
(64.2%)
7 YY1
macromolecule metabolic process (76.1%), regulation of macromolecule metabolic 
process (63.3%), organic substance metabolic process (80.7%), negative 
regulation of biological process (56.9%), negative regulation of cellular process 
(54.1%)
8 GCR‑alpha
positive regulation of cellular metabolic process (48.6%), positive regulation of 
metabolic process (53.3%), positive regulation of cellular process (61.0%), 
positive regulation of biosynthetic process (37.1%), regulation of cellular 
metabolic process (66.7%)
9
Androgen 
receptor
positive regulation of cellular process (67.7%), positive regulation of biological 
process (71.7%), positive regulation of cellular metabolic process (51.5%), 
positive regulation of metabolic process (56.6%), positive regulation of 
macromolecule metabolic process (48.5%)
10 c‑Jun
positive regulation of macromolecule metabolic process (52.3%), positive 
regulation of cellular metabolic process (53.5%), response to organic cyclic 
compound (36.0%), response to oxygen‑containing compound (41.9%), positive 
regulation of metabolic process (55.8%)
11 E2F1
mitotic cell cycle (39.3%), cell cycle (46.4%), cell cycle process (42.9%), mitotic 
cell cycle process (35.7%), positive regulation of macromolecule metabolic 
process (56.0%)
12 GATA‑3
regulation of macromolecule metabolic process (70.4%), regulation of cellular 
metabolic process (71.6%), regulation of primary metabolic process (69.1%), 
positive regulation of macromolecule metabolic process (48.1%), regulation of 
protein modification process (37.0%)
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Figure 4.13. SYBR ® Green Q-PCR validation of the gene targets identified with a fold change >2/-2 
from the RNA-seq database.  A, E2F1 and E2F4 were significantly downregulated with PHB over-
expression. B, MCM2,3,4,6,7 were significantly downregulated with PHB over-expression. C, the 
upregulation of cell cycle inhibitors, p21 and p27 with PHB over-expression, and the stress induced gene 
GADD45a.  Values were normalised to GAPDH, RPL19 and β-actin.  , p<0.05*, p<0.01**, 
p<0.001***.n=3.  
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Figure 4.14. Schematic of the MCM5&6 promoter. A, Schematic of the cloned promoter region of 
MCM5&6 with predicted E2F binding sites (-56 & -118 for MCM6) and (-40 for MCM5). B, Schematic 
diagram of the promoter-reporter fusion plasmids generated linked to luciferase. 1Kb of the proximal 
gene promoter cloned upstream of luciferase. Numbered lines indicate the position of predicted strong 
E2F1 binding sites (ALGGEN software). 
 
 
 
A 
B 
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Figure 4.15. The activity of the promoter regions of pGL4-MCM5&6 is reduced with PHB over-
expression. A, Bar graph showing luciferase activity for MCM5 promoter activity from COS-7 cells 
transfected with pSG5-PHB for 24 hr. B, Bar graph showing luciferase activity for MCM6 promoter 
activity from COS-7 cells transfected with pSG5-PHB for 24 hr. C, LNCaP/TR2/PHB cells treated with 
doxycycline (16 hr) and monitoring MCM5 promoter activity.  D, LNCaP/TR2/PHB cells treated with 
doxycycline (16 hr) and monitoring MCM6 promoter activity. Luciferase signal normalised to β-
galactosidase values.  p<0.05*, p<0.001***, p <0.0001****.  n=3. 
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Figure 4.16. Mutagenesis of the MCM6 promoter abolishes PHB repression.  A, wt MCM6 reporter 
plasmid is repressed with increasing concentrations of pSG5-PHB plasmid (0-400ng). n=3, p<0.05*.  B, 
mutated MCM6 reporter plasmid.  Repression is not seen in the presence of PHB, n=3.  C, schematic of 
the MCM6 reporter plasmid with the predicted E2F binding site.  This site was mutated with a single base 
substitution of T>A.  D, Q-PCR analysis of LNCaP cells transfected with an E2F1-overexpression 
construct.   
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4.4 Discussion 
The aim of this chapter was to identify how PHB over-expression caused cell cycle 
arrest in PC cells as shown in chapter III.  Therefore, an RNA-seq experiment was 
carried out as PHB has been documented to have a profound effect on gene expression. 
Revealing information about a particular transcriptome is essential in understanding the 
development of diseases such as cancer.  In this case, the transcriptome of 
LNCaP/TR2/PHB cells treated with and without doxycycline, to produce ectopic PHB 
cDNA over-expression, was analysed. There are a few technologies available to quantify 
the transcriptome included hybridisation and sequence based approaches, in this case an 
RNA-seq was carried out.  
RNA-seq showed how PHB over-expression influenced the transcriptome of androgen 
sensitive cells, LNCaPs.  It was vital to perform both unbiased and biased analysis with 
the data produced to yield an in-depth and comprehensive analysis. Unbiased analysis of 
the RNA-seq data entailed inputting the data into pathway analysis programs such as 
METACORE, DAVID and IPA.  METACORE depicted that several stages of the cell 
cycle were heavily influenced with PHB over-expression.  DAVID in particular, is a 
high-throughput data-mining program that analyses gene expression data.  Analysis 
demonstrated that the key networks associated with the inputted datasheet were cell 
cycle and the regulation of the cell cycle.  The IPA pathway analysis showed that E2F3 
was the top transcriptional factor associated with the inputted gene list.  Accumulating 
both gene ontology analysis and RNA-seq data, lead to the assumption that PHB has a 
repressive function on the cell cycle through interactions of genes associated with the 
progression of the cell cycle. The unbiased data also depicted that cellular metabolism, 
cell adhesion and Wnt signalling were within the top ten processes to be altered with 
PHB over-expression.  Interestingly, altered cellular metabolism is an essential initiator 
in prostate adenocarcinoma. Without metabolism transformation, neoplastic cells are 
unable to survive.  Moreover, altered cell adhesion, particular altered expression of 
integrin proteins has been documented in ‘castration-resistant PC’. Similarly, over-
activated Wnt signalling has been seen in aggressive PC(138).  Both these processes will 
be discussed further in proceeding chapters.  However, the biased analysis entailed data-
mining for genes associated with the regulation and progression of the cell cycle and 
DNA replication.  Previous data has suggested that PHB has a direct influence on E2F1 
in breast cancer cells (139). Moreover, Dart et al., (128) described PHB that over-
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expression induced androgen responsive LNCaP cells to accumulate in the G0/G1 
phase of the cell cycle.   E2F binding sites have been identified in promoter regions of 
the MCM gene family that are responsible for DNA replication, genes essential for S 
phase progression (136).  Thus gathering this data together, PHB’s role on the E2F, 
CDKs and MCM gene families was investigated.   
Interestingly, PHB over-expression caused an up-regulation of p21 alongside a down-
regulation of CDKs, E2Fs and MCMs.  Data pertaining to a p21-promoter luciferase 
reporter plasmid, showed that increasing concentrations of PHB lead to heightened 
promoter activity through an increase in luciferase production (137).  Whereas 
increasing concentrations of PHB led to the repression of a TK1-promoter luciferase 
reporter plasmid (137).    This highlights PHB’s role in suppressing the activity of genes 
involved in DNA replication, whilst enhancing the function of cell cycle inhibitors such 
as p21. p21 initiates the arrest of the cell cycle through stimuli such as anti-proliferative 
signals (140). Whereas CDK1 forms a complex with cyclin A and B to create the 
maturation-promoting factor, essential for early phase mitosis (141). Thus, accounting 
for the above data, one can assume that the over-expression of PHB causes a synergic 
effect of both the down-regulation of cell cycle activators with an increase in cell cycle 
inhibitors.  Interestingly, the Growth Arrest and DNA Damage-inducible 45 
(GADD45a) was up-regulated with PHB over-expression.  GADD45a plays a role in 
senescence and genotoxic stress (142), suggesting PHB is able to hinder uncontrolled 
damage cellular proliferation through the up-regulation of GADD45a as it was 
previously reported that PHB induces senescence in yeast, limiting their proliferative life 
span (143).  
The mechanism of how PHB influences key genes involved in the regulation of the cell 
cycle was investigated.  Binding sites for members of the E2F family have been 
identified in promoter regions of both MCM5 and MCM6. This was evidenced by 
mutations within the E2F binding sites causing failed promoter regulation even in the 
presence of exogenous E2F expression (136).    Therefore the activity of these 
promoters was assessed with PHB over-expression.  Data revealed that PHB can 
significantly reduce the activity of the promoter region of MCM5&6.  Interestingly, 
upon mutating the predicted E2F binding site within the promoter region of MCM6, 
this repression was not seen.  It has been reported that the recruitment of PHB to the 
promoters leads to HDAC1-dependent transcriptional repression which resembles Rb’s 
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mode of repression (144).  Interestingly, previous work demonstrates that with the 
addition of cyclin dependent kinases (CDKs), PHB’s repressive function on gene 
promoters is not affected (144).  This potentially could be due to PHB’s being part of a 
larger repressive complex (144). Further analysis could potentially provide a preliminary 
mechanism linking PHB, MCMs and E2Fs to the inhibition of the cell cycle (figure 
4.17).   
Interestingly, ectopic expression of E2F1,2,3 is sufficient to induce the S-phase of the 
cell cycle in serum starved cultured cells, unlike E2F4 and E2F5 that are unable to carry 
out the same function.  Therefore E2F1,2,3 are the main instigators of cell cycle 
progression. The DNA binding sites of E2F have been identified in promoters of genes 
that are responsible for DNA replication and cell cycle control.  Such genes include; 
dihydrofolate reductase (DHFR), DNA polymerase α, and regulatory molecules for the 
initiation of DNA replication, such as HsOrc1 and HsCdc6.  As shown by (Ohtani, et 
al., 1999) both promoter regions of MCM5 & MCM6 containing E2F binding sites were 
regulated by E2Fs and that endogenous expression of E2F1 led to the expression of all 
the members of the MCM family in REF52 cells (136).   
Collectively, these results indicate that MCM and E2F genes were downregulated by 
over-expression. It was seen that PHB has a repressive effect on the promoter regions 
of both MCM5&6 that was abolished when predicted E2F binding sites were mutated.  
PHB’s repressive function on E2F1 is further explored as it has such a prominent role 
in controlling the progression of the cell cycle.  Moreover, both gene expression analysis 
and bio-analysis indicated that E2F1 was the main E2F transcriptional factor affected 
by PHB over-expression.  
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Figure 4.17. Schematic representation of a preliminary mechanism involving PHB, MCM promoters and 
cell cycle progression. A, PHB can repress E2F activity on E2F binding sites, preventing the downstream 
transcription of genes associated with the cell cycle. B, through some mechanism, potentially by AR 
signalling activation, PHB can no longer bind to the MCM promoter regions, thus cell cycle progresses.   
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4.5 Conclusion 
RNA-seq showed an array of genes that were altered as a result of PHB over-
expression.  Analysis of this gene list gave insight that the cell cycle GO pathway was 
heavily influenced by PHB over-expression.  This was supported by the evidence that 
key genes involved in the cell cycle were down-regulated as a result of PHB over-
expression.  Specifically, members of the E2F and MCM gene family with the validation 
of Q-PCR were significantly downregulated.  RNA-seq confirmed that PHB arrests the 
cell cycle via E2F-repression.  
4.6 Key points 
 RNA-seq showed PHB over-expression caused the down-regulation of E2Fs, 
MCMS and CDKs. 
 RNA-seq showed PHB over-expression caused the up-regulation of cell cycle 
inhibitors such as p21 and p27. 
 Bioanalysis programmes such as METACORE, DAVID and IPA, all suggested 
that PHB over-expression heavily influenced the regulation of the cell cycle. 
 The bioanalysis programmes also indicated that E2Fs were the main 
transcriptional factor associated with PHB over-expression. 
 PHB was able to reduce the activity of both MCM5 and MCM6 promoter 
regions via E2F binding sites.   
 Accumulating data, it is theorised that PHB is able to suppress the cell cycle 
repressing E2F from binding to MCM promoter regions, preventing E2F gene 
transcription that in turn causes cell cycle arrest.  
Chapter V: Results 
166 
 
 
 
 
 
 
 
 
 
Chapter V. The interaction of PHB and 
E2F1 is lessened with AR activation. 
  
Chapter V: Results 
167 
 
5 Chapter V.  The interaction of PHB and E2F1 is lessened with AR      
activation. 
5.1 Introduction 
It was established that PHB’s role in causing cell cycle arrest may be mediated through 
E2F repression and down-regulation. In particular, both RNA-seq and bio-informatic 
analysis indicated that E2F transcription factors were down-regulated with PHB over-
expression.  Moreover, PHB was able to regulate E2F responsive genes such as MCM’s 
and TK1 reducing their promoter activity. This repressive response was abolished upon 
mutation of the E2F binding site within the MCM promoter.  As MCM genes are 
involved in DNA replication, this could explain why fewer cells were seen in S phase 
and an accumulation of cells was seen in the G1 phase, with PHB over-expression.   
Specifically, as the Q-PCR data indicated E2F1 was the most significantly down-
regulated member of the E2F gene family and E2F1 targets E2F3’s gene transcription 
(122) which was the most affected gene according to IPA and DAVID analysis, further 
experiments were carried out with this key gene. There is evidence to suggest that in 
breast cancer PHB directly interacts with E2F1 within the nucleus of T47D and MCF7 
cells where it also co-localises with p53 (89).  Therefore, it was of interest to evaluate 
whether PHB can directly interact with E2F1 in androgen sensitive PC cells.  This could 
be key in unveiling a mechanism to how PHB is able to repress the cell cycle and how 
androgens may influence it. 
Two key methods were adopted to observe if there was a direct interaction between 
PHB and E2F1 in the LNCaP cell line; the Checkmate ™ Mammalian two-hybrid assay 
and co-immunoprecipitation.  As the AR is the main pathogenic signalling pathway in 
PC, the role the AR pathway plays in the interaction of E2F1 and PHB was 
investigated.  
The aim was to identify if there was an interaction between E2F1 and PHB in the 
LNCaP cell line.  As activation of the AR signalling pathway results in PHB dissociating 
from the chromatin, it was investigated if PHB’s interaction with E2F1 was influenced 
by androgens and the AR.  This could then lead to a preliminary mechanism alluding to 
how PHB is down-regulated as PC progresses, leading to an increased E2F activity and 
progression of the cell cycle.  
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5.2 Methods 
 Molecular cloning (refer to chapter 2.12). 
 Checkmate ™ Mammalian two-hybrid assay (refer to chapter 2.15). 
  Co-immunoprecipitation assay (refer to chapter 2.11.8). 
 Cell fractionation and chromatin isolation of protein lysates (refer to chapter 
2.11.7).  
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5.3 Results 
5.3.1 Checkmate™ Mammalian Two-hybrid system 
In order to assess if there was a physical interaction between E2F1 and PHB, a 
CheckMate™ Mammalian Two-Hybrid assay was carried out. In this system, interaction 
of two proteins results in the transcription of the firefly luciferase reporter gene.  Firstly, 
production of plasmids expressing fusion proteins was carried out.  
5.3.2 Production of pACT-E2F1 and pBIND-E2F1 plasmids 
Firstly, the fusion plasmids were made via a two-step cloning procedure (figure 5.4).  
The coding sequence of E2F1 was amplified from the pCMV6- E2F1 plasmid 
(Origene) by PCR, using primers with attached restriction sites for BamH1 and Xba1 
(figure 5.1A).  Next the PCR product was cut out of the 0.8% (w/v) gel and purified 
using a gel purification kit.  The purified PCR product was ligated into the pEF6 vector.  
Transformation of E.coli was carried out using this pEF6-E2F1 plasmid. The E.coli was 
spread onto an LB-ampicillin agar plate to grow overnight.  Colonies were checked for a 
positive orientation of the insert using PCR (figure 5.1B).  Plasmids that had a positive 
orientation of the E2F1 insert were sent for sequencing. BLAST was used to align the 
sequence produced by the PCR product to Homo sapiens E2F transcriptional factor 1 
(E2F1) mRNA (Figure 5.1C).  
Following on from confirming the PCR product was E2F1, the insert was cut out of 
pEF6 using the restriction enzymes BamH1 and Xba1.  These restriction enzymes were 
used as the Checkmate™ assay plasmids pACT and pBIND contain these restriction 
sites in the multiple cloning sites (figure 5.3).  Next the insert of E2F1 was ligated into 
linearised pBIND and pACT plasmids (figure 5.1D) and left to ligate for 2 hours at 
room temperature.   
Both pACT-E2F1 and pBIND-E2F1 were transformed into E.coli and left to grow 
overnight on LB-ampicillin agar plates.  Colonies were picked and were grown 
overnight in LB-ampicillin broth.  The plasmids extracted from these colonies were 
screened for the E2F1 insert using the orientation check. Plasmids with positive 
orientations that were sequenced, were re-transformed and DNA was extracted using a 
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maxiprep DNA extraction kit to ensure a high DNA concentration needed for the 
Checkmate™ assay.  
5.3.3 Production of pBIND-PHB and pACT-PHB 
The Checkmate™ assay involves assessing the interaction of two proteins, thus the next 
step was to create a PHB plasmid that could interact with either the pACT-E2F1 or 
pBIND- E2F1 plasmid. Firstly, the coding sequence of PHB was amplified from the 
pSG5-PHB plasmid (figure 5.2A). Next, the PHB PCR product was cut out of the 0.8% 
(w/v) gel and purified using a gel extraction kit.  This purified PCR product was then 
ligated into the pEF6 vector.  The ligated pEF6-PHB plasmid was used to transform 
E.coli.  Colonies grown were chosen and amplified in LB-ampicillin broth.  The DNA 
was extracted using a miniprep DNA extraction kit. A single and double restriction 
enzyme digest was carried out to check if the PHB insert had successfully ligated into 
the pEF6 plasmid (figure 5.2B).  The enzymes used were BamH1 and EcoRV.  
Subsequently the PHB insert cut out of the pEF6-PHB plasmid was ligated into the 
linearised pACT and pBIND plasmids for the CheckMate™ assay.  The PHB insert was 
cut with Xba1 and BamHI as these were the enzymes used to linearize both pACT and 
pBIND.  Next the ligation reaction was performed to successfully ligate the insert into 
both vectors.  The reactions were transformed into E.coli.  Colonies were picked and the 
plasmids extracted which were sent for sequencing. The sequencing data was inputted 
into BLAST and the results indicated 99% identify with Homo sapiens prohibitin (PHB) 
transcript variants 1-4 (figure 5.2C).  As the checkmate ™ assay relies on two 
complementary plasmids interacting, pACT-E2F1 and pBIND-PHB were chosen.  
 
  
Chapter V: Results 
171 
 
5.3.4 Confirming PHB and E2F1 physically interact 
Once the fusion plasmids were made, COS-7 cells were transfected with the 
Checkmate™ plasmids, as their transfection efficiency are much higher than that of 
LNCaP cells.  Firstly, cells were transfected with the pGL5 plasmid to monitor 
luciferase production.  As a positive control, pBIND-ID and pACT-Myo were 
transfected into the cells.  As a negative control, pBIND-empty and pACT- E2F1 was 
used.  The two positive plasmids (pBIND-ID and pACT-Myo), producing the two 
proteins with a known interaction, produced a high luciferase activity as predicted 
(figure 5.5).  The negative controls used produced little luciferase activity, indicating this 
as the baseline luciferase production was from pGL5.  Cells transfected with pACT- 
E2F1 and pBIND-PHB produced luciferase activity significantly higher than the 
negative controls, indicating a positive interaction (figure 5.5).     
5.3.5 PHB dissociates from the chromatin in response to androgen 
Previous literature suggests PHB dissociates from the chromatin when the AR signaling 
pathway is stimulated with androgen (4 hr) (94).  This experiment was carried out in 
androgen dependent cell lines; VCaP and LNCaP cells.  Figure 5.6 illustrates that when 
R1881 (10 nM) was added to these hormonally starved cells, thus stimulating 
downstream AR signaling events, the AR associated with the chromatin while PHB 
dissociated from the chromatin (4hr).  The reason why there are two bands for PHB in 
VCaP and PC3 cells is yet to be investigated, potentially PHB2 was also present on the 
chromatin. To make sure that the AR signaling cascade was activated in the presence of 
R1881, figure 5.6 shows an increase in chromatin bound AR, where the AR is 
presumably binding to sites within promoter regions of androgen responsive genes, 
amongst others. It was then analysed to see if the AR null line cell; PC3 would respond 
similarly. PC3 cells no longer express the AR nor are they androgen dependent. Figure 
5.6 illustrates that in PC3 cells no AR was bound to the chromatin in the cells as 
expected, when they were stimulated with ethanol (vehicle) or the hormone R1881 (10 
nM). Moreover, PHB levels were very low in comparison to the wt LNCaP cells and 
were unaffected by hormone treatment in PC3 cells. Thus figure 5.6 demonstrates no 
change in the little chromatin bound PHB with or without R1881 stimulation.   
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5.3.6 The novel interaction of PHB and E2F1 in LNCaP cells 
Luciferase signal produced by the Checkmate™ assay showed an interaction between 
the pACT-E2F1 and pBIND-PHB fusion proteins. Therefore immunoprecipitation 
assays were also carried out to determine if a direct protein:protein interaction existed 
between PHB and E2F1 in wt LNCaP cells within the nuclear fraction.  Figure 5.7 
shows the immunoprecipitation of PHB when probed with PHB primary antibody.  
Further, the AR rabbit polyclonal IgG, was seen to co-immunoprecipitate PHB in the in 
hormonally starved cells (figure 5.7).   Interestingly, although PHB is a well-established 
co-repressor of the AR, it has not previously been shown to directly interact with the 
AR.  However in the presence of androgen, the interaction of PHB and the AR in the 
LNCaP cell is lessened (R1881 10nM, 4 hr).   Figure 5.6 also depicts a novel interaction 
between PHB and E2F1 in the LNCaP cells.  Significantly, this novel interaction was 
reduced when the cells were treated with R1881.   
5.3.7 PHB is potentially dephosphorylated in response to androgen 
Since the chromatin dissociation was so rapid (4 h), it was assumed that a movement of 
proteins within the cell was occurring, which are frequently regulated by post-
translational modifications of proteins. Such modifications include phosphorylation, 
ubiquitination and acetylation that can alter the size and overall charge of PHB. Thus, 
analysis of post-transcriptional modification by 2D western blot was carried out, in 
order to assess if the isoelectric point of PHB was affected in presence of hormone.    
Figure 5.8 illustrates that with the addition of hormone (R1881, 10 nM, 4 hr), wt LNCaP 
cells that had been serum starved for 72 hr showed a pattern change in PHB’s 
isoelectric point.  In the presence of hormone, the immunoblot detected spots for PHB 
shifted more towards pH 10.  The same pattern was seen in the VCaP cell line that was 
serum starved for 72 hr and treated with hormone (R1881, 10 nM, 4 hr), VCaPs are also 
AR positive, thus signifying the pattern is not cell line specific. The shift change was 
thought to be potentially a post-transcriptional modification.  In particular as there was 
no size change, it was speculated that the stimulation of the AR pathway was causing 
PHB to become dephosphorylated.  The suggestion that it could be a 
dephosphorylation event was due to the isotypes of PHB shifting towards pH 10, thus 
the isoforms are less acidic as phosphate groups are acidic.  The same experiment was 
carried out on PC3s, a cell model representative of androgen independent PC.  The 
isoelectric spots for PHB were the same pattern as the isoelectric spots of PHB in the 
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LNCaP cells treated with R1881 (figure 5.9).  This pattern is also seen in Hela cells that 
are AR negative and non-prostate cancer cells (94). 
5.3.8 PHB is likely to be dephosphorylated in response to androgen 
An immunoprecipitation assay was carried on protein lysates that had been treated with 
calf intestinal phosphatase (CIP). This was to confirm that the post-transcriptional 
modification was a dephosphorylation event.  CIP is an enzyme that removes the 
phosphate group from the protein and other molecules.  Removal of a phosphate 
group, resembling dephosphorylation led to the reduced interaction of E2F1:PHB in wt 
LNCaP cells (figure 5.10).  Thus, potentially, androgen stimulation of the AR could be 
leading to the dephosphorylation of PHB, leading to its dissociation from E2F1.  
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Figure 5.1.  Cloning of E2F1 into the plasmids pACT and pBIND.  A, PCR amplification of E2F1 
coding sequence using a high fidelity enzyme (Pfu) and GoGreen Taq enzyme.  B, orientation check of 
pEF6-E2F1.  C, screenshot of BLAST (NCBI) results of E2F1-PEF6 sequencing result.  D, the digestion 
of pEF6-E2F1 with BamH1 and Xba1, illustrating the insert of E2F1 free of the pEF6 backbone.  pACT 
and pBIND were also digested with the same enzymes.  E, pEF6 vector circle map (image taken 
pEF6/V5-His TOPO®, ThermoFisher Scientific) used for the first step of the cloning procedure.  F, 
schematic of the pEF6 ligated with the E2F1 insert, and how the orientation check is carried out using 
the T7 forward and BGH reverse primers.   
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Figure 5.2. Cloning of the PHB insert into pEF6.  A, PCR product of PHB’s coding sequencing from 
pSG5-PHB. B, Restriction digest of pEF6-PHB plasmid with BamH1 and EcoRV.  Single digest 
represents the plasmid being cut with only BamHI to give a linearized plasmid.  In the case of the double 
digest, both restriction enzymes (BamH1 and EcoRV ) were used, dropping out the PHB insert (800bp) 
and producing a smaller linearized plasmid.  C, screenshot of BLAST results representing the sequence of 
pBIND-PHB aligned to Homo sapiens PHB mRNA.  
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Figure 5.3.  Plasmid maps for pACT and pBIND.  A, pACT vector circle map and sequence reference 
points (image taken from Promega CheckMate™ Mammalian Two-Hybrid System). B, pBIND vector 
circle map and sequence reference points (image taken from Promega CheckMate™ Mammalian Two-
Hybrid System). In the MCR (multiple cloning region) of pACT, the insert of E2F1 was ligated in.  In the 
MCR of pBIND, the insert of PHB was ligated in.   
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Figure 5.4. Schematic representation of the two-step cloning procedure.   First the coding sequence of 
the gene of interest is amplified using primers with added restriction enzyme (RE) sites.  This PCR 
product is then ligated into the cut pEF6 plasmid via a T-A ligation.  This plasmid is then amplified via 
competent E.coli cells.  The PCR insert is then cut out of the plasmid using restriction enzymes 
compatible to those used in the Checkmate™ plasmids.  The insert is now ready to ligate into either 
pBIND or pACT to create the fusion plasmids needed for the Checkmate™ Mammalian two-hybrid 
assay.   
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Figure 5.5. The interaction of PHB and E2F1. A, The CheckMate™ Mammalian Two-Hybrid assay 
carried out in the COS-7 cell line.  Positive control where luciferase production was highest between 
pACT-MYO and pBIND-ID. Negative control was pACT-empty and PHB-pBIND.  Interaction was 
seen with the fusion plasmids; pBIND-PHB and pACT-E2F1. Luciferase production was normalised to 
the positive control. n=3, p <0.05*. B, schematic of the interaction of E2F1 and PHB leading to 
luciferase activity (137).  
A 
B 
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Figure 5.6. The AR and PHB are in dynamic opposition on the chromatin.  Western blot for the AR, 
PHB, H3 from the chromatin cell fraction of PC3, VCaP and LNCaP cells for the AR, PHB and H3.  
PC3s, VCaPs and LNCaPs were serum starved for 72 hr and treated with R1881 (10 nM,4 hr).  As a 
loading control, chromatin histone H3 was assessed.  n=1.  
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Figure 5.7. The interaction of E2F1 and PHB in the wt LNCaP as shown by co-immunoprecipitation.  
A, immunoblot for PHB from nuclear cell lysates +/-R1881 (4 h, 10 nM).  Inputs are total nuclear PHB, 
pull-down of each protein was normalized to its input counterpart.  B, relative percentage pull-down of 
PHB, AR and E2F1 with PHB.  n=3. Error bars represent SEM.  
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Figure 5.8. 2D western blot of PHB in androgen dependent cell lines. A, LNCaP cells serum starved for 
72 hours and treated with ethanol or R1881 (10 nM,4 hrs).  B, VCaP cells serum starved for 72 hours and 
treated with ethanol or R1881 (10 nM,4 hrs).  VCaP cells stimulated with R1881 displayed a basic shift 
change of PHB isotypes (isotypes are shifted towards pH 10). Right hand side shows a magnified image.   
A 
B B 
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Figure 5.9. 2D western blot of PHB in wt PC3 cells serum starved for 72 hours and treated with ethanol 
or R1881 (10 nM,4 hrs).    
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Figure 5.10. Western blot showing PHB interaction with E2F1 the LNCaP hormonally starved for 72 
hrs (+/- CIP) via co-immunoprecipitation.  Hormonally starved LNCaP cells were treated with CIP for 1 
hour prior to immunoprecipitation at 37°C before immunoprecipitations with E2F1.  Pull down of E2F1 
is seen when immunoblotted for PHB.  
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5.4 Discussion 
PHB has pleiotropic roles within the cell depending upon its localisation with the cell 
compartments.  Within the nucleus, PHB carries out its repressive function via 
interaction with retinoblastoma (Rb) and nuclear co-repressor (NCoR) that then form a 
complex with E2Fs, rendering their function inactive within the cell cycle (107).  
However, within the mitochondria, PHB is essential for the dynamics and integrity of 
the mitochondria as it interacts with SLP-2, a protein essential for mitochondrial 
biogenesis (79).  The novel interaction between PHB and the transcriptional factor; 
E2F1 in the androgen dependent LNCaP cell line was depicted by immunoprecipitation 
and the Checkmate ™ Mammalian two-hybrid assay. Although novel in PC, this 
interaction was also seen in experiments carried out by Wang et al,. (107) that describes 
PHB as an Rb binding protein that is able to suppress E2F (1-5) activity in T47D breast 
cancer cells.  Within the nucleus PHB recruits histone deacetylases such as histone 
deacetylase 1 (HDAC1) to aid the repression of E2Fs, similar to how Rb represses E2F 
activity.  However, one way in which PHB differs from Rb in its repressive function is 
that PHB can recruit N-CoR.  Moreover, PHB’s repressive function on E2F1, was not 
overcome when T47D cells were stimulated with adenovirus E1A protein. E1A protein 
is able to inactive Rb and its two family members; p107 and p130, thus allowing 
transactivation of E2F target genes, even in the absence of growth factor stimulation.  
This deregulation of E2F activity can contribute to tumour development. Therefore, 
PHB’s ability to repress the activity of E2F1-5 even in the presence of E1A protein, 
perhaps due to PHB forming a large repressive complex involving other proteins that 
are able to withstand stimulation of the cell cycle (107).    This could explain why the 
signal for the CheckMate™ Mammalian Two-Hybrid assay was not relatively high as 
PHB interacting with E2F1 may be a part of a larger protein complex involving Rb and 
N-CoR and potentially other histone deacetylases.  
Interestingly, PHB was found to be complexed with either Rb or E2F1 in an array of 
cells.  Such include Ramos cells (B lymphocyte cell line) (139) and from this data, 
LNCaP cells.   Distinct binding sites of E2F1 (amino acids184-214) and Rb (amino 
acids 74-116) are found on PHB, thus it is possible that all three proteins bind together 
at the same time to form a large complex.  Work carried out by (107) also described 
PHB’s ability to repress the transcriptional activity of E2F2-5 by binding to the highly 
conserved marked box region.  As Rb can only influence the activity of E2F1-3, this 
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suggests that PHB may interact with other proteins to render the activity of E2F4-5 
inactive, independent of Rb.   
Previous data carried out by D Dart, from a Nanobit assay that assesses protein:protein 
interaction in real time, showed that the interaction of PHB and E2F1 was diminished 
with androgen within 1 hour (137).  Data shown here by the co-immunoprecipitation 
and the CheckMate™ Mammalian Two-Hybrid assay agrees with the Nanobit assay, 
confirming that PHB can directly interact with E2F1 in the wt LNCaP cell line.  This 
could explain how PHB causes cell cycle arrest as shown in chapter III.  This also 
confirms how PHB is able to repress the promoter activity of MCM5&6.  Interestingly, 
as the immunoprecipitation experiment illustrates, the interaction between E2F1 and 
PHB was reduced when the AR signaling cascade is stimulated with hormone.  The 
dynamic opposing interaction between PHB and the AR has been well established, 
particularly as androgen stimulation causes a down-regulation of PHB at both an 
mRNA and protein level (at 16-24 hr), however this is too slow to account for 
chromatin changes (seen at 4 hr) (58). However with data presented here, hormone 
stimulation of the AR caused PHB to rapidly dissociate from the chromatin.   Although 
PHB has no specific DNA binding motifs, it does strongly associate with chromatin as 
shown here and also in serum starved HeLa cells (94). However, the mechanism to how 
PHB dissociates from the chromatin is still not well understood.  Therefore it was 
interesting to find that a potential post-translational modification seen on a 2D western 
blot could be the reason to why PHB dissociates from the chromatin and E2F1.  It was 
theorized that the activation of the AR signaling cascade was causing PHB to undergo a 
post-translational modification, the main likely event being dephosphorylation, as 
phosphate groups are acidic, removal of the phosphate group by a phosphatase enzyme 
resulted in a more basic protein.  A more basic species of PHB was seen after androgen 
stimulation upon 2D western blotting. Phosphorylation of proteins is a fundamental 
process that governs protein activity, location and degradation and when aberrantly 
regulated can lead to diseases such as cancer.  Mutation analysis of the human PHB 
gene (by the Human Gene Mutation Database, Institute of Medical Genetics, Cardiff), 
stated no recorded mutations in PC (figure 5.11) only one recorded mutation in breast 
cancer, stressing that only post-translational modification of PHB governs its 
intracellular movement, as mutations within the PHB gene may be lethal. This is 
evidenced by PHB knockout in mice resulted in embryonic lethality (97).   
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The entire PHB protein comprises of 17 serine, 14 threonine and 4 tyrosine residues all 
of which could serve as phosphorylation sites (114).  There are only four tyrosine 
phosphorylation sites found within the PHB protein; Tyr28, Tyr114, Tyr249 and Tyr259 all 
that are highly conserved from human, rat, mouse and Drosophila. Results collected from 
Ande et al,. (114) suggest that at least two of these tyrosine residues on PHB are 
phosphorylated in response to insulin treatment in C2C12 cells.   The 2D western blot 
analysis showed 2 isoelectric spots of PHB with a third small, spots possibly indicating 
several phosphorylation changes. However, there are also 23 sites that are 
ubiquitination, acetylation, methylation or glycosylation sites.  
Ubiquitination involves the attachment of ubiquitin (8.5kDa) to a target protein by an 
isopeptide bond on a lysine residue (145).  As the molecular weight of ubiquitin is small 
(8.5kDa) and does not bear a charge, this post-translational modification was ruled out 
as there was no size change observation.  Moreover, acetylation involves the transfer of 
one acetyl functional group from one protein to another.  Acetyl groups are polar, thus 
addition of this group to a positive amino acid would incur a shift change of PHB to 
give an overall negative charge.  Numerous proteomics studies concur that acetylation 
occurs on approximately 2,500 proteins and is as widespread as phosphorylation.  In 
human cells, acetylated proteins are involved not only in the cell cycle but also 
chromatin remodeling, membrane trafficking and RNA metabolism.  Therefore, 
acetylation of PHB could be a potential post-translational modification occurring upon 
AR signaling pathway activation (146).  Methylation of non-histone proteins can also 
occur.  It is now known that lysine, arginine and histidine residues can be post-
transcriptionally methylated by methyltransferases.  This modification has been 
impacted in gene regulation and signal transduction (147). However, the addition of a 
methyl group to PHB bears no relevance as it carries a neutral charge.  Therefore no 
shift change in PHB would occur.  Finally, glycosylation involves the attachment of 
sugar side chains to a protein and is considered the most complicated post-
transcriptional modification.  Glycosylation has been identified in an array of organisms 
that leads to a production of mature carbohydrate units on glycoproteins that either 
become a part of the cell itself or is secreted (148). As a mature carbohydrate unit 
attached onto PHB would significantly alter the molecular weight, glycosylation as a 
post-translational modification occurring to PHB was ruled out.     
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Compiling evidence together, either a dephosphorylating, neutralising or an acetylating, 
or all at the same time, may be occurring to PHB in response to hormone stimulation of 
the AR pathway in the wt LNCaP cells, as PHB underwent only a shift charge change 
and not a molecular weight change.  PHB is often phosphorylated in response to 
various stimuli such as insulin, insulin-like growth factor and epidermal growth factor 
(EGF). In particular aberrant tyrosine phosphorylation of PHB is implicated in an array 
of diseases such as type I diabetes, irritable bowel syndrome and different types of 
cancers.  Thus as it was likely that it was a dephosphorylation event happening to PHB 
as removal of a phosphate group led to a reduced interaction between PHB and E2F1, 
the likelihood that PHB could be acetylated was reduced. This needs to have further 
validation.   
To relay this information back to understanding how PC transitions from androgen 
dependent to an androgen independent disease, PHB’s status within PC3 cells (an 
androgen independent cell line) and VCaP cells (androgen dependent) was also 
assessed.  PHB’s isotypes pattern within the VCaP cells resembled the same pattern as 
identified in the LNCaP cell line, thus signifying the shift pattern of PHB in response to 
hormone is dependent on the AR. As PHB bears no charge shift change with or 
without hormone stimulation in the androgen independent cell line; PC3s, but 
resembles the same PHB isotype pattern of that found in wt LNCaP cells stimulated 
with hormone, it can be argued that in PC3 cells, PHB has already undergone a 
permanent post-transcriptional modification without androgen stimulation or the AR.  
Therefore potentially as PC progresses to a more advantaged stage, PHB perhaps is 
dephosphorylated by an unknown pathway and is no longer able to bind to chromatin, 
and is no longer able to repress genes associated with the regulation of the cell cycle. 
This unknown pathway may be a novel mechanism of the development of unregulated 
cell cycle activation in PC and androgen independence.   
 The main therapeutic intervention for PC is androgen deprivation (149). However, this 
type of treatment often leads to transition of the cancer to an eventual androgen 
independent state, where the androgen receptor signaling cascade is no longer required 
for cell survival.  There are several mechanisms that could allude to how advanced PC is 
able to survive without androgen stimulation.  One explanation could be that the AR is 
non-specifically activated by a non-specific ligand due to mutations within the ligand 
binding domain of the AR.  Such non-specific ligands include adrenal androgens.  
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This is due to ligand bound AR being able to associate with molecular substrates within 
the cytoplasm and the cell membrane to activate intracellular kinase cascades.  This is 
known as rapid non-genomic actions of the AR that lead to enhanced cell proliferation 
and survival. Non genomic actions of the AR normally occur within minutes, preceding 
transcriptional events (150). Non-genomic activation of the AR can lead to activating 
cAMP response element-binding protein (CREB), promoting cell survival.  Loss of 
ligand specificity could explain receptor activation, thus tumour growth in the absence 
of androgen, resulting in therapy failure.  One such signaling pathway known to be 
elevated in androgen independent PC cases is Src-family kinases.  In particular, FGR is 
the only Src family member to be elevated in androgen independent PC (37%) (151).  
Post-transcriptional modification of the AR may be responsible for its constant 
activation in the absence of hormone.  For example, phosphorylation of the AR by Src 
at Y534 was identified by mass spectrometry (152).  To highlight that the AR may be a 
SRC-target, inducing PC cells with a Src-AR complex led to heightened cell 
proliferation (153).  Moreover, with the use of a Src kinase inhibitor, transactivation of 
the AR was inhibited (153).  On the contrary, expression of activated Src was able to 
induce growth of androgen independent cells in vivo (151).   
5.5 Conclusion 
Gathering both previous literature alongside novel data presented here, PHB was seen 
to directly interact with E2F1 in LNCaP cells as shown by immunoprecipitation and the 
Checkmate™ assay.  This could explain how PHB is able to repress the cell cycle, as it 
directly interacts with a cell cycle regulator; E2F1, thus hindering its activity.  
Highlighting the dynamic opposing interaction between the AR signalling pathway and 
its co-repressor; PHB, the interaction between E2F1 and PHB was lessened when 
LNCaP cells were stimulated with hormone.  This shows that the activated AR 
signalling pathway can override PHB’s repressive function on the cell cycle, as it induces 
PHB to dissociate from the chromatin.  The dissociation of PHB from the chromatin 
was thought to be due to a post-transcriptional modification.  This was due to 
observing a basic shift change of PHB protein in response to hormone stimulation of 
the LNCaP cell line.  The post-transcriptional modification was narrowed down to 
likely be a dephosphorylation event occurring to PHB.  To conclude, PHB’s repressive 
function on the cell cycle could be due to a direct interaction with E2F1; a key cell cycle 
regulator.  However this interaction was disrupted once the AR signalling pathway was 
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activated, causing PHB to dissociate from the chromatin due to a potential 
dephosphorylation event.  
5.6 Key points 
 Interaction between E2F1 and PHB was established by a CheckMate™ 
Mammalian Two-Hybrid assay in COS-7 cells.  
 Interaction between E2F1 and PHB was established by a co- 
immunoprecipitation assay in LNCaP cells.  
 The interaction between E2F1 and PHB was reduced when the LNCaP cells 
were stimulated with hormone, activating the AR signalling pathway. 
 PHB dissociated from the chromatin once the AR signalling pathway was 
activated. 
 A 2D western blot showed a basic shift charge change of PHB protein when the 
AR signalling cascade was stimulated with hormone in an androgen dependent 
cell line; LNCaPs. 
 The post-translational modification was thought to likely be a 
dephosphorylation event. 
 A 2D western blot showed no net shift change of PHB isotypes when the AR 
signalling cascade was stimulated with hormone in an AR-negative cell line; 
PC3s. 
 However, the isotypes of PHB seen in PC3 and HeLa cells resembled a similar 
pattern to PHB isotypes found in the LNCaP cells that had been stimulated 
with hormone.  
 This suggests that as PC transitions to an androgen independent state, PHB may 
be post-transcriptionally modified aberrantly and thus can no longer carry out 
its tumour suppressor activities
Chapter V: Results 
190 
 
 
 
 
Figure 5.11. Screenshot of mutations in the human PHB gene from the Human Gene Mutation Database (Institute of Medical 
Genetics, Cardiff University).   
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6 Chapter VI. Inhibiting the Src-pathway heightens PHB’s function. 
6.1 Introduction 
Castration resistant PC has very limited treatment options, often with a poor prognosis 
(32).  As the dissociation of PHB from chromatin was too quick to account for 
transcriptional changes in response to androgen stimulation (4hr), it was thought that 
PHB protein was being post-transcriptionally modified in response to androgen.   It was 
identified that in response to androgen, a dephosphorylation event was the likely event 
occurring to PHB.  Potentially, it was this phenomenon occurring to PHB that leads to 
its dissociation from E2F1 and the chromatin, allowing the progression of the cell cycle.  
However, in castration resistant PC, the cancer has developed mechanisms to survive in 
the absence of androgen stimulation of the AR.  One such mechanism is known as non-
genomic activation of the AR.  Non-genomic activation of the AR has been 
documented to progress PC in an androgen depleted environment (150). Here, non-
specific ligand (adrenal androgens, growth factors and cytokines) activate the AR 
leading to activation of intracellular signaling cascades (Src, cAMP, PI3K) that occurs 
within minutes (150).  It is these signaling cascades that can propagate AIPC, causing 
patient relapse to anti-androgen therapy.  Moreover, it is likely that the non-genomic 
activation of the AR, leading to the activation of these signaling pathways can lead to 
the deactivation of PHB’s tumour suppressive functions.  To assess and identify AR 
non-genomic pathways we aimed to study what proteins were phosphorylated in 
response to AR activation.   
6.2 Methods 
 2D western blot (refer to chapter 2.11.6). 
 Kinexus array (refer to chapter 2.11.9). 
 Chromatin isolation (refer to chapter 2.11.7). 
 Luciferase assay (refer to chapter 2.12.8). 
 SYBR® Green Q-PCR (refer to chapter 2.8.3). 
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6.3 Results 
6.3.1 Src phosphorylation is the most significant change in response to 
androgen treatment in LNCaP cells 
As the discovery that androgen activation of the AR led to the post-translational 
modification of PHB (as shown in chapter V), was rapid (4 hours), signalling pathways 
were investigated in response to androgen treatment in an androgen dependent cell line. 
There are a huge amount of post-translational modifications happening to proteins with 
the cell at one time, proving too complex to study.  However, here a Kinexus protein 
array was used as they offered the most numerous targets and phosphorylation changes 
available in one screen.   LNCaP cells were hormonally starved for 72 hours (using 
charcoal stripped FCS-media) and treated with R1881 (10nM, 4hr).  As a vehicle 
control, 100% ethanol was used.  Protein lysates were extracted and sent to Kinexus 
(Canada).  Results were presented as a KinexTM Antibody Microarray Data Report on 
an Excel file sheet (figure 6.1).  The data was sorted in Excel by the highest % CFC 
(percentage change from control) in response to androgen treatment.  The data was 
separated into the top ten total and specific phosphorylated proteins (figure 6.2). Figure 
6.2 describes that ROCK1/ROKB was the most total phosphorylated protein. Whereas 
Src-Y418 was the top most specific phosphorylated protein.  This was validated by a 
western blot showing that androgen stimulation led to an increased phosphorylation of 
Src-Y418 (supplemental figure 3).  
6.3.2 Inhibiting the Src pathway leads to reduced AR activity 
The activation of the Src pathway is heavily influenced in the non-genomic activation of 
the AR. Data from figure 6.2 demonstrated that Src-Y418 was the most phosphorylated 
protein changed from the control, alongside several protein components having Src as 
their apical kinase (ErbB2, FAK). Therefore, the Src pathway was further investigated.  
To assess the inhibitory effects of blocking the Src signalling pathway, a Src inhibitor 
was used; Src-inhibitor-1 (SrcI-1) (20μM working concentration). LNCaP cells were 
hormonally starved for 72 hours and stimulated with R1881 (10nM, 4hr).  Alongside, 
Src-inhibitor-1 was added to the cells with and without R1881.  SYBR® Green Q-PCR 
was carried out to assess if inhibiting the Src pathway influenced the androgen 
responsive genes, PSA. As seen in figure 6.3 with the addition of the Src-inhibitor-1, the 
PSA fold expression was significantly reduced when compared to cells stimulated with 
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R1881 (figure 6.3). Moreover, cells treated with the Src-inhibitor-1 had a slight increase 
in PHB gene expression, when compared to cells treated with R1881. Figure 6.3 
illustrates a trend but it was not statistically significant.   
6.3.3 Inhibiting the Src pathway increases chromatin-bound PHB 
As it has been previously described, treatment of cells with R1881 results in PHB 
dissociating from the chromatin.  However, cells treated with the Src-inhibitor-1 (20 
μM) demonstrated an increase in chromatin-bound PHB, as shown in figure 6.4.  An 
increase in chromatin-bound PHB was also seen in cells with simultaneous activation of 
the AR with hormone and inhibition of the Src pathway with Src-inhibitor-1.  This 
suggests that potentially activation of the Src pathway by the AR leads to the 
dissociation of PHB from the chromatin.  
6.3.4 Inhibiting the Src-pathway stops the likely dephosphorylation event on 
PHB in response to androgen 
As it has been previously shown in Chapter V that hormone activation of the AR 
results in a likely dephosphorylation event on PHB, it was assessed if inhibition of the 
Src pathway could stop this from happening.  A 2D western blot was carried out on 
LNCaP cells treated with the Src-inhibitor-1. LNCaP cells were hormonally starved for 
72 hr, and treated as follows; +/-R1881 (10nM), +/-Src-inhibitor-1 (20μM) for 4 hr.  
The pattern of the PHB protein in cells stimulated with R1881 only, demonstrated a 
shift towards pH 10 as seen in chapter V, resembling a dephosphorylation event 
occurring to PHB upon AR activation. Interestingly, cells stimulated with Src-inhibitor-
1 alone illustrated that the PHB protein had no longer shifted towards pH 10 (figure 
6.5).    This suggests that inhibiting the Src-pathway alone, inhibits PHB from 
potentially being dephosphorylated, thus PHB can still retain its tumour suppressive 
functions. This pattern was also mirrored for the cells treated simultaneously with 
R1881 and Src-inhibitor-1.  This signifies that blockade of the Src-pathway even upon 
AR activation is enough to inhibit PHB from becoming dephosphorylated.  This could 
allude to how inhibiting the Src pathways leads to more PHB bound chromatin.   
  
Chapter VI: Results  
195 
 
6.3.5 Down-regulation of PHB is seen in an anti-androgen resistant cell line  
A cell model for an anti-androgen resistant phenotype was derived from the wt LNCaP 
cell line.  First, the LNCaPs were grown in the presence of a clinically approved anti-
androgen drug (Bicalutamide) for up to 6 months at varying concentrations (as 
described in chapter 2.7.1).  Conferring to the Geodatasets presented in chapter VII, it 
was identified that in chemotherapy-resistant cell lines (docetaxel-resistant DU-145 and 
PC3) , PHB was significantly down-regulated at a gene level.  Therefore, RNA extracted 
from a Bicalutamide-resistant LNCaP (Bicalutamide-R) cell line was reverse transcribed 
and analysis of PHB gene expression was carried out.  SYBR® Green Q-PCR results 
depicted that PHB gene expression was significantly down-regulated in the 
Bicalutamide-R cell line when compared to LNCaP cells (figure 6.6A).  Moreover, RNA 
extracted from wt PC3 cells was reversed transcribed and analysed for PHB gene 
expression. Figure 7.4 describes a significant down-regulation of PHB gene expression 
in PC3 cells when compared to LNCaP cells.  This also emphasises that PHB is down-
regulated in androgen independent cells.  Moreover, a 2D western blot analysis 
compared the difference in PHB protein isoelectric points in wt LNCaP and 
Bicalutamide-R LNCaPs.  Figure 6.6B depicts that the isoelectric point of PHB in the 
Bicalutamide-R LNCaPs has shifted more towards pH 10 than the wt LNCaP cells.  
This suggests that in an anti-androgen resistant phenotype, PHB has already undergone 
a post-translational modification, a similar trend since when the AR is activated.   
6.3.6 Anti-androgen treatment heightens PHB’s repression of the MCM 
promoter 
LNCaP/TR2/PHB cells were transfected with the pGL4-MCM6 reporter plasmid as 
described in chapter IV.  However, the efficacy of PHB over-expression was assessed in 
the presence of another anti-androgen drug; enzalutamide (MDV3100).  Interestingly, 
the activity of the MCM6 promoter was significantly reduced in the presence of 
enzalutamide.  However, the biggest significant decrease in MCM6 promoter activity 
was seen in cells treated with both doxycycline and enzalutamide (3 fold decrease) 
(figure 6.7A).  This highlights that PHB heightens the function of the anti-androgen 
treatment; enzalutamide, repressing AR responsive genes such as MCM6. 
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6.3.7 Anti-androgen treatment prevents the likely dephosphorylation event on 
PHB  
As inhibiting the Src pathway inhibited the likely dephosphorylation event on PHB, it 
was investigated if enzalutamide (MDV3100) could also mirror the same pattern. 
LNCaP cells were hormonally starved for 72 hr and treated with (+/-R1881 10nM, 4hr) 
(+/-MDV3100 10μM, 4hr).  Cells treated with MDV3100 illustrated the isoelectric 
point of PHB had no longer shifted towards pH 10, resembling inhibition of a 
dephosphorylation event (figure 6.7B).  This suggests that the likely dephosphorylation 
on PHB is due to an AR related event, as enzalutamide inhibits AR activity. 
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Figure 6.1. Screenshot of Kinexus™ antibody Microarray data report. CFC (change from control) was used to sort data.  Data is alphabetical.  
This is the original data file prior to sorting into top ten most and least phosphorylated proteins. 
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Figure 6.2. Kinexus protein array data of the top ten total and specific phosphorylated proteins in 
response to androgen stimulation in the LNCaP cells.  A, the top ten total protein changes in response to 
R1881 treatment (10 nM, 4hr) from LNCaP cells (72 hr serum starved).  B, the top ten phosphorylated 
proteins in R1881 treatment (10 nM, 4hr) from LNCaP cells (72 hr serum starved).  
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Figure 6.3. Gene expression of PHB and PSA in the LNCaP cell line. A, SYBR® Green Q-PCR data 
showing PSA expression +/-R1881 (10 nM, 4 hr) +/-Src inhibitor 1 (20 μM,4 hr). B, SYBR® Green Q-
PCR data showing PHB expression +/-R1881 (10 nM, 4 hr) +/-Src inhibitor 1 (10 μM,4 hr) n=3, p 
<0.05*. A one-way ANOVA statistical test was used. Error bars represent standard error of mean.   
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Figure 6.4. Chromatin isolation and western blot of PHB (+/-R1881 (10nM, 4h), (+/-Src-inhibitor-1 
(20μM, 4h). PHB dissociates from the chromatin in the presence of R1881.  As a loading control, histone 
H3 was used, n=1.   
 
 
 
 
 
 
 
 
Chapter VI: Results  
201 
 
 
 
 
Figure 6.5. 2D western blot of PHB.  LNCaP cells were hormonally starved for 72 hours and treated 
with (+-R1881(10nM), +/-Src-inhibitor-1(20μM), 4h) n=1.   
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Figure 6.6. SYBR® Green Q-PCR analysis of PHB in Bicalutamide-R LNCaP cells and PC3 cells. A,  
PHB gene expression  in Bicalutamide-R  LNCaP cells, n=3 *p<0.05. B, PHB gene expression in PC3 
cells, n=3 *p<0.05. C, 2D western blot analysis of the PHB protein in the wt LNCaP cell line and the 
Bicalutamide-R  LNCaP cell line. n=1.  
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Figure 6.7. MCM6 promoter activity in the presence of PHB over-expression and enzalutamide 
(MDV3100).  2D western blot of PHB +/-R1881 (10nM), +/-MDV3100 (10μM), 4hr.   A, Reduction of 
MCM6 promoter activity is seen in cells treated with doxycycline and MDV3100, n=3, p<0.001****.  B, 
MDV3100 inhibits the dephosphorylation of PHB isotypes.   
 A 
B 
LNCaP R1881 + MDV3100 (4h) 
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6.4 Discussion  
Treating metastatic, castration resistant PC with androgen deprivation therapy (ADT) 
remains controversial, as relapse often ensues. It is the first line therapy for patients 
with symptomatic metastatic PC, however it is also used as a neoadjuvant to 
radiotherapy and clinically localised PC (154).  Unfortunately, with the use of ADT 
overtime, it is inevitable that a majority of patients relapse due to the propagation of 
androgen independent PC (154).  Patients receiving androgen deprivation therapy 
alongside chemotherapy with docetaxel and prednisone have a medium survival rate of 
18.9 months. Worryingly, progression of the disease following a docetaxel containing 
treatment plan leads to a drop in medium survival to 15.1 months (155).   This 
highlights a need for treatment that inhibits the progression of the cancer to an 
androgen independent state.  Firstly, PHB’s expression in aggressive chemotherapy 
resistant and androgen independent cell line was shown to be significantly down-
regulated.  A potential mechanism for patient relapse could be due to the down-
regulation of PHB, allowing deregulated AR activity.  Assessing the effects of a clinically 
used anti-androgen treatment; enzalutamide in the presence of PHB showed an 
increased efficacy, especially in reducing the activity of the MCM6 gene, a key instigator 
in DNA replication. Enzalutamide (MDV3100) is approved for patients with metastatic 
castration resistant. One of its mechanisms of actions is inhibiting the translocation of 
the AR to the nucleus. Remarkably, PHB’s role in increasing the efficacy of clinically 
used treatment has already been seen in breast cancer, whereby the growth suppression 
of breast cancer cells is PHB mediated, through the recruitment of Brg1/Brm 
remodelling proteins (59). Thus, targeting the down-regulation of PHB could heighten 
the efficacy of anti-androgen therapy, currently used for PC treatment.    
As the change in PHB localisation was rapid (4 hr), investigations into kinase pathways 
were carried out. Previous data showed phosphorylation changes on PHB, identified by 
co-immunoprecipitation and 2D western blot, therefore Kinexus array analysis was 
carried out.  Although the Kinexus array is not exhaustive, there was a good indication 
that the Src pathway was activated by androgen treatment. Data presented here indicate 
that activation of the AR lead to the rapid phosphorylation of Src on tyrosine418.  
Tyrosine 418 is located within the catalytic domain of Src and is one of the auto-
phosphorylation sites.  Phosphorylation of Tyrosine 418 is essential for full catalytic 
activity of Src (156).   
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Inhibiting the Src-pathway led to an increase in PHB bound chromatin, perhaps 
through an inhibition of the AR signalling pathway.  This could potentially allow PHB 
to recruit chromatin-modelling proteins such as HDACs to repress the transcription of 
genes associated with the cell cycle, e.g E2Fs and MCMs (as previously described).  
Moreover, inhibiting the Src pathway prevented the PHB protein shifting towards pH 
10 in response to androgen, thus preventing PHB’s likely dephosphorylation event. 
It has been well established that c-Src drives the development of castration-resistant PC 
and bone metastasis (157).  The family of Src kinases comprises of 9 structurally similar 
non-receptor protein tyrosine kinases.  The amino acid composition of Src kinases are 
made of four distinct peptide domains, known as Src homology domains (SH), 
alongside a regulatory sequence.  SH4 regulates membrane attachment, kinase activity 
and intracellular stability (157)  Whereas SH2 and SH3 domains allow the interaction of 
Src with signalling proteins. Negative regulation of Src is mediated through the 
phosphorylation of Y530 that resides in the catalytic domain (SH1) that is joined to the 
carboxyl terminal. Upon phosphorylation, Src undergoes a ‘closed’ molecular 
conformation with low enzyme activity (157).  Under the closed conformation, Y530 
interacts with SH2. Disruption between these interactions allows the activation of Src 
and undergoes an open conformation.  The open conformation is aided by SH2 having 
a higher affinity for other tyrosine phosphorylated proteins than Y530 (157).  
Consequently, the c-terminal phosphate becomes available for phosphatases that 
dephosphorylate Y530, stabilising Src’s active form.  Src can also be activated by 
cytoplasmic proteins such as focal adhesion kinase (FAK) (158). In the active form, Src 
is able to bind to ATP and substrates to induce signal transduction and regulation of the 
cytoskeleton.  Src kinase activity is increased in the majority of solid tumours including 
PC, and is often found to be over-activated in more malignant stages of cancer (157).  
Normal prostate epithelium expresses six of the Src kinase family members (Src, Lyn, 
Fyn, Yes, Hck, Fgr).  However, their expression increases during PC tumorigenesis. For 
example, Lyn (a family member of Src kinase) is expressed in 95% of primary PC, and 
worryingly in 100% of metastatic cases (159).  Moreover, (Goldenberg et al., 2004), 
showed that as the Gleason score increased in the primary tumours, the expression of 
Lyn also increased (159).    Src, Lyn and Fyn all have been shown to participate to the 
development of PC in mouse models.  Constitutively active Src is correlated with 
increasing the chance of transforming the prostate epithelium, followed by 
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constitutively active Fyn and Lyn.  Evidence supports that not only does Src kinases 
promote tumourigenesis, they also partake in increasing the proliferation and growth of 
cancer cells.  Src kinase inhibitors such as Dasatinib can cause a 50% reduction in cell 
proliferation of both LNCaP and PC3MM2 cells (157).  Moreover, another Src inhibitor 
known as Saracatinib also led to a 50% reduction in the proliferation of PC3 and 
DU145 cells (157). Although inhibitors of Src have a profound effect on the 
proliferation of PC cells, the cytotoxic effects are minimal.   
Ligand activation of the AR causes the autophosphorylation of Src, however this 
autophosphorylation does not occur in LNCaPs grown in serum starved media (160).    
Progression of the cell cycle to the S phase was noted in cells with AR-induced Src 
activation.  In vivo studies demonstrated that the synergic over-expression of both the 
AR and Src induced the transformation of prostate epithelium to invasive 
adenocarcinoma.  There is a positive feedback loop between the AR and Src, as Src 
phosphorylation induces the phosphorylation at tyrosine, serine and threonine residues  
(160) Phosphorylation of Src leading to the phosphorylation of AR can feed back to 
further phosphorylation of Src-eventually resulting in the down-regulation of PHB. 
Growth factors (IGF-1 and EGR), interleukins (Il-6 and IL-8) and neuropeptides 
(bombesin) have been associated with ligand-independent phosphorylation of the AR 
(160).   Activation of all of these pathways lead to the activation of Src, highlighting the 
vast amount of signalling pathways that can activate Src, thus leading to the direct 
phosphorylation of the AR. Moreover, Src activation has also been shown to repress 
the interaction of co-repressors such as LCoR and the AR (160).  This could also be the 
case with PHB, non-genomic activation of the AR leading to the phosphorylation of 
Src, thus inhibiting the interaction of PHB and the AR, facilitating AR function and cell 
growth.   
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Figure 6.8. Image provided by Dr Alwyn Dart.  Androgen induced phosphorylation of cellular signalling 
pathways. Src appears upstream of PKC, MAPKs and AR activation (137).   
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6.5 Conclusion 
Since the discovery that PHB is likely to be dephosphorylated in response to AR 
stimulation in a short amount of time (4 hr), signalling pathways were investigated.  
Interestingly, Src was the top most phosphorylated protein in response to androgen.  
There is a large amount of evidence to indicate that Src can activate the AR in the 
absence of ligand, therefore targeting the Src pathway was carried out.  Inhibition of the 
Src pathway led to an array of effects, and activation of the AR led to Src 
phosphorylation.  Firstly, androgen responsive genes were significantly down-regulated 
such as PSA whereas PHB was increased.  Moreover, inhibition of the Src pathway led 
to more PHB bound chromatin, potentially because inhibition of the Src pathway 
prevented the likely dephosphorylation on PHB that in turn could prevent PHB 
dissociating from the chromatin and E2F1 in response to androgen.  Thus a preliminary 
mechanism was propagated, phosphorylation of Src, leads to the activation of the AR 
leading to the dissociation of PHB from the chromatin due to a potential 
dephosphorylation event (figure 6.9). Finally, the role PHB had in increasing the 
efficacy of anti-androgen therapy was assessed.  Interestingly, the repressive function of 
PHB on the MCM promoter was heightened in the presence of an anti-androgen 
treatment; enzalutamide. Therefore, potentially during the development of androgen 
independent/castration resistant PC, aberrant Src signalling leads to independent AR 
activation leading to the dephosphorylation of PHB causing PHB to dissociate from the 
chromatin.   
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Figure 6.9. Preliminary mechanism involving Src, the AR and PHB. 1, ligand binding of the AR leads to 
the phosphorylation of Src. 2, phosphorylation of Src leads to an unknown mechanism leading to PHB 
dissociating from the chromatin, potentially through a dephosphorylation event. 3, PHB dissociates from 
the chromatin and E2F1 due to AR signalling. 4, E2F1 is free from PHB to bind to E2F binding site 
within the promoter region of MCM5/6. This leads to transcription of genes associated with cell cycle 
progression (E2Fs, CDKs, Cyclins, MCMs).  
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6.6 Key points 
 Activation of the AR in LNCaP cells leads to the phosphorylation of Src at 
tyrosine 418. 
 Inhibiting the Src pathway reduces AR activity as measured by a reduced PSA 
expression. 
 Inhibiting the Src pathway stops the dissociation of PHB from the chromatin. 
 The inhibition of the Src pathway also prevents the likely dephosphorylation 
PHB. 
 PHB gene expression is significantly down-regulated in Bicalutamide-resistant 
LNCaP cells and also androgen independent cells; PC3s. 
 The efficacy of PHB repressing the MCM6 promoter is increased in the 
presence of an anti-androgen treatment; Enzalutamide.  
 Enzalutamide prevents the likely dephosphorylation on PHB-demonstrating the 
dephosphorylation of PHB is AR regulated-potentially through Src signalling. 
 A preliminary mechanism: ligand binding of the AR leads to Src 
phosphorylation, activating cascades that led to the dissociation of PHB from 
the chromatin potentially through a dephosphorylation event.   
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7 Chapter VII.  PHB inhibits the migration of both androgen dependent and 
androgen independent PC cells.  
7.1 Introduction 
The androgen dependent subtype of PC, if diagnosed at an early stage where the cancer 
is confined with the prostate gland, displays little or no metastasis and is 100% treatable 
(161).    However, as the cancer progresses to a more malignant state through adapting 
to a low androgen environment, the transition of the cancer to an ‘androgen 
independent’ state can occur.  Once the cancer has progressed to an androgen 
independent state (AI), the survival rate is less than 30% for 5 years.   
Although recently, there has been a steady decline in the cases of newly diagnosed 
metastatic PC, the risk of clinically localised PC transitioning to extra-prostatic disease is 
still high (30-60%) (162). If left untreated, metastatic PC is more than likely to become 
resistant to therapy.      
Cells migrating to the pelvic lymph nodes is one of the initial stages of PC metastasis, 
where the bloodstream spreads the cells to distant organs such as the bones (37).  
Worryingly, PC cells have a strong affinity for the bone environment as the majority of 
patients diagnosed with advanced stage PC have histological skeletal involvement.  The 
prognosis given from the initial identification of bone metastases and death has a 
median value of 3-5 years (37).    Complications that ensue with PC bone metastasis are 
bone pain, resultant from the stimulation of periosteum pain receptors and spinal cord 
compression.   
The mechanism of PC cells migrating and invading out of the prostate gland is poorly 
understood. Analysing PHB’s role in PC metastasis could allude to a novel mechanism. 
Previous data showed that PHB knockout increased PC xenograft growth in mice, and 
also increased metastasis of LNCaP cells, a cell line that rarely metastasises 
(supplemental figure 3). As data presented in chapter III, IV and V indicate PHB has a 
prominent role in inhibiting the proliferation of androgen dependent cells and also 
halting the cell cycle, mediated by E2F-repression. Therefore, it was investigated if PHB 
down-regulation was associated with the migration of PC, as the cell cycle and cell 
motility are related mechanisms.  Thus, over-expression of PHB in PC cells was carried 
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out in several functional assays to depict its role in migration, invasion and adhesion 
assays in both androgen dependent and androgen independent PC cell lines.   
7.2 Methods 
 Analysis of data retrieved from RNA-sequencing (refer to chapter 2.10). 
 Scratch assay (refer to chapter 2.9.2).  In the case of PC3 cells, after the scratch 
formation, the well plate was placed into an incubation chamber onto an Evos 
FL auto machine (life technologies).  Each well had three beacons assigned, and 
each condition was carried out in triplicate.  Cells were incubated at 5 % CO2 at 
37˚C.  At the end of the experiment, the percentage of wound closure was 
analysed as stated in chapter 2.4.2.  
 Transwell assay (refer to chapter 2.9.3). 
 SYBR®Green Q-PCR (refer to chapter 2.8.3). 
 Geodatabase analysis (data available from GSE6919, GDS3973 geodatasets).  
Data was taken from freely available Geodatasets and was analysed via 
GraphPad Prism 6. 
 Adhesion assay (refer to chapter 2.9.5). 
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7.3 Results 
7.3.1 Geodatabase data of PHB 
Supplemental figure 4 entailed PHB knock-down in LNCaP xenografts injected 8-week 
male BALB/c strain nude mice. PHB knockdown led to growth in xenografts of PC 
cells in mice (data provided by Dr D Dart), therefore PHB’s status within malignant 
metastatic cancer was assessed via a geodatabase (GSE6919) (163, 164). This study 
involved a comprehensive gene expression analysis of 152 human samples.  These 
samples were divided into normal tissue, PC tissue, normal adjacent tissue and 
metastatic tissue.  Here analysis in this dataset was carried out using the Affymetrix 
U95a, U95b and U95c chip sets.  Firstly, figure 7.1A illustrates a graph representing the 
gene expression levels of PHB in normal and tumour tissue.  There was a significant 
decrease in PHB expression in tumour tissue when compared to normal tissue.  This 
highlights PHB is down-regulated in tumour tissue and in advanced stages of PC.  
The groups were further subdivided into normal adjacent tissue and metastatic tissue 
derived from patients.  Figure 7.1B represents the data analysis of the four groups. A 
Man U Whitney test was carried out and a significant decrease in PHB expression was 
seen in metastatic tissue.  This highlights that potentially PHB’s loss is also linked to the 
migration and invasion capacity of PC cells.  Interestingly, figure 7.1C (GDS1439) 
depicts the significant down-regulation of PHB as the PC transitions from a normal 
state to a malignant state, that agrees with the data presented in figure 7.1A-B.   
Moreover, Figure 7.1D illustrates that when two metastatic PC cell lines; DU145 and 
PC3 were compared with their docetaxel resistant counterpart a down-regulation of 
PHB was observed.  This could link PHB down-regulation with chemotherapy resistant 
PC cases.  
Moreover, analysis of 70 primary gastric tumors representing 3 subtypes (invasive, 
metabolic, and proliferative) from the Australian patient cohort (figure 7.2) also showed 
some differences in PHB expression.  The invasive subtype displayed the lowest 
expression of PHB, whereas the proliferative subtype showed the highest.  This may 
link to there being higher levels of PHB in the earlier stages of gastric cancer that then 
diminishes as the cancer progresses to an invasive type.   
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7.3.2 Metacore analysis describes Wnt-signalling as a top network affected by 
PHB over-expression 
The analysis carried out by the bioanalysis platform, Metacore is described in chapter 
IV. The top network that was affected by PHB expression was the Wnt-signal 
transduction pathway (figure 7.3A).  This agrees with figure 7.3B-C that depicts PHB 
over-expression down-regulating key non-canonical Wnt genes (Wnt10B and Wnt7B). 
Moreover, expanding into the Wnt-signalling network, the pathway is highlighted in red 
showing that this signalling pathway is being suppressed.  Consequently, there is an 
inhibition of an accumulation of the transcriptional factor; β-catenin shown in figure 
7.4. This is relevant as β-catenin has been documented to activate the AR in the absence 
of androgen (165).  
7.3.3 RNA-seq identified genes involved in migration are down-regulated with 
PHB over-expression 
As Metacore analysis highlighted that the Wnt-signalling pathway was the top most 
affected pathway in response to PHB over-expression, data mining into the RNA-seq 
transcript list was carried out.  This identified that members of the Wnt family were 
down-regulated in response to PHB over-expression.  Interestingly, Wnt10B and 
Wnt7B were both down-regulated with PHB over-expression with a fold change greater 
than -2 (figure 7.3B).  To validate these genes, a SYBR® Green Q-PCR was carried out.  
LNCaP/TR2/PHB cells were treated (+/-dox) for 16 hr prior to RNA extraction.  The 
RNA was reverse transcribed and the gene expression of Wnt10B and Wnt7B were 
analysed against untreated cells. Both genes were significantly down-regulated by more 
than 2 fold with PHB over-expression (figure 7.3C).   
7.3.4 Over-expression of PHB leads to decreased migration in an androgen 
dependent and androgen independent cell line  
Two experiments were carried out to assess the role of PHB in migration of PC cells. 
Firstly, a scratch assay was carried out.   The LNCaP/TR2/PHB cell line was left to 
seed in a 24 well plate until a confluent monolayer was formed.  After the scratch 
formation (or wound), the migration across the wound was monitored.  Figure 7.5A 
illustrates that at the 24 hr time point, cells with PHB over-expression had 40 % less of 
the wound closed when compared to control cells.  At 48 hr when complete wound 
closure was seen, there was a significant decrease in the migration of cells with PHB 
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over-expression (approx. 50 % decrease).  In synergy with this experiment, a transwell 
filter migration assay was carried out.  The LNCaP/TR2/PHB cells (+/-dox 10 μM) 
were left to migrate for 24 hr.  At the 24 hr time point, cells with PHB over-expression 
had a 50% decrease in migration when compared to control cells (p value < 0.05) 
(figure 7.5B).  This has the same pattern as the scratch assay at the 24 hr time point.  
Moreover, the same experiments were carried out on the androgen independent cell 
line; PC3.  48 hours prior to the scratch formation, PC3s were transfected with either 
pSG5-empty or pSG5-PHB.  The cells were then left on the evos FL auto machine for 
24 h.  At 24 hr PC3’s with PHB over-expression had a significant decrease in migration 
(approx. 20%) (Figure 7.5C).  Further, the transwell filter migration assay displayed a 
similar trend.  In 4 hr, PC3’s over-expressing PHB has a significant decrease in 
migrating cells when compared to the control cells (Figure 7.5D).  Figure 7.5E-F 
confirms the over-expression of PHB in LNCaP/TR2/PHB cells treated with dox (10 
μM) and PC3 cells transfected with pSG5-PHB at a protein level. 
7.3.5 Over-expression of PHB leads to a decreased adhesion of cells 
To assess the adhesion of cells to a basement membrane in the form of Matrigel™, an 
adhesion assay was carried out. LNCaP/TR2/PHB cells were treated with doxycycline 
(10 μM) 24 h prior to the assay.  45,000 cells were then seeded onto a Matrigel™, 
coated 96-well plate.  The cells were left to adhere to the Matrigel™ at 37˚C for 1 hour 
15 minutes.  Cells that had adhered to the Matrigel™ were counted in each field of 
view. There was a significantly large difference in adhesion in dox-treated cells and 
control cells.  PHB over-expression led to a reduced amount of Matrigel™-adhered 
cells as shown in figure 7.7. Quantitative analysis highlighted that with PHB over-
expression there was a 5.8 fold decrease in the adhesion of cells when compared to 
control cells as highlighted by figure 7.7. Interestingly, this data agrees with the 
Metacore analysis (figure 7.3). Cadherin-mediated adhesion, integrin-mediated cell 
matrix adhesion and integrin priming were all depicted as networks associated with 
PHB over-expression. Thus highlighting PHB does play a role in the adhesive and 
motility behaviour of androgen dependent cells.   
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Figure 7.1. Geodataset analysis (GSE6919, GDS1439, GDS3973) of PHB gene expression.  A, 
Expression analysis of PHB gene levels between normal tissue and PC tissue, n=171. B, expression 
analysis of PHB levels between normal tissue, PC tissue, primary tumour and metastatic tissue n=171. C, 
expression profiling of prostate cancer tumors that are benign, clinically localized and metastatic, n=19. 
D, Analysis of prostate cancer cell lines resistant to docetaxel chemotherapy, DU-145 resistant and PC-3 
resistant, which were derived from cell lines DU-145 and PC-3, respectively, n=12. p value <0.05*, 
<0.01**, <0.001***.   All geodatasets were analysed by a Kruskal–Wallis one-way statistical test.  
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Figure 7.2. PHB gene expression in gastric cancer.  GDS4198 geodataset displaying 70 primary gastric 
tumors representing 3 subtypes (invasive, metabolic, and proliferative) from the Australian patient cohort.  
p value <0.01**, <0.0001**** between proliferative and metabolic and proliferative and invasive.   
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Figure 7.3. The Wnt signalling pathway is associated with PHB over-expression.  A, Metacore analysis 
showing that the Wnt signalling pathway is the top most affected network with PHB over-expression.  B, 
RNA-seq data illustrating members of the Wnt family; Wnt10B and Wnt7B are down-regulated with PHB 
over-expression. C, Q-PCR validation that Wnt10B and Wnt7B are significantly down-regulated with PHB 
over-expression, n=3 *p<0.05, ***p<0.001.  
 
 
A 
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Figure 7.4. Metacore analysis of the top network associated with PHB over-expression.  The Wnt 
signalling pathway shown in red is being inhibited.   
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Figure 7.5. Migration assays for LNCaP and PC3 cells. A, scratch assay for LNCaP/TR2/PHB cells (+/-
dox 16 hr) for 48 hr. B, Transwell filter migration assay for  LNCaP/TR2/PHB cells (+/-dox 16 hr) for 
24 hr. C, scratch assay for PC3 cells (+/-pSG5-PHB) for 21 hr. D, Transwell filter migration assay for 
PC3 cells (+/- pSG5-PHB) for 21 hr. E, western blot of PHB over-expression in cells treated with pSG5-
PHB in PC3 cells. F, over-expression of PHB in LNCaP/TR2/PHB cells treated with dox (10 μM). 
GAPDH was used as a loading control.  G+ H densitometry values for E + F. n=3, p<0.05*, p<0.01**. 
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Figure 7.6.  Scratch assay showing wound closure of PC3 cells after scratch was made +/- pSG5-PHB.  
At T0 (time 0) cells were imaged after wound was made.  At T21 (time 21) wound closure was seen. 
Images are representative of n=3.  
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Figure 7.7. Adhesion assay for LNCaP/TR2/PHB cells.  Cells were stained with crystal violet after 
adhering to a Matrigel™ basement membrane. p<0.0001****. Images are representative of n=3. Error 
bars represent SEM. 
 
 
 
Chapter VII: Results  
224 
 
7.4 Discussion 
The high rate of mortality and morbidity caused by PC is due to metastasis of the 
primary tumour (166). Information on how PC metastasises from the primary tumour 
to sites such as the bone is lacking.  The course of PC migration from the primary 
tumour entails several stages.  Firstly, tumour cells acquire the ability to invade the 
surrounding tissues by passing through the basement membrane and extracellular 
matrix (167).  This is where the cells invade the lymphatic or circulatory system.  The 
tumour cells will eventually settle in a secondary site, proliferate and form a secondary 
tumour.  Loss of cell to cell adhesion is essential for tumour cells to dissociate from the 
primary tumour and begin migrating but ability to adhere to distant organs is essential 
for successful metastasis, therefore there is a fine balance involved in adhesion of cells 
(167).   Changes in the cell matrix interactions allow the tumour cells to invade the 
surrounding stroma, this is known as cell invasion.  The degradation of the basement 
membrane and extracellular matrix is necessary for invasion to secondary sites alongside 
up-regulation of proteins or signalling pathways associated with cell motility (167).    
Therefore the metastasis cascade is reliant on loss of cell adhesion, and the ability of the 
tumour cell to acquire a phenotype that is motile through changes of cell to matrix 
interactions.   
Although PHB’s role in repressing the cell cycle has been hypothesised as being E2F-
mediated (refer to chapter V), PHB’s role in the migration of PC cells has yet to be 
identified. It was interesting to note, that analysis of Geodatasets showed PHB’s down-
regulation at a gene level as prostate cancer advances to a metastatic state.  This 
highlighted PHB’s role in suppressing migration from the primary tumour.  As PC3’s 
display more aggressive characteristics of PC, they are more malignant and metastatic, 
thus potentially accounting for PHB’s ability to only inhibit the migration by 20 %.  
According to chapter V, in PC3 cells, PHB already has been post-translationally 
modified (a likely dephosphorylation event) thus already hold the mechanism in place 
allowing the down-regulation of PHB.  Therefore, trying to counteract this mechanism 
by inducing PHB over-expression may be difficult.   
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Analysing the RNA-sequencing, data revealed that genes involved in migration such as 
wnt genes were down-regulated with PHB over-expression.  Moreover, Metacore 
analysis showed that integrin-mediated cell adhesion was affected by PHB over-
expression.  This data was confirmed by carrying out functional assays. It appeared that 
PHB over-expression plays a key role in suppressing the migration of both androgen 
dependent and androgen independent cell lines.   
However, although there is documented evidence to suggest there is cross-over between 
components that regulate the cell cycle and cell migration, PHB could also be 
suppressing the migration of PC cells through down-regulation of genes involved in cell 
migration.  Such genes include Wnt7B and Wnt10b identified by RNA-seq. Moreover, 
Wnt-signalling was identified as the top most affected network by PHB over-
expression.   
Interestingly, Wnt signalling plays a role both in developmental and oncogenic 
processes.  Binding of Wnt proteins to the frizzled receptor causes the activation of 
either the canonical or non-canonical pathway (168).  The canonical pathway causes the 
down-stream transcription of Wnt-associated genes by preventing the phosphorylation-
mediated degradation of β-catenin by a destruction complex. In the canonical pathway 
β-catenin acts as a co-activator for transcriptional factors TCF/LEF (168). Whereas 
activation of the non-canonical pathway leads to the activation of intracellular signalling 
pathways such as c-Jun-NH2 kinase (JNK), protein kinase C (PKC) and Ca
2+ dependent 
protein kinase II (CaMKII). The accumulation of β-catenin within the nucleus, caused 
by the activation of the canonical pathway has been identified in advanced PC (169). 
Metastatic PC cells found in bone showed homogenous expression of β-catenin in 77% 
of patients (169). Moreover, β-catenin has been shown to activate the AR in the 
presence of androgens, leading to the heightened transcription of androgen regulated 
genes.  Transcriptional factors AR and TCF/LEF both compete for β-catenin.  Both 
pathways once activated, promote cell growth (168).   
Wnt signalling has been documented to play a role in the initiation of castration 
resistant PC (CRPC)(168).  Aberrant Wnt-signalling allows the progression and survival 
of PC cells in an androgen deprived environment.  Thus Wnt-signalling could be a key 
pathway contributing to relapse to anti-androgen therapy.  Particularly as β-catenin, a 
downstream target of Wnt signalling, increases AR-mediated transcriptional activity in 
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androgen deprived conditions (170).   Moreover, the interaction of AR and Wnt 
signalling pathway is heightened in castration-resistant mice when compared to non-
castrated mice (171).  Moreover, sequencing of exomes revealed mutations in Wnt 
signalling components in castration resistant tumours when compared to castration 
sensitive tumours (172).  Wnt signalling is involved in castration resistant PC, however 
the key components of the pathway are yet to be identified.  However, Wnt7B has been 
shown to be androgen-regulated and remains at a high expression in CRPC cells (168). 
Wnt7B activates the non-canonical pathway leading to an increased PC growth and 
survival in an androgen deprived environment (168). Moreover, Wnt7B was identified 
to promote osteoblastic responses in the bone.  Thus Wnt7B plays a vital role in the 
progression of castration-resistant PC to bone metastasis (168).    
Interestingly, supplemental figure 5 demonstrates that both Wnt7B and Wnt10B have 
predicted binding sites of E2F within their promoter regions.  This could explain how 
PHB is causing a decrease in migration. As documented in chapter V, PHB has a direct 
interaction with E2F1, preventing progression of the cell cycle.  This could also be the 
case for how PHB prevents migration of PC cells. PHB could prevent E2F binding to 
the predicted E2F binding sites in the promoters of Wnt7B and Wnt10B, preventing 
down-stream transcription of the Wnt genes associated with migration.  A preliminary 
mechanism is shown in figure 7.8. 
Recently, it has been established that the cell cycle and migration of tumour cells are 
interlinked at a molecular level (173).  For example, for cells to begin migrating, 
formation of actin arrays at the leading edge of the cell is needed, thus forming 
lamellipodia.  Proteins that regulate the formation of lamellipodia include the Arp2/3 
complex and the WAVE regulatory complex (173).   Inhibiting the lamellipodia 
suppresses the proliferation of normal fibroblasts however it cannot arrest cancerous 
cell proliferation.  Depletion of the Arp2/3 protein in normal fibroblasts causes an 
inhibition in cell migration. Moreover, they also cannot proliferate, unless loss of the 
p16INK4a/p14Arf tumour suppressor locus has also occurred.  This locus is essential 
to initiate cell cycle arrest in response to cellular stress.  Loss of Arp2/3, leading to 
inhibition of migration therefore acts as a stress signal causing cell cycle arrest through 
transcription of p16INK4a/p14Arf (173).    Interestingly, linking loss of Arp2/3 with 
the cell cycle, a mechanism was suggested.  Firstly, extracellular signals stimulate 
lamellipodial machinery through integrin-mediated activation of Rac1 (a small GTPase) 
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Activated Rac1 can then activate the cell cycle through activation of cyclin D1 (173).     
Therefore, mechanisms are in place that link the cell cycle and cell motility via the cross-
talk of signalling pathways.   
Moreover, another study carried out by Kagawa, et al,. 2013 (174), analysed the 
spatiotemporal properties of both cell cycle and cell motility simultaneously in vivo. The 
molecular components that regulate the cell cycle also play a vital role in cellular 
functions such as motility.  Particularly ARHGAP11A, a potential E2F1 regulated gene 
that alters its expression through a cell cycle dependent manner. ARHGAP11A induced 
cell mobilisation through activation of Rac1 (174). Fuci-green cells expressing high 
levels of ARHGAP11A exhibited elongated shapes, consistent with previous work that 
elongated migration is mediated through Rac1 (174).   This leads to the assumption that 
perhaps PHB inhibiting E2F1’s function could inhibit the transcription of 
ARHGAP11A, leading to less cell motility. What is more, it was identified that key 
genes that regulate the cell cycle such as p27 and p21 also influence cell motility. p27 
was shown to bind to RhoA whilst p21 was shown to bind to ROCK (174). 
Interestingly chapter IV depicted that both p21 and p27 were significantly up-regulated 
with PHB over-expression. Regulation of cell motility by Rho-family proteins has been 
extensively studied.  Both ROCK mediated and Rho mediated signalling play a crucial 
role in cancer metastasis (174).  
Adhesion of circulating PC cells to a microvascular endothelium and low adhesion to 
the primary tumour is critical for cancer metastasis.  This highlights the importance of 
PHB over-expression significantly reducing the adhesion of androgen dependent cells.  
Metastasis from the primary tumours is one of the leading causes of cancer-related 
mortality (175).   Two events coordinate PC cell dissemination into the blood stream to 
distant sites; anoikis and cell adhesion to vessel endothelium (175).   For circulating 
tumour cells to survive within the blood stream, firm adhesion to the vessel 
endothelium is essential in an organ microenvironment.  PC cells tend to adhere to 
vessel endothelia that express E-selectin.  E-selectin ligands include PSGL-1, ESL-1 and 
other adhesive molecules such as α2-integrin and β1-integrin (175).  Interestingly, 
Metacore analysis described integrin-mediated cell-matrix adhesion as one of the top 
networks associated with PHB over-expression.  It could be that PHB is decreasing the 
cell adhesion of PC cells by down-regulating integrins that in turn could reduce the 
amount of cell-basement membrane adhesion.  
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Both cell proliferation and metastasis need continuous interaction with ECM 
(extracellular matix) components.  ECM is mainly made of tissue components such as 
fibronectin, laminin and collagen IV.  The adhesion signal of these molecules is essential 
for successful metastasis (175).   This response is dependent on the activation of various 
signalling pathways such as Rho GTPases, JNK and FAK that are recruited to the ECM 
ligand/integrin binding site. In PC, integrins are expressed abnormally with aberrant 
ECM (138).  Integrins particularly play a role in PC primary tumour growth and are 
heavily implicated in the ability of cancer cells to grow and survive in distant sites.  PC3 
and DU145, both metastatic PC cell lines, express integrin αIIbβ3, suggesting a role for 
integrin αIIbβ3, in PC metastasis.  Studies showed a higher expression of integrin αIIbβ3 in 
DU145 cells derived from the prostate when compared to the subcutis-depicting 
integrin αIIbβ3 role in the progression of prostate adenocarcinoma (176). Bone metastasis 
is one of the lethal outcomes of PC. Targeting integrin αV with siRNA in xenografts 
inhibited the growth of PC tumours in the bone, whilst increasing the number of 
cancerous cells undergoing apoptosis.  Further, the expression of functional integrin 
αvβ3 promoted tumour growth in the bone, whereas mutated forms did not (138).  This 
data suggests integrin αvβ3 plays a key role in bone metastasis.  It is clear that integrins 
subunits are involved in the progression of PC that then go on to activate down-stream 
signalling pathways.  Although the exact molecular mechanism of how integrins 
contribute to the cancer progression still needs to be identified, it is interesting to note 
that PHB does play a role in decreasing the adhesion of PC cells, probably through the 
alteration of integrin expression.  
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Figure 7.8. Preliminary mechanism to how PHB decreases migration of PC cells. A, in the absence of 
PHB, E2F binds to the predicted binding sites in the promoters of Wnt10B/Wnt7B causing downstream 
transcription of genes associated with migration.  B, in the presence of PHB, E2F is inhibited from 
binding to the promoter region-migration is reduced.  
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7.5 Conclusion 
PHB’s role in the migration of PC cells is yet to be defined.  However previous data 
reported that PHB knockdown increased PC xenograft growth in mice, and also 
increased metastasis of LNCaP cells.  Data presented here highlights that PHB is down-
regulated at a gene level as PC metastasises from the primary tumour.  PHB over-
expression was seen to significantly reduce the adhesion and migration of PC cells, both 
functions essential for local and distant migration of tumour cells.  Interestingly, Wnt 
genes; Wnt10B and Wnt7B were significantly down-regulated with PHB over-
expression.  Wnt genes are heavily involved in the progression and migration of PC 
cells.  Wnt7B is androgen regulated and is highly expressed in castration-resistant PC 
cells. Thus PHB inhibiting Wnt7B could provide a therapeutic option for castration 
resistant PC.   Finally, a preliminary mechanism involving PHB, E2F, Wnt10B/Wnt7B 
and migration is described in figure 7.8. 
7.6 Key points 
 Geodatasets show that PHB is lost at a gene level as PC progresses to a 
malignant aggressive state. 
 Q-PCR identify that PHB over-expression decreases two Wnt genes; Wnt10B 
and Wnt7B. 
 Wnt genes are heavily influenced in the progression and migration of PC. 
 Metacore analysis depicted that both Wnt-signalling and integrin-mediated 
adhesion are in the top 10 most affected networks by PHB over-expression.  
 The migration of androgen dependent cells; LNCaP and androgen independent 
cells; PC3 is significantly decreased with PHB over-expression. 
 PHB over-expression significantly decreases the adhesion of androgen 
dependent PC cells to a basement membrane Matrigel™ coating. 
 Adhesion of tumour cells to the basement membrane is essential for primary 
tumour metastasis.  
 E2F binding sites are predicted in the promoter regions of Wnt10B and Wnt7B 
genes. 
 A preliminary mechanism of how PHB decreases migration: PHB binds to E2F 
preventing its interaction with predicted E2F binding sites in the promoters of 
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Wnt10B/Wnt7B.  This inhibits downstream transcription of genes associated 
with migration. 
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8 Chapter VIII. General discussion. 
PC still remains a debilitating disease, with disease progression and metastasis remaining 
the main obstacles for new treatment options. Typically, PC relies on androgen 
stimulation for its survival and proliferation.  The identification that the prostate 
requires hormone stimulation was observed in the 1940s by Charles Huggins, where 
castrated canines had a reduced prostate gland size and a reduction in acid phosphatase 
secretion.  However addition of testosterone counteracted these effects.  PC’s survival is 
based upon the ratio of cells proliferation to cells undergoing apoptosis.  Androgen 
stimulation results in a synergic effect of heightening proliferation whilst inhibiting 
apoptosis in PC cells.  Thus the clinically used androgen ablation treatment essentially 
increases the cells undergoing apoptosis whilst inhibiting proliferation, thus causing 
cancer cell regression (177).    As PC is heavily regulated by hormone stimulation, 
blockade of the AR with current treatment options such as anti-androgens are often 
used in clinics.  An example of anti-androgen therapy is gonadotropin-releasing 
hormone agonists. The hypothalamus releases gonadotropin-releasing hormone that 
acts on the anterior lobe of the pituitary.  In response, the pituitary releases luteinizing 
hormone that acts on the testes to produce testosterone.  Long-term treatment with 
gonadotropin-releasing hormone agonists leads to castration levels of testosterone 
within 3 weeks (178).  While androgen deprivation therapy (ADT) improves overall 
survival, relieves bone pain and suppresses the PSA levels by up to 90% in patients 
suffering with malignant PC, it is often used as palliative treatment.  Subsequent 
expected survival rates drops to 16-18 months from the time of progression.  Many 
patients undergoing ADT eventually relapse as the cancer has sensitised to a low 
androgen environment, thus transitioning to androgen independence.  AIPC is a lethal 
form of PC, and unfortunately there is no effective treatment available at present.   
Firstly, AIPC can arise through several different pathways.   For example, non-specific 
ligand activation of the AR. Adrenal androgens and growth factors such as insulin like 
growth factor-1(IGF-1) can cause activation the AR in the absence of androgen. This is 
due to mutations within the LBD domain of the AR that can arise through the use of 
anti-androgen therapy.   This results in the current treatment of androgen ablation 
becoming less effective, increasing the likelihood of patient relapse.  Further, AR gene 
and protein amplification has been documented in 25-30 of AIPC cases (69). An 
increase in AR co-activators has been identified in AIPC cases, causing an increased 
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recruitment of transcriptional machinery, enhancing the transcription of AR-regulated 
genes.  Another proposed mechanism leading to aberrant AR activation is the down-
regulation of AR co-repressors.  One well established co-repressor of the AR is known 
as PHB, and PHB has been shown to be down-regulated at both a gene and protein 
level in PC.  PHB can co-repress the AR by recruiting chromatin remodifying proteins 
such as HDAC, N-CoR and BRG1/Brm, repressing transcription of AR sensitive 
genes, such as PSA.    However in PC, once the AR signalling cascade has been 
activated, PHB dissociates from the AR, allowing downstream transcription of genes 
with androgen responsive elements in their promoter regions.  This leads to heightened 
proliferation, a decrease in apoptosis and an overall increased survival of the cancer. 
Therefore, it was explored whether PHB over-expression had any adverse effects on the 
cell cycle, proliferation and migration of both androgen dependent and androgen 
independent cell lines.  Investigating how PHB is down-regulated in PC could provide a 
novel mechanism involving the transition of PC from androgen dependence to true 
androgen independent PC (AIPC).   
Accumulating the data collected throughout this project and previous literature has 
shown that PHB is a ubiquitously expressed pleiotropic protein.  Along with its 
homologue; PHB2, it carries out a varied role within the cell.  Within the mitochondria, 
it serves as a chaperone for newly synthesised proteins.  Within the nucleus it interacts 
with transcriptional factors that regulate genes essential for cell cycle regulation and 
DNA replication.  More importantly, relevant to this project, PHB serves as a co-
repressor to the AR, whereby it represses the translocation of the AR to the nucleus, 
inhibiting the transcription of androgen responsive genes (130).  PHB localises in the 
nucleus in a variety of diseases such as irritable bowel syndrome (IBS), inflammatory 
disorders and cancers.  Such cancers include gastric, breast and prostate (179).  Online 
analysis of the PHB gene highlighted no detected mutations in prostate adenocarcinoma 
(The human gene mutation database).  
Previous work that led onto this project identified that PHB gene levels are seen to be 
reduced with high grade cancer and metastasis, demonstrated by both in vivo models and 
geodatasets analysis.  Stimulation of the AR in androgen dependent PC cells (LNCaPs) 
led to a 50% reduction in PHB protein levels (24 hr) (128). The same effect was seen in 
the androgen independent cell line PC3s, when they were stably transfected with the AR 
(30% decrease) (128).  Further,  PHB over-expression was able to inhibit the 
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progression of the cell cycle in LNCaP cells by increasing the sub-population of cells in 
the G1 phase, whilst decreasing the number of cells entering the S phase (130).  
PHB’s role in the cell cycle has been identified in breast cancer, whereby interaction of 
Rb family proteins with PHB was seen, alongside repression of E2F transcriptional 
activity.  One of the aims of this thesis was to identify how PHB modulates the cell 
cycle and how this regulation is influenced by AR activation.   As PHB has been found 
to have a profound effect on gene expression an RNA-sequencing experiment was 
carried out.  Data provided from the RNA-sequencing experiment and Q-PCR data 
showed that PHB renders the cell cycle inactive via an E2F-dependent mechanism, 
downregulating genes involved in DNA replication (MCMs).  The RNA-seq data was 
also subjected to analysis from bioanalysis programs.  IPA and Metacore analysis 
determined E2F to be one of the top ten transcriptional factors to be regulated by PHB.  
Gene ontology pathways were also centred on E2F3/4.  There is a large amount of 
redundancy in the E2F gene family, their functions switching between repression and 
activation during different stages of the cell cycle.  The role PHB has on E2F3/4 has 
yet to be investigated. The members of the E2F gene family are vital for the regulation 
of the cell cycle, especially in the G1/S transition phase.  E2F transcription factors are 
bound by members of the retinoblastoma (Rb) family, rendering their functions inactive 
during early G1 phase.  Supplemental figure 6 depicts that LNCaPs stimulated with 
androgen incur a cyclinA/D phosphorylation leading to the phosphorylation of Rb, 
freeing E2F1 to progress the cell cycle. Over-expression of E2F1 in mesangial cells 
induced the protein expression of cyclinD1 and cyclinE, both crucial for cell cycle 
progression (180).  When bound to phosphorylated Rb (pRb), E2Fs function as 
transcriptional repressors, whereas in free form, E2Fs act as activators of transcription 
(135).  The repression of E2Fs by pRb is enhanced by their phosphorylation by 
cyclinD, and this repression is inhibited by cyclinD inhibitors.  Rb has a vital role cell 
cycle progression as well as regulating apoptosis, differentiation of myoblasts and 
adipocytes and their development  (135).  To highlight Rb’s role as a tumour 
suppressor, mice carrying a one mutant Rb1 allele were predisposed to cancer 
development.  pRb role within the terminal differentiation of certain cell types can be 
divided into two mechanisms.  Repression of E2F dependent promoters such as those 
found in the MCMs genes, allows the regulation of the cell cycle and apoptosis.  
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Secondly, pRb family members can interact with transcriptional regulators such as 
MyoD and HBP1 that aid the regulation of differentiation  (135).   
It was then investigated if PHB was able to repress E2F activity on the promoters of 
E2F-regulated genes e.g. the MCM gene family.  MCMs encode for proteins with DNA 
helicase activity that is vital for replication elongation during DNA replication. They 
also participate in other chromosomal activities such as chromatin remodelling, 
transcription and genome stability.  Data established in this project highlighted that with 
increasing concentrations of PHB measured by Q-PCR and luciferase production, the 
promoter activity of both MCM5 and MCM6 were reduced.  This led to a preliminary 
mechanism that PHB physically interacts with E2F1, repressing its function, leading to 
the repression of the cell cycle.  Mutating a single amino acid in a predicted E2F binding 
site within the MCM6 promoter region 1Kb upstream of the starting codon, abolished 
PHB’s repressive function on the promoter.   Moreover, PHB in combination with 
Enzalutamide (anti-androgen treatment) led to heightened efficacy in repressing the 
MCM6 promoter activity.   
An exciting and novel interaction was found between E2F1 and PHB in hormonally 
starved LNCaP cells by a co-immunoprecipitation assay.  This interaction was reduced 
upon AR activation (cells stimulated with androgen) suggesting that the AR pathway 
hinders PHB’s repressive function on E2F1.  This could allude to how PHB is able to 
inhibit the cell cycle, through direct protein interaction with E2F1.   The two hybrid 
assay (Checkmate™) determined a weak interaction between E2F1 and PHB, 
suggesting that the two proteins do not interact in a 1:1 ratio, but rather part of a larger 
complex of proteins such as HP1, Brg1/Brm and Rb.  This then led to the assumption 
that PHB is able to interact with E2F1, preventing its transcriptional activity on the 
MCM genes, leading to cell cycle arrest.  
The next step was to identify the effect androgen signalling had on the PHB protein. 
The PHB protein is known to undergo a variety of post-translational modifications 
(PTM) such as, palmitoylation, ubiquitation, phosphorylation, O-GlcNAc modification 
and cysteine oxidation, however androgens effect on PHB was unknown (181).  The 
PHB protein contains four tyrosine residues at positions 28, 114, 249 and 259 that are 
highly conserved among different species (182).  PHB can undergo tyrosine 
phosphorylation by activation of various stimuli.  Stimuli include insulin, insulin-like 
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growth factor and epidermal growth factor.  Insulin receptor can phosphorylate PHB at 
tyrosine-114, which creates a binding site for SH2 domain containing protein tyrosine 
phosphatase-1 (Shp1), that in turn phosphorylates Akt and glycogen synthase kinase-3β 
(183).  Unfortunately, the only commercially available phosphorylated PHB antibody 
available is at the position Y-259.  Therefore 2D western blot analysis was carried out.  
A novel finding that could explain how androgen-independent PC occurs, is depicted in 
the 2D western blot analysis of PHB.  Firstly, as PHB dissociates rapidly from the 
chromatin when the AR is activated with hormone (2-4 hr), this suggested that post-
translational modifications were occurring as opposed to transcriptional changes.  This 
led onto studying the non-genomic actions of androgens on the LNCaP cell line. 
Hormonally starved LNCaP cells that had been treated with androgen (4hr) showed a 
pattern change of the isoelectric point of PHB with a shift towards pH 10, as opposed 
to hormonally starved LNCaP cells where PHB had an isoelectric point of pH 6 
(approximately).  This indicated that upon AR activation, PHB loses a negative charge, 
suggesting that PHB is being dephosphorylated.  The conjugation of a ligand or protein 
to PHB was ruled out as there was no protein size change seen.  The same isoelectric 
point pattern of PHB was seen with androgen treatment in the AR positive VCaP cell 
line, highlighting it is an AR related event. Interestingly, the charge shift of PHB (the 
dephosphorylation event) was inhibited when the LNCaP cells were treated with 
Enzalutamide; a clinically used anti-androgen therapy.  Moreover, PC3 cells that are AR 
null and represent androgen independent PC, displayed no charge shift of PHB in the 
presence of hormone.  However, the isoelectric point of PHB in the PC3 cells 
resembles the same pattern of PHB in the androgen-treated LNCaP cells.  This 
insinuates that in androgen independent PC, PHB has already undergone this post-
translational modification, inhibiting the repressive function of PHB through its 
dissociation from the chromatin.  This could allude to a novel mechanism that may 
have allowed PC to transition from androgen dependence to androgen independence. 
Particularly as it was shown that PHB gene expression was significantly lower in 
Bicalutamide-resistant LNCaP cells when compared to control LNCaP cells.  This 
together with the down-regulation of PHB through this potential dephosphorylation 
event could be involved in current PC treatment resistance.  
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Further investigations were carried out to assess the non-genomic actions of androgens, 
as it was too rapid to account for gene expression changes, by using a Kinexus array on 
hormonally starved LNCaP cells treated with androgen (4 hr), the same amount of time 
that it takes for PHB to dissociate from the chromatin in the presence of androgen.  
Firstly, the Kinexus protein array identified that Src was phosphorylated at tyrosine 418 
in response to AR activation.  Moreover, focal adhesion kinase (FAK) was also 
phosphorylated at tyrosine Y577.  Src is a known up-stream regulator of FAK and Src-
mediated phosphorylation of FAK is essential for actin and adhesion dynamics and 
survival signalling, which is turn aids the migration of cancerous cells (184).  Cells 
lacking FAK demonstrated impaired migration and displayed large focal adhesion 
structures.  Moreover, cells lacking the three members of the Src family; Src, Lyn and 
Yes, also displayed impaired migration and altered dispersal of focal adhesions (184).   
Activation of Src is essential for tyrosine phosphorylation of focal adhesion substrates 
such as FAK that in turn aids cell motility and focal adhesion turnover.  How the 
relationship between Src and FAK aid cell motility still remains vague.  However, 
signalling cascades activated through FAK have been identified to play a role in cell 
migration.  Such pathways include the PI3K pathway (phosphatidylinositol 3-kinase), or 
phosphorylation of paxillin or various other focal adhesion substrates (184).    
Interestingly, FAK’s expression and not its kinase activity, is essential for platelet 
derived growth factor and epidermal growth factor stimulated cell motility.  FAK also 
plays a role in apoptosis, by preventing cells from undergoing apoptosis in response to 
anoikis.  A study entailing mutating each of the putative Src-induced tyrosine 
phosphorylation sites (Tyr 407, 576, 577, 861, and 925) highlighted that Src-induced 
phosphorylation of FAK is essential for calpain-mediated focal adhesion turnover 
during cell migration and cell transformation  (184).  Moreover, Src-induced 
phosphorylation of FAK is necessary for survival and anchorage-independent growth of 
transformed cells.  Therefore this evidences that both Src and FAK are essential for cell 
motility, and androgen-activation of the AR leads to activation of these signalling 
cascades (184).  Data collected in this thesis showed that PHB up-regulation reduced 
the activity of the AR, thus this could potentially stop the rapid phosphorylation of 
Srctyr-418 that is essential for Src’s full catalytic activity.  This in turn could prevent the 
phosphorylation of FAK, leading to reduced downstream effects such as cell migration. 
A Src-inhibitor that was in use in clinical trials for metastatic castration resistant PC is 
known as Dasatinib.  However, Dasatinib failed to be translated into clinical benefit in 
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combination therapy alongside Docetaxel for castration resistant PC, as no improved 
survival was seen with the combination therapy when compared to patients treated with 
Docetaxel alone (185).  However targeting the Src pathway still is a promising target for 
PC treatment, as treating Bicalutamide-resistant LNCaP cells with a Src-inhibitor led to 
reduced proliferation of these cells in response to Bicalutamide, suggesting targeting the 
Src pathway can reverse some aspects of current anti-androgen therapy resistance.   
Growth factors and downstream tyrosine kinases are notably increased during androgen 
ablation (IL-6, IGF-1, Src, MAPKs,PKC) and can induce the tyrosine phosphorylation 
of the AR, which can sensitise the AR to a low androgen environment, increasing the 
likelihood of PC developing an androgen independent phenotype. Studies carried out by 
Guo, et al., 2006 (152) showed that levels of AR tyrosine phosphorylation were higher in 
samples from castration-resistant prostate xenograft tumours when compared to their 
hormone sensitive counterparts.  Src kinase activity was identified to be elevated in the 
same castration-resistant prostate xenograft tumours, highlighting Src kinase to be 
responsible for the AR tyrosine phosphorylation (152).  A kinase-inactive mutant 
SrcK295M failed to induce the tyrosine phosphorylation of the AR in LNCaP cells, 
suggesting that Src kinase induces the EGF induced AR tyrosine phosphorylation (152).  
Vandetanib, a dual inhibitor of both the EGF receptor and the vascular endothelial 
growth factor receptor-2 (VEGFR-2) failed to improve the efficacy over Bicalutamide 
alone in castration resistant PC patients.    
The next aim of the study was to address PHB’s role in PC metastasis.  It has been 
established that if diagnosed early, local stage PC has a 100% survival rate for more than 
5 years.  Once the cancer progresses to a distant site, this survival rate drops to 28% for 
more than 5 years(186).   Therefore, it is essential to uncover mechanisms that evolve 
the cancer from an indolent local stage to an aggressive distal stage.  There is limited 
literature linking the role PHB has in the migration and metastatic potential of PC.  
However, data collected in the thesis via Geodatasets analysis showed that PHB is 
downregulated in advanced PC, particularly in distant metastatic sites.  Further in vivo 
work carried out by Dr.D.Dart, demonstrated that knock-down of PHB led to local and 
distal metastases of LNCaP xenografts in a mouse model (supplemental figure 4).  
Moreover, data collected here, indicate that up-regulation of PHB inhibited the 
migration of both androgen dependent and androgen independent cell lines.  Therefore, 
by targeting the down-regulation of PHB in PC, there could be a synergic effect of 
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inhibiting both the proliferation of the PC cells and their migration from the primary 
tumour.  Bio-analysis of the RNA-seq data showed that migration and adhesion were 
pathways affected by PHB over-expression. Mechanistically, up-regulation of PHB 
could, thus, have a negative effect on genes associated with PC migration.  Interestingly, 
data mining into the RNA-sequencing database revealed that PHB up-regulation caused 
members of the Wnt gene family to be down-regulated.  After validation of key genes 
via Q-PCR, both Wnt10B and Wnt7B were significantly down-regulated.  The Wnt 
proteins are secreted as glycosylated and palmitoylated peptides. The family of Wnt 
proteins are involved in migration, stem cell differentiation and integrity of the stem cell 
niche (187). Deregulated Wnt signalling has been documented in the development and 
progression of cancer. For example, in acute myeloid lymphoma (AML), β-catenin, a 
downstream target of canonical Wnt signalling can progress pre-leukaemia initiating 
cells to a leukemic initiating state. In chronic lymphocytic leukaemia (CLL) canonical 
Wnt signalling is up-regulated and upon inhibition of the signalling pathway, apoptosis 
of CLL cells ensues in vitro (188).   Moreover, somatic Wnt gene mutations were found 
in 14% of studied cases.  Targeting these mutated Wnt genes led to a decrease in cell 
viability whereas non-mutated Wnt genes were unaffected when targeted.  There is 
strong evidence to suggest that aberrant canonical Wnt signalling has a prominent role 
in the progression subtypes of leukaemia.  Heightened Wnt signalling has also been 
documented in both melanoma and breast cancer (188).  Firstly, in 50% of breast cancer 
cases, Wnt signalling is activated leading to reduced overall survival rate.  Worryingly, 
Wnt antagonists are silenced whereas Wnt ligands and receptors are over-expressed in 
breast cancers (188).   Moreover, in melanoma the non-canonical Wnt5A led to 
increased motility as well as causing a pseudo-senescent phenotype.  This pseudo-
senescent phenotype consists of melanoma cells that are increasingly chemo resistant 
(188).   Therefore Wnt5A mediated signalling leads to an invasive and resistant 
phenotype within melanomas.   
Wnt signalling has been implicated in cancer metastasis.  One of the hallmarks in cancer 
metastasis is epithelial to mesenchymal transitioning (EMT).  Here polarised epithelial 
cells transform into migratory mesenchymal cells (189). One of the transcriptional 
factors associated with EMT is known as SNAI2 (190). Activation of the non-canonical 
Wnt pathway leads to the stabilisation of SNAI2 by preventing GSK3β kinase activity, 
thus instigating EMT in breast cancer cells (188).  However in colon cancer, over-
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activation of the canonical Wnt pathway leads to nuclear accumulation of β-catenin 
resulting in cancer metastasis (188).  This highlights that both non-canonical and 
canonical Wnt signalling are implicated in cancer metastasis, and thus PHB over-
expression having a negative effect on their gene expression resulting in reduced 
migration could prevent local and distal PC metastasis.  Moreover, Kinexus data 
revealed that ROCK-1 was the most phosphorylated total protein in response to 
androgen stimulation.  Interestingly, ROCK-1 plays a pivotal role in tumour cell 
motility.  ROCK proteins are a downstream target of the small GTPase Rho.  The Rho 
family of small GTPases are integral for the metastatic potential of cancerous cells (191)  
Interesting, Rho proteins can interact with Src proteins, ultimately leading to actin 
cytoskeleton remodelling and increased cell motility.  This is of particular importance as 
it was shown here that activation of the AR pathway leads to Src phosphorylation.  A 
specific Rho GTPase protein; Rac1 can induce growth of androgen independent PC 
cells in cell culture and in vivo, suggesting that Rac1 is an important mediator of ligand-
independent AR activation in PC progression (192).  Therefore, inhibition of the AR 
through PHB up-regulation could prevent the activation of Rho GTPase proteins, 
leading to inhibition of PC progression and metastasis.  
This thesis supports an accumulating amount of evidence to suggest that up-regulating 
PHB hinders malignant characteristics of PC.  Such functions include cell cycle arrest, 
inhibition of cell proliferation, adhesion and migration.  Stopping these functions in PC 
is critical in reducing the malignancy of the cancer, and improving prognosis.  However, 
therapeutically it is difficult to induce the over-expression of PHB within the cells due 
to its protein size (32kDa).  However, there are ways in which PHB is down-regulated 
at a genetic level.  For example, it is well known that microRNAs (miRNAs) are able to 
fine tune its gene expression.  miRNAs are single stranded RNAs around 22 nucleotides 
long that are able to bind to mRNA, silencing their expression (193). They are able to 
negatively regulate their gene targets one of two ways.  Firstly, miRNAs that bind to 
their gene target with almost 100% complementarity induce the RNA-mediated 
interference pathway.  Secondly, miRNAs that bind to their targets with less 
complementarity occurs in the 3’ untranslated regions (UTR), inhibiting translation of 
mRNA through a RISC complex similar to the RNA-mediated interference pathway 
(193).  Work carried out by Kang et al., 2013 (194) identified that miR-27a and miR-128 
were predicted to be conserved miRNA families among vertebrates that target human 
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PHB by using the TargetScan Database.  Interestingly, miR-27a has been seen to down-
regulate PHB both in prostate and gastric cancer.  Firstly, in gastric cancer studies 
carried out by Lui, et al., 2009 (195) identified miR-27a as an oncomiR and knockdown 
of miR-27a could suppress cancer cell growth.  Interestingly, further studies revealed 
that the 3-UTR of PHB contained a binding site for miR-27a.  Blocking the function of 
miR-27a led to an increase in both PHB mRNA and PHB protein.  Therefore, it was 
identified that miR-27a can bind to PHB’s 3’UTR inducing the cleavage of PHB 
mRNA, resulting in PHB’s loss of function.  A similar effect was also seen in PC, 
whereby it was detected that AR activation led to an increase in miR-27a, leading to the 
down-regulation of PHB in a positive feedback system (92).  miR-27a down-regulation 
of PHB could therefore propagate PC’s oncogenic phenotype, through aberrant AR 
signalling.  Therefore, therapeutically targeting miR-27a could prevent the down-
regulation of PHB that in turn could prevent the progression of PC.  Inhibiting 
oncomiRs using antisense oligomers is emerging as a therapeutic strategy.  However, in 
order to target such oncomiRs, certain information is needed.  Firstly, to understand the 
miRNAs mechanism of action, what is the most efficient form of delivery of miRNA 
therapy, and its action in vivo.  Once this information has been discovered, targeting 
miRNA-27a’s downregulation of PHB may be a therapeutic option of PC.   
8.1 Future work 
The data collected throughout this thesis has lead onto promising mechanisms that 
could explain how androgen independent PC arises through the use of anti-androgen 
therapy.  However, although complete knockout of PHB is lethal in embryonic cells, 
experiments can be carried out using a knock-down ribozyme plasmid targeted to the 
3’UTR of PHB to induce the partial knockdown of PHB (approx. 30%).  Functional 
experiments carried out in this thesis could then be repeated using the PHB targeted 
ribozyme plasmid, to note if the reciprocal pattern occurs.   Mass spectrometry could 
aid identifying the residue or residues on PHB that is being dephosphorylated, that 
could lead to raising an antibody specific to this residue.  Further protein:protein 
interaction assays could be carried out to further validate if PHB directly or indirectly 
interacts with E2F1. Chromatin immunoprecipitation (ChIP) could validate regions on 
the chromatin where PHB is binding, and how hormone activation of the AR could 
disrupt this binding.   
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Moreover, analysis into the expression of the Wnt genes throughout the phases of the 
cell cycle could be carried out. If in silico analysis predicts E2F binding sites within the 
promoter regions of Wnt10b and Wnt7b, an E2F1 plasmid could be transfected into 
LNCaP cells, and promoter activity of both Wnt10b and Wnt7b could be analysed to 
identify if they are E2F-regulated.  If they appear to be E2F regulated this could link to 
PHB’s direction interaction with E2F1, repressing E2F1s activity on the wnt genes, 
leading to an inhibition of down-stream effect of wnts such as cell migration in PC. 
More PC cell lines could be used for validation.   
Identifying the amino acid residue or residues of PHB that is targeted for the 
dephosphorylation in response to androgen treatment, would be the next step.  This 
sequence could then be used to identify the phosphatase responsible for the 
dephosphorylation.  This phosphatase could then be therapeutically targeted, to prevent 
the dephosphorylation of PHB leading to its dissociation from the chromatin.  
Moreover, an antibody for this residue could be manufactured, and a screening 
procedure for PC biopsies could be made available. If the PC biopsy is positive for the 
dephosphorylated PHB in patients that are undergoing anti-androgen therapy, it is a 
good indication that the therapy is not effective and can be stopped preventing the 
patients from suffering unnecessary side effects and can be used as a prognostic 
indicator.  Once in vitro validation was complete, use of animal models and primary 
tissue samples would be obtained to prove proof of principle.   
8.2 Conclusion 
To conclude this thesis, there is a large body of data to suggest PHB down-regulation is 
a mechanism that aids the development of ‘androgen independent’ or ‘castration-
resistant PC’.  This is due to the novel identification that androgen stimulation of the 
AR leads to the potential dephosphorylation of PHB.  This in turn may lead to the 
dissociation of PHB from the chromatin, and dissociation of PHB from promoters that 
contain E2F binding sites such as MCM genes that are responsible for DNA 
replication.  A novel interaction of E2F1 and PHB was identified in the LNCaP cell 
line.  This interaction was disrupted upon androgen stimulation, allowing E2F1 to carry 
out its function in cell cycle progression.  PHB’s repressive role on the cell cycle was 
due to causing the down-regulation of several members of the E2F gene family and the 
MCM gene family, alongside causing an up-regulation of cell cycle inhibitors such as p21 
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and p27.  Moreover, up-regulation of PHB was also seen to play a role in hindering the 
cellular adhesion and cellular migration of both androgen dependent and androgen 
independent PC cells.  Mechanistically this was narrowed down to PHB causing the 
down-regulation of Wnt genes that are predominantly influenced in cell motility and PC 
progression.  To confirm this, bioanalysis data verified that Wnt signalling and integrin 
signalling were within the top networks to be effected by PHB over-expression.  Both 
of these pathways are essential for progression of the PC from the primary tumour, 
leading to local and distant metastasis.  Thus, accumulating the data presented here, 
PHB is a multi-functional protein that upon up-regulation leads to an inhibition of 
several cascades of events that eventually leads to a regression of malignant PC. This 
thesis has provided data that has alluded to a novel suggested mechanism involved in 
androgen independent PC as shown in figure 8.1. 
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Figure 8.1. Final mechanism that could allude to how androgen independent PC occurs, involving AR activation leading to Src-phosphorylation, PHB dephosphorylation and how 
these events increase PC malignancy through increased cell cycle progression, cell migration and adhesion (137).
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Supplemental figure 1. Stages of PC progression from normal epithelium to metastasis.  
Supplemental figure 2. ALGGEN in silico analysis of the MCM6 promoter.  A, four predicted E2F binding sites 
are found in the wt MCM6 promoter. B, the mutated MCM6 promoter has an abolished predicted E2F binding 
site.  
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Supplemental figure 3. Western blot of total and Src-y418 phosphorylation from LNCaP cells.  
LNCaP cells were grown in charcoal stripped serum for 72 hr and then treated with ethanol or R1881. 
(10nM, 4 hr).    
Supplemental figure 4. Bio-luminescence imaging of male mice carrying LNCaP/PHB siRNA 
xenografts treated with or without doxycycline.  
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Supplemental figure 6. LNCaP cells treated with androgen incur a phosphorylation of 
cyclinA/D leading to Rb phosphorylation.  
Supplemental figure 5. ALGGEN in silico analysis of the wnt10B and wnt7B promoter regions 
1Kb up-stream of the stop codon.  Both wnt10B and wnt7B have predicted E2F binding sites.   
